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ABSTRACT

Introduction: An inherent risk from an incident stroke is recurrence. The most effective

method to reduce stroke risk is to reduce the incidence of hypertension.

Thus,

antihypertension therapy has become imperative in the prevention of primary and
recurrent stroke. In this dissertation we examine the confounding effects of race and age
on recurrent stroke risk and the consistency of secondary prevention treatment regimens.
Methods: One-year recurrent stroke risk was determined in relation to race, age, gender,

and comorbid hypertension and diabetes by mixed effects regression and Kaplan-Meier
survival analyses among hospitalized patients in South Carolina. A subset of patients
were used to estimate race- and age-speciY9" rate ratios for stroke incidence and
.y/~; "/;I"
recurrence based on symptomatic and asymptomatic discharge diagnoses modifier code
selection.

A hospital-based subset of stroke survivors was surveyed via structured

telephone interviews to detennine predictors of

antih~pertensive

regimen persistence

from hospital discharge to one-year by logistic regression analyses.
Results: One-year recurrent stroke was identified in 11.3% of hospitalized patients with

highest rates among African Americans, patients age 45-64 years, and patients with
diabetes. The magnitude of the racial disparity rate ratios for both stroke incidence and
recurrence was significantly higher when only symptomatic stroke diagnoses were
considered. Advanced age, comorbidity, uncontrolled blood pressure (2:140/90 mmHg),
premorbid antihypertensive therapy, and receipt of antilipidemics or antithrombotics were
significantly associated with receipt of antihypertensive therapy at discharge. Within
one-year post stroke hospitalization, 87% of the treated patients remained on some type

v

of antihypertensive therapy, while only 390/0 were persistent on the same regImens.
African Americans and comorbid conditions were inversely associated with persistence
on antihypertension therapy.
Conclusions: The results of this study identified one-year recurrent stroke impacting one

in ten stroke survivors.

Further, younger age, African American race, and prevalent

diabetes significantly increases recurrent stroke risk and emerge as factors to consider in
risk-reduction strategies.

Persistence on antihypertensive regimen one-year post

discharge was significantly lower for certain medication classes, African Americans, and
patients with high comorbidities. Recurrent stroke risk for these high risk groups could
be reduced by understanding the effects of race and comorbid conditions on medication
persistence.

VI

CHAPTERl
Introduction

Stroke represents a significant death risk for men and women and is a major cause
of long-term disability in the United States. 1-4 Significant geographic and racial
disparities are evident. South Carolina has long been recognized as a geographic area of
high prevalence and mortality for stroke. 5, 6 African Americans, comprising nearly 30%
of the SC population have significantly higher stroke rates than Caucasians. 7- 1o The
higher prevalence of hypertension among Afht~ Americans especially in the southeast
is thought to be a major cause of the high stroke mortality rate in the stroke belt region. 5
In addition to higher risks among African Americans, the rates are higher at younger
1

ages.

l1

As much as 250/0 of stroke cases are recurrent events that occur within the first
year post index stroke. 12 -15 The adverse impact of a recurrent stroke is often more severe
than the index stroke, and is associated with twice the 30-day mortality rate.

14 18
-

Comorbid conditions including history of hypertension, diabetes, and arrhythmias are
. d WIt
. h an Increase
.
dris
' k
thaught to be aSsocIate

0f

16
recurrent strok e.'

19 , 20

Thus,

secondary stroke prevention in both the acute phase and long-term follow-up is of critical
importance.

1

The most effective method to reduce stroke risk is to reduce the incidence of
hypertension. Hypertension poses a major public health burden and will continue to do
so if the lifetime risk of elevated blood pressure remains unatlenuated. 21 -23

Blood

pressure is recognized as an important risk factor for stroke in both hypertensives and
nonhypertensives. Thus, antihypertension therapy has become imperative in the
prevention of primary and recurrent stroke.
The purpose of this dissertation is to examine the confounding effects of race and
age on recurrent stroke risk and the consistency of secondary stroke prevention treatment
regimens one-year post stroke discharge.
Chapter 1 provides a brief introduction to the dissertation, specific research aims,
an expanded review of the literature,

prelimin~FY'fesearch
,~.".~,

-'.,1'--

findings, and the significance

'/

of this dissertation. In Chapter 2, we examine one-year recurrent stroke risk in relation to
race and age disparities with the association of comorbid hypertension and diabetes. In
Chapter 3, we consider the effects of standard Internatipnal Classification of Diseases,
Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic modifier code selection on

race-age specific stroke rate estimated using administrative databases. In Chapter 4, we
assess the persistent use of antihypertensive medications one-year post stroke
hospitalization among stroke survivors. Chapter 5 provides an overall summary of the
findings in this dissertation and outlines future research directions for improved stroke
care with a focus on secondary stroke prevention.
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Specific Research Aims

Overall Hypothesis: Patterns of recurrent stroke are influenced by population
demographics, comorbid hypertension and diabetes, and treatment practices.

AIM 1:

To examine the association of one-year recurrent stroke risk with race-age
disparities and comorbid hypertension and diabetes.

African-American race will be associated with an increased risk of one-year
recurrent stroke when compared to Caucasian race, controlled for age, gender,
and comorbid covariables.

.f"" '. ~ . ,t;;'"
,

'

~

Age less than 65 years will be associated with an increased risk of recurrent
stroke when compared to subj ect greater than 65 years of age, controlled for
race, gender, and comorbid covariables.
Comorbid hypertension will be associated with an increased risk of recurrent
stroke, controlled for age, race, and gender.
Comorbid diabetes will be associated with an increased risk of recurrent
stroke, controlled for age, race, and gender.

3

AIM 2:

To determine the effects of using the traditional International Classification of

Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic
modifier codes for ischemic stroke (ICD-9-CM 433, 434, and 436) on the
estimates of race-age specific stroke rates and the patients' perception of
stroke hospitalization.

Ha2 l :

Race and age disparity estimates will be greater when only symptomatic ICD9-CM codes are considered when compared to the traditional codes for stroke.

Ha2 2 :

The patients' perception of being hospitalized for a stroke will differ based on
symptomatic versus asymptomatic diagnosis at discharge.

AIM 3:

To assess differential patterns of antihypertensive regImens prescribed at
discharge and persistent use of antihypertepsives at one-year post stroke
hospitalization comparing race, age, prior stroke and recurrent stroke among
stroke survivors.

Ha3 l :

Prescribed antihypertensive regimen at discharge and persistent use at oneyear will differ by race, age, and history or prior and recurrent stroke.

4

Review of the Literature

The Burden of Stroke

Death and disability resulting from stroke and cardiovascular disease increases
with age, accounting for half of all deaths in those greater than 65 years of age. As much
as 20% of these deaths are due to stroke. However, stroke and cardiovascular disease not
only affect the elderly but also are the leading causes of death for individuals 30 years of .
age and older. I,

2

Hypertension and diabetes are established, independent predisposing

risk factors for developing cerebrovascular disease.

Subjects with a normal blood

pressure less than 120/80 mm Hg have approximately half the lifetime risk of stroke
compared to hypertensive subj ects. 24 Diabetes ,has been shown to increase age-specific

"'~'~/'Y"

incidence rates and rate ratios for ischemic stroke at all ages, especially among AfricanAmericans less than 55 years of age and Caucasians less than 65 years of age. 24
Stroke and the Stroke Belt

South Carolina has one of the highest incidences of stroke and age-adjusted stroke
mortality in the nation. The United States stroke belt, first identified in 1965 includes the
eight southeastern states of Alabama, Arkansas, Georgia, Louisiana, Mississippi,
Tennessee, North Carolina, and South Carolina.
mortality rate than the rest of the country.S'

6

This area has a 50% higher stroke

The National Heart, Lung, and Blood

Institute (NHLBI) has identified South Carolina, Georgia, and the coastal plain of North
Carolina as "the buckle of the stroke belt", where stroke mortality rates have consistently
been higher than in the other stroke belt states. 5 In 2007, stroke was the 3rd leading cause
of death, accounting for 2,460 deaths, approximately 6% of the state's deaths and is one

5

of the leading causes of long-term disability. 3,

4

South Carolina has a relatively high

African-American population, comprising 28% of the state's overall population
according to the United States Census population estimates in 2009. In the late 1990s,
stroke rates were confirmed high in the southeast and among African Americans, and still
remain high today. 25 Thus, racial factors may contribute to excess rates in the stroke belt.
Lackland et al reported that African-Americans living in the southeast experience more
cerebrovascular deaths than their Caucasian counterparts living in the same region. 7
However, race is not the only contributing factor in stroke mortality.

Nativity

(birthplace) has been suggested as a significant risk marker that may contribute to the
geographic variations in stroke mortality. Lackland et al found that regional disparities
for birthplace and subsequent stroke mortalitx, '~ere greater among African-Americans

/"11"
than Caucasians, as well as for men than wom~n. 8 The Charleston Heart Study reported
'/'.,,~

higher prevalence rates of hypertension in the African-American population, and
significantly higher population attributable risks especially at the higher blood pressure
categories in African-Americans. 9, 10 Thus, the higher prevalence of hypertension among
African-Americans especially in the southeast is thought to be a major cause of the high
stroke mortality rate in the stroke belt region. 5
In addition to racial disparities associated with stroke, the age at stroke onset is
younger in South Carolina, especially among African-Americans. Feng et al reported a
significant increase in stroke admissions in the younger, less than 65 years old, AfricanAmerican population in South Carolina. 11 As well, Feng et al reported that the acute
outcomes due to stroke were worse among African-Americans compared to Caucasians,
which resulted in significantly higher cost for the young African-Americans population. 1I

6

Patients 65 years and older are covered by the Medicare program, which typically covers
the medical cost accumulated for these patients.

However, patients less than 65 are

covered by various health care insurance types or have no form of health insurance; thus
increasing the financial burden on the state.

Therefore, stroke in younger patients

represents an important area of study that may have significant financial implications for
the state health care system. 11

Overall Stroke Risk
There are a number of population based studies concerning stroke epidemiology.
The Greater CincinnatilNorthern Kentucky Stroke Study and the Rochester, Minnesota
study showed that the overall incidence rates among African-Americans are 288 per
100,000 (95% Confidence Interval (CI): 250-325) compared with 179 per 100,000 (950/0
'f·~·~/·.1··

CI, 164-194) among the Caucasian population in Rochester, Minnesota for all age
categories except> 75 years; with the greatest relative risks (RR) (2-5 fold) comparing
African-Americans and Caucasians seen in the young anp middle aged population

« 65

years).26,27 These data reveal that a disproportionate number of strokes are seen among
the African-American population. The Northern Manhattan Stroke Study (NOMASS)
revealed a similar finding in a young population (age < 45 years)?8,29 In 1998, Lackland
et al reported that incidence rates for African-Americans in South Carolina were nearly
twice the rates for Caucasians, with differences being more dramatic in the younger age
groups (35-64 years).30 Examination of the data above illustrates racial disparities in
stroke incidence rates, primarily in African-Americans under the age of 65. A logical
cut-point for considering age in studies assessing stroke would be less than 65 and greater
than 65 years due to the qualification of Medicare.

7

Stroke Risk and Hypertension

Hypertension is an established, independent predisposing risk factor for
developing cerebrovascular disease. Hypertension directly impacts stroke occurrence by
two primary pathways: lacunar infarction and intracerebral hemorrhage. Increased blood
pressure causes damage to small resistance arteries at the base of the brain; if these
arteries occlude or rupture this can cause lacunar infarction or intracerebral hemorrhage
(ICH), respectively.

Hypertension can also contribute to stroke risks by progressing

atherosclerosis. 31 Since 1972 stroke incidence and mortality has continued to decline,
which could be contributed to improved blood pressure control during this time period
markedly shown with the decline of hemorrhage incidence compared to brain
infarctions. 31

U sing the Joint National C'ommission on Prevention, Detection,
I

.'.~~~.¥

.

Evaluation, and Treatment of High Blood Pressure, Seventh Report (IN C 7) classification
of hypertension, Seshadri et al reported that 10-year and life-time risk of first-ever stroke
increased with the severity of hypertension in the Framilfgham study. Subjects 65 years
of age whose blood pressure was in the "NormaP' range (Systolic Blood Pressure (SBP)
<120/ Diastolic Blood Pressure (DBP) <80 mm Hg) had a 14.6% (95% CI, 9.2-20.4)
mortality-adjusted cumulative lifetime risk of first-ever stroke for women and 10.4%
(95% CI, 6.0-14.9) for men. Whereas, the mortality-adjusted cumulative life time risk
estimate increased to 18.2% (95% CI, 15.1-21.3) for women and 14.9% (95% CI, 12.017.9) for men at age 65 in the "Pre-hypertensive" category (120 < SBP < 140/ 80 :::; DBP
< 90 mm Hg); increased to 25.8% (95% CI, 21.9-29.7) in women and 20.5% (95% CI,
16.3-24.6) in men in the "Stage 1 hypertension" category (140 :::; SBP < 160/ 90 < DBP <
100 mm Hg); and further increased to 25.6% (95% CI, 21.6-29.6) in women and 22.1 %

8

(95% CI, 16.8-27.4) in men in the "Stage 2 hypertension" category (SBP > 1601 DBP 2:
100 mm Hg).32 Furthermore, as evident in the Framingham Study, "elevated midlife"
systolic blood pressure during the previous decade increased the relative risk of stroke at
60 years of age by RR 1.68 (95% CI, 1.25-2.25) in women and RR 1.92 (95% CI, 1.392.66) in men. 33 , 34
Stroke Risks and Antihypertension Agents

Stroke, hypertension, and diabetes are all major risk factors for cardiovascular
disease in which the JNC 7 has release recommendations for cardiovascular risk factors
and treatment regimens?2 Blood pressure is recognized as an important risk factor for
stroke in both nonhypertensives and hypertensives. Thus, antihypertension therapy has
become imperative in the prevention of primary and recurrent stroke.

""'~~/'Y"

However, the

optimal antihypertensive drug regimen and which patients to treat, depending on previous
history of vascular disease, age, and baseline blood pressure level remains unclear?O, 35,36
The JNC 7 reported that recurrent stroke rates are lower9d by using a combination of an
angiotensin-converting enzyme (ACE) inhibitor and thiazide-type diuretic. 22

The

Perindopril Protection Against Recurrent Stroke Study (PROGRESS) Collaborative
Group found that a perindopril-based blood pressure lowering regimen reduced the risk
of stroke for both hypertensives and normotensives with a history of stroke or transient
ischemic attack (TIA).23 Combination therapy produced larger risk reduction and blood
pressure reductions than the single drug therapy in the PROGRESS randomized clinical
trial; and should be considered for all patients with a history of stroke or TIA, even for
normotensive patients. 23
A large meta-analysis of 147 randomized trials of blood pressure lowering drugs

9

recording stroke events was published by Law et al in 2009. 37 In this meta-analysis,
antihypertensives were found to have preventative effects in reducing stroke in a majority
of these studies; however, there was no difference in the preventative effects of the drugs
in individuals with a prior history of stroke. 37 Thus, the reduction in stroke risk was
similar in those with and without a prior history of stroke. Therefore, since there are no
differences in the preventative effects based on prior history, it begs the question if the
blood pressure reduction alone accounts for the preventative effects of the
antihypertensive treatment seen in these study, regardless of the drug class prescribed. In
blood pressure difference trials where blood pressure was standardized to a reduction of
10 mrn Hg systolic and 5 mm Hg diastolic, both cohort studies and trials showed similar
magnitUdes of reduction in stroke risk. 37 · The estimates from the blood pressure
"<'~~/y"
difference trials together showed a 41 % (33% to 48%) reduction in stroke with a RR of
0.59 (95% CI, 0.52-0.67).37

The cohort studies showed similar results with a 36%

reduction is stroke with a RR of 0.64 (95% CI, 0.62-0.96) for the same blood pressure
difference of 10 systolic and 5 diastolic mm Hg?7
The degree of the reduction in stroke risks was similar in all studies. 38 When
examining drug comparison trials, the meta-analysis revealed that the average blood
pressure reduction was relatively zero between the different classes of drugs. 37 , 39 Thus,
each class of drug reduced blood pressure to approximately the same degree, and thereby
reducing the risk of stroke to approximately the same extent. Therefore, this brings to
light the preventative effects of the mechanism of each drug class. If they all reduce
blood pressure and stroke risk to the same degree, it is reasonable to suggest that it is the
actual lowering of blood pressure itself that offers the preventative effects, not the

10

mechanism by which it is reduced. 38 Thus, if reduction of blood pressure in itself is the
preventative component, it raises the question of whether we should only treat patients
with a history of hypertension. Again, cohort studies and trials produced similar results,
showing a constant proportional effect of disease reduction with lower blood pressures. 37 ,
40 By lowering the systolic by 10 mm Hg and diastolic by 5 mm Hg the reduction in
stroke risk is about one-third, regardless of blood pressure level prior to treatment. 37
Thus, there is a benefit in lowering blood pressure in anyone who has an increased risk of
cardiovascular disease because of the preventative effects against stroke, which is
proportional to the given blood pressure reduction even in those who are not hypertensive
before treatment. 38
The Antihypertensive and

Lipid-Lower~ng

Treatment to Prevent Heart Attack

"·"~/·'~/·,

/

Trial (ALLHAT) showed a decrease in blood pressures resulting in increased control of
hypertension, with a reduction in stroke risk with the use of thiazide diuretics, calcium
channel blockers (CCB), and ACE inhibitor. 41 The perctflt of controlled blood pressures
less than 140/90 mm Hg was lower in African-Americans for all three antihypertensive
drugs. 42 The ACE inhibitor arm had significantly more stroke events and
higher blood pressure level than the CCB arm.

all

average

However, there was no significant

difference in stroke risk between the CCB and diuretic treated patients. 43 In a metaanalysis of four trials including the Appropriate Blood Pressure Control in Diabetes
(ABCD),44 the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial
(F ACET),45 the Swedish Trial in Old Patients with Hypertension (STOP-2),46 and
ALLHAT41 comparing CCBs and ACE inhibitors, CCBs were shown to have benefits
over ACE inhibitors (RR 0.89 (95% CI, 0.80_0.99)).43,47 Verdechia et al confirmed that

11

CCBs were superior to ACE inhibitors in a meta-regression analysis for the prevention of
stroke. 43 ,48 Boutite et al suggested that angiotensin II may have a protective effect on
stroke, due to the fact that the relative risk of stroke was approximately 17% (p

=

0.003)

greater in antihypertensives that reduce angiotensin II levels, such as beta blockers and
ACE inhibitors, compared to those drugs that increase angiotensin II levels such as
CCBs, diuretics, and angiotensin receptor blockers (ARB).49 The Ongoing Telmisartan
Alone and in combination with Ramipril Global Endpoint (ONTARGET) trial directly
compared ramipril (ACE inhibitor) versus telmisartan (ARB) alone and in combination
among high risk hypertensive patients, and suggested a slight advantage of ARBs
compared to ACE inhibitors for stroke prevention. 50

In assessing these two

antihypertensives in combination, ONTARGET -showed that there was no benefit for the
"'~~J'

y"

prevention of stroke as compared to ramipril (ACE inhibitor) alone, and actually
conferred an increase renal adverse effects. 50
Combination versus Monotherapy
Taking any class of antihypertensive drug, regardless of pretreatment of blood
pressure or history of vascular event, has benefits in reducing stroke risk.

JNC 7

indicated achieving blood pressure control in most patients with hypertension will require
two or more antihypertensive medications whether in combination as a fixed-dose
regimen or as a two single pills in combination?2,

51,

52 Thus, this begs the question if

combination antihypertensive therapy is more preventative in lowering blood pressure
and reducing stroke risk compared to monotherapy.

A meta-analysis was used to

compare the reduction effects of one drug at standard dose versus combination drugs at
standard dose and half dose on blood pressure from baseline and on stroke risk reduction.

12

The results showed a reduction in stroke risk of 33% in individuals 60-69 years old
whose systolic was approximately 150 mm Hg and diastolic was approximately 90 mm
Hg on single drug at standard dose. 37 In this same age group, a combination of three
drugs at half dose reduced the incidence of stroke by 60%, thus doubling the preventative
effects. 37 , 53, 54 Even at higher and lower blood pressure levels, the reduction effects of
the combination therapy were about 10 percent higher in reducing incidence for every 30
mm Hg systolic or 5 mm Hg diastolic increase in blood pressure. 37
The Second European Stroke Prevention Study (ESPS2) demonstrated that stroke
and TIA patients are at high risk for recurrent or secondary strokes, comprising 29% of
all stroke patients in the United States. 55 This study reported that combination therapy
treatments were more effective in secondary;.'.,stroke prevention irrespective of the

.' . .

patients' age.

55

~J.'?--

The PROGRESS randomized clinical trial reported a reduction in stroke

risk with combination therapy of 44% (95% CI, 28-57%) among hypertensive subjects
and 42% (95% CI, 19-58%) among normotensive subjefts; whereas the reduction with
single drug therapy was 100/0 (95% CI, 25-35%) and 1% (95% CI, 34-26%) among
hypertensive and normotensive subjects, respectively.23
From the afore mentioned epidemiological and interventional studies we can
conclude that the preventative effects of lowering blood pressure is substantially
important in reducing stroke risks in the general population regardless of their blood
pressure level, age, or prior history of vascular disease. Also, from this data we can
conclude that any antihypertensive therapy that reduces blood pressure will be beneficial
no matter the mechanisms chosen; however, if combination therapy proves to lower
blood pressure at a greater degree, then the idea of "the lower the bettee' is supported and

13

thus will lead to an increased reduction in stroke risk. 37 From pre-hypertension up
through Stage II hypertension, the effects of blood pressure on stroke risk is progressive
and continuous and has been shown to double in risk with each increase of 20 mm Hg
systolic and 10 mm Hg diastolic in blood pressure. 56
Importance of Data Regarding Hypertension Control for Stroke Prevention

Although information regarding the level of hypertension control is useful, it is
not essential in evaluating the extent of blood pressure importance on detennining stroke
risks. As Du et al reported, "hypertension ever" had an odds ratio (OR) of 2.45 (95% CI,
1.62-3.71) regardless of antihypertensive therapy; whereas the odds of stroke based on
quality of blood pressure among poorly controlled or untreated hypertensives only
increased to OR 3.10 (95% CI, 1.94-4.96).57 lIowever, the more important factor in

'tI,"

...
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accessing stroke risk was the additional comorbid risk factors, including diabetes,
obesity, past medical history of cardiovascular event, etc., which reflected in an increased
odds of having a stroke more so than an increase in bloo~ pressure category. 57 Therefore,
when assessing stroke risk data it is beneficial to know the baseline level of blood
pressure, antihypertensive regime, current blood pressure measurements, along with any
previous history of vascular events, because not having this infonnation may lead an
investigator to underestimate the true stroke risk of an individual. This is also true for
controlled hypertension. 58 As Ishikawa et al reported, even controlled hypertensives had
a three-fold increase in risk of stroke as nonnotensives; however, this again could be
more due to the potential excess of additional risk factors that initiated the use of
antihypertension therapy, thus putting them at a greater risk of stroke. Therefore, an
investigator should not assume that an individual is not at risk for stroke based on their

14

blood pressure level falling within the normal range, because they may miss the fact that
they could be a controlled hypertensive or a pre-hypertensive on antihypertension therapy
for prevention. Even so, level of stroke risk can be assessed without hypertension control
infonnation as long as it is understood that the results will be an underestimate of the true
stroke risk.

Importance of Data Regarding Types of Antihypertension Therapy
Some studies including ALLHAT,41 ABCD,44 STOP-2,46 and FACET,45
suggested that angiotensin II increasing drugs, such as CCBs, ARBs, and diuretics, may
41
be more effective in reducing stroke risk compared to angiotensin II decreasing drugS. 43,49 However, these studies have failed to prove that it is the pathway by which these
drugs reduce blood pressure that accounts for the reduction in stroke risks and not the

"'~'~;':'1"

reduction in blood pressure itself that causes the reduction in stroke risks. 59
Thus, even though information regarding the level of hypertension control
achieved through the use of antihypertensive therapies 1is useful, it is not essential in
evaluating hypertension as a risk factor for stroke. The antihypertensive regimen informs
the investigator of the level of treatment the patient is receiving to achieve the blood
pressure level recorded in the data. Patients that were originally at stage I or II, or who
would be within that range if they were not on antihypertensive therapy, who are on
aggressive combination therapy may be at a much higher risk than a stage I or II that is
only on monotherapy at a standard dose. Thus, as Law et al suggested a patient that
could potentially be controlled with an increase or changing of therapy may appear to be
at the same risk as a patient that is a truly uncontrolled or resistant hypertensive. 37 Lawet
al and the Blood Pressure Lowering Treatment Trialists' Collaboration reported that each

15

of the classes of drugs were equal in reducing blood pressure and thus stroke risk. 37 , 38
Lowering the systolic blood pressure by 10 mm Hg and the diastolic blood pressure by 5
mm Hg attributed to a decrease in stroke risks by one-third regardless of prior blood
pressure measurements before treatment. 39, 60
The lower the blood pressure measurement below the normal range has shown to
be beneficial in reducing stroke risk. 37

Thus, as discussed in the Avoiding

Cardiovascular events through Combination therapy in Patients Living with Systolic
Hypertension (ACCOMPLISH) trial, it is more beneficial to know other modifiable and
non-modifiable risk factors in addition to hypertension; such as age, race, comorbidities,
and previous history because these factors contribute more to estimating stroke risk than
the level of blood pressure reduction and use- of·.antihypertensives. 6o , 61 The absence of
.,.~~/, ;~j"
'f

control and drug information may introduce a slight underestimate of stroke risk per level
of blood pressure control; however, you will know that the absolute risk of stroke in a
patient within a specific blood pressure category will

b~

included. Thus, any estimate

provided will only underestimate the true risk, because including the level of control and
antihypertensive data will increase the level of risk in the patient population.
It has been widely reported that one of the most effective methods to reduce
stroke risk is to reduce the incidence of hypertension. 35 ,

37, 47, 62

Hypertension poses a

major public health burden and will continue to do so if the lifetime risk of elevated
blood pressure remains unattenuated. Although it is very beneficial to know the level of
achieved hypertension control and extent of antihypertensive therapy in a population,
valuable research is attainable in the absence of this data as long as information is
available on additional risk factors that strongly effect the assessment of stroke risk. The
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value of lowering blood pressure to goal is greater than the mechanism by which it is
achieved.

Nonetheless, the consensus of hypertension treatment trials for stroke

reduction is that the lower the blood pressure level achieved, the lower the stroke risk
. d38 ' 40 ~ regardl ess 0 f th
'
'f
' 37 ' 39 ,
attalne
e aggressIveness
or comb'InatIon
0 treatment th
eraples.
47

Recurrent Stroke Definition
Investigators agree that prImary stroke patients are at an increased risk of
experIencIng a secondary stroke event; however, the definition of 'secondary' or
'recurrent' stroke is of much debate.

The most basic definition of recurrent stroke

reported by Couillard et al included "functional deterioration in neurological status or a
new sudden focal neurological deficit of vascular'"origin lasting more than 24 hours" ,16 It
'~'J"J' ~~)("
'/

is thought that the early risk associated with stroke is a recurrent stroke event; however,
Coutts et al showed that up to 90% of early clinical deterioration may not be a true
recurrent stroke but rather the progression of symptotps or infarct growth from the
primary stroke event. 16, 63 Several studies defined 'stroke' according to the World Health
Organization definition of "rapidly developing symptoms and/or sings of focal, and at
time global [subarachnoid hemorrhage], loss of cerebral function, with symptoms lasting
more than 24 hours or leading to death with no apparent cause other than that of vascular
origin".12,64 The studies further defined 'recurrent stroke' using the WHO definition in
which "( 1) there was clinical evidence of the sudden onset of a new focal neurological
deficit with no apparent cause other than that of vascular origin (ie. the deficit could not
be ascribed to an intercurrent acute illness, epileptic seizure, or toxic effect) occurring at
any time after the index stroke; or (2) there was clinical evidence of the sudden onset of
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an exacerbation of a previous focal neurological deficit with no apparent cause other than
that of vascular origin occurring> 21 days after the index stroke". 12, 13,65 Bravata et al
used the International Classification of Diseases, Ninth Revision, Clinical Modification
(ICD-9-CM) codes: 434.XX or 436 to define the index stroke and identify subjects at
increased risk for acute ischemic stroke.

The recurrent event and associated

comorbidities were then defined using the primary diagnostic related group (DRG) codes
to identify hospital readmission in which similar DRGs were grouped in closely related
subgroups (eg. Stroke: DRGs 14 and 16, TIA: DRG 15).18, 66 Hier et al further described
a recurrent stroke as a "cerebrovascular event subsequent to the index stroke that met one
of the following criteria: (1) the event produced a neurologic deficit different from that of
the index stroke, (2) the event occurred in an ,anatomic site or vascular territory different
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from that of the index stroke, or (3) the event was of a stroke subtype that was different
from that of the index stroke".19 However, in this study Hier et al used the Stroke Data
Bank in which any event occurring less than or equal to f 1 days post index stroke in the
same anatomic site or vascular territory were considered to be "evolving stroke" and not
"recurrent stroke", thus contradicting its own definition of recurrent stroke. 19
A majority of epidemiological studies exclude recurrent stroke events if they
occurred within the first 28 days post stroke or within 21 days in the same anatomic or
vascular territory.67, 68 However, several studies have suggested an increase in the risk of
recurrence during this early time period and thus using this definition could
underestimate the true recurrent stroke rates and therefore offset the importance of early
prevention techniques. 69 Studies excluding recurrent events occurring within the first few
weeks post stroke index report an average of stroke risk of 1% in 7 days and 2% at 30
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days; however, when investigators used more rigorous definitions of recurrent stroke the
risk increased to 10% at 7 days and 20% at 30 days.67, 70 Coull et al examined the 90-day
risk of recurrence using the three most common definitions of recurrent stroke: "(A) any
stroke > 24 hours after the incident event excluding early deterioration not caused by a
stroke, (B) same as A but excluding any stroke within 21 days in the same territory as the
incident event, and (C) any stroke 2: 28 days after the incident".67 Coull et al reported
that the 90-day risk of recurrent stroke was 18.3% using definition A, and 7.0% and 5.9%
using definitions B and C, respectively. 67 Thus, they suggest the use of definition A
which includes early stroke recurrence 24 hours post index stroke whenever possible to
avoid underestimating the true risk of recurrent stroke. 67 Most epidemiological studies
use the ICD-9-CM codes to identify stroke occurrence; however, the inclusion of the
.t.~
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codes varies between studies. 71 , 72 Tseng et al used all cerebrovascular codes (ICD-9-CM
430-438) to define stroke and included immediate readmissions 24 hours post stroke
event. 69 Feng et al excluded ICD-9-CM code 438 and 4~7 (except 437.1) whereas Allen
et al only included recurrent ischemic stroke using ICD-9-CM codes 433, 434, and 436. 14 ,
15

Such diverse use of definitions may cause an underestimation of the true recurrent

stroke risks, and lead to an underrepresentation of the importance of immediate
secondary stroke prevention techniques.

Recurrent Stroke Risks
The Oxford Community Stroke project and Ois et al reported a short term
increase risk of recurrent stroke within 7 days post TIA at 8.6% and 5.3%, respectively.16,
17 Several studies reported an increased risk of recurrent stroke at 1 month post index
stroke including approximately 1.2-3.3% of the subjects with Kaplan-Meier estimates of
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risk between 1.8-8.0% within the first 6 months. 12, 14 Dhamoon et al reported the risk of
recurrent stroke to be more than twice that of a cardiac event, including nonfatal MI at 1
month post index stroke. 73 The rate of recurrent stroke at 1 year post index stroke has
been reported from 6 to 27%, with an average of approximately 10%, and Kaplan-Meier
estimates as high as 12.5% within the first year post index stroke. 12-15, 74 Recurrent stroke
rates seemed to increase further when complicated by subtypes including carotid stenosis,
partial anterior circulation infarct, or events due to extracranial large-artery disease
approaching eight times that of small-vessel disease. 16, 70, 75 Andersen et al documented a
case-fatality rate of25-30% within one year and 60-70% within 5 years.13
Racial disparities have also been shown to be associated with increase in recurrent
stroke risk. Sheinart et al reported an increased, 'fisk for African-Americans relative to
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Caucasians of 2.4 (95% CI, 1.02-5.5) and Hispanics 2.9 (95% CI, 1.2-7.4).76 McGruder
et al showed an increased likelihood of receiving an "ill-defined" stroke subtype
diagnosis (ICD-9-CM 436-437) was 1.31 (95% CI, 1.28-l.33) among African-Americans
and 1.27 (95% CI, 1.20-1.34) among Hispanics. 77
Whether the secondary events are the progression of the original stroke or a
separate new event, prevention and treatment strategies are needed to reduce the
occurrence of recurrent stroke. However, to prevent such readmissions, it is crucial that
clinicians, researchers, and policy makers determine accurate estimations of hospital
readmission rates, associated and/or secondary diagnoses, and temporal patterns, as well
as identify an accurate definition for recurrent stroke.
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Comorbid Conditions Associated with Recurrent Stroke
Comorbid conditions including history of hypertension, diabetes, and arrhythmias
are thought to be associated with an increased risk of recurrent stroke. 16

Hier et al

showed that subjects with an elevated blood pressure, abnormal Computerized
Tomography (CT) scan, or with a history of hypertension, diabetes, or a blood glucose 2:
140 mg/dl were associated with stroke recurrence:::; 30 days.19 Friday et al also showed
an increased risk of recurrent stroke was associated with a DBP 2: 90 (RR 1. 73, p=O. OJ),
SBP 2: 140 (RR 1.69, p=O.06), history of hypertension (RR 2.15, p=O.OJ2), and
arrhythmia (RR 1.78, p=O.038).20 In addition to hypertension, aging seems to be one of
the most important independent risk factors for stroke, and advanced age, 2: 65 years, has
been showed to be an independent risk factor f9.~.',recurrent stroke.

78

Those subj ects over
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the age of 65 years have a 3-fold increased risk of recurrent stroke within the 10 years
following stroke index. 78 , 79
A few studies have used the Charlson Index

~omorbidity

scorIng system to

evaluate and control for comorbidities associated with primary and recurrent stroke,
which allows for the weighting of different factors based on disease severity.

Each

outcome is assigned a weight which is then summed to determine the outcomes score. 80
It was originally developed as a prognostic tool for general medical services, but it has
not been validated for stroke outcomes specifically. 81 A Charlson ~ s Index of > 2 was
considered a high comorbidity index. 80, 82 Goldstein et al reported a high Charlson Index
had a 36% increased odds of having a poor outcome at discharge and 72% increased odds
of death at one year. 81 Feng et al showed an increase hazards ratio for 1 year recurrent
stroke with a Charlson Index of 2: 2, hazard ratio (RR) 1.20 (95% CI, 1.05-1.37).14
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However, Tseng et al did not find an association between 1 year recurrent stroke and the
Charlson Index (p=O.094).69 Other comorbidity scoring indices used in recurrent stroke
studies include the Deyo Score which is based on the Charlson Index, and the ABCD
Score. IS, 17,
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The ABCD was recently validated and is based on a 6 point score using

clinical parameters to identify patients at a 7 day increased risk after TIA for recurrent
ischemic stroke. 17

Motor symptoms and speech impairment were associated with

recurrent stroke within 7 days post index stroke. I7
Prevention Methods for Recurrent Stroke

Several studies have examined various evidence-based intervention programs to
improve recurrent stroke rates. 16 Hackam et al suggested five specific interventions that
if appropriately used could reduce the risk of recurrent stroke as much as 80%.83 The
,,~.
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five interventions were dietary modification, exercise, aspirin, a statin and an
antihypertensive agent. 83 Both the Early Use of Existing Preventive Strategies for Stroke
(EXPRESS) and Lavallee et al' s SOS-TIA studies indjcated a reduction of recurrent
stroke risk by 80% also with hyper-acute evaluation and treatment post stroke index
event. 84,

85

Another study conducted by Andersen et al examined two intervention

strategies compare to standard of care. 13

One arm (INTI-HVP) received physician

intervention that consisted of three I-hour home visits at 2, 6, and 12 weeks post
discharge, in which the physician discussed early detection and treatment of
complications, functional capacity, and life style changes with the patient. The second
intervention (INT2-PI) was conducted by the hospital physiotherapist during the 6 weeks
after stroke discharge at the patients' home averaging approximately 3 times during the 6
week period. These patients received instruction and reeducation along with evaluations
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of functional mobility and daily living activities. The control group received "standard
aftercare", which included outpatient rehabilitation and home care for disabilities if
needed; however, there were no follow-up home visits. 13 The readmission rate for the
intervention groups were significantly reduced as compared to the control group (INTlHVP 26%, INT2-PI 34%, control 44%, p=0.028).13

The Preventing Recurrence Of

Thromboembolic Events through Coordinated Treatment (PROTECT) study was a
hospital-based study that examined a total of eight intervention programs consisting of
both inpatient and outpatient interventions. 86,

F our of the interventions focused on

87

appropriate discharge medication utilization consisting of in-hospital initiation on an
antithrombotic, a statin, an ACE/ARB, and a thiazide diuretic. 87 The remaining four
interventions focused on lifestyle modification changes consisting of smoking cessation
,/-' "I· ~~;r'
,

./

counseling, exercise counseling, diet counseling, and education about personal stroke risk
factors and the need to call 911 if new stroke symptoms occurred. 87 A "toolkit" was
provided to healthcare personnel to provide program guiflelines and treatment algorithm
to aid in clinical care decisions. The PROTECT program was shown to be associated
with a significant improvement in rates of hospital discharge treatment utilization, as well
as improved adherence and achievement of target biomarker goals. 87
Additional studies suggest prevention methods including, life style modifications,
family education, and specialty of the primary admitting physician to be neurologist or
neurosurgerist related; as well as early imaging to identify stroke subtype to tailor
treatment therapies immediately, all of which have been shown to be associated with a
reduction in risk of recurrent stroke. 16,

69, 88

Ay et al has developed a web-based

prognostic scoring system to quantify risk of early recurrent stroke within 90 days,
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referred to as the Recurrence Risk Estimator (RRE-90), which has demonstrated highquality predictive capabilities (receiver operating characteristic (ROC) curve area under
the curve (AVC) 0.70-0.80).89, 90 Thus if clinically validate, the RRE-90 could be a
promising tool for clinicians to evaluate recurrent stroke risk in the acute setting.
Healthcare providers are often too focused on the immediate management during
the acute stroke hospitalization and thus may miss the opportunity to institute evidencebased prevention strategies.

The long-term treatment is then deferred to the post

discharge clinical setting in which there is a risk of loss of adequate follow-up of care. 91 ,
92

Thus it is critical to develop specific guidelines with regards to patient and healthcare

provider education, therapy and treatment protocols, as well as patient data collection.
Secondary Preventative Treatments for Reeur,rent Stroke
"'''.J;~j',
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A meta-analysis of the Prevention Regimen For Effectively Avoiding Secondary
Stroke (PRoFESS)93 and Telmisartan Randomized Assessment Study in ACE-intolerant
Subjects

with

Cardiovascular

Disease

(TRASCE1)JD)94

studies

reported

that

antihypertensive therapy was efficient in reducing recurrent stroke, the most effective
intervention occurred with an ACE inhibitor + diuretic in reducing recurrent ischemic and
hemorrhagic stroke. 3s , 95, 96 The Heart Protection Study (HPS)97 and Stroke Prevention by
Aggressive Reduction of Cholesterol Levels (SP ARCL )98 studies reported a 16% risk
reduction in time to recurrent ischemic stroke with the use of atorvastatin (adjusted HR
0.84; 95% CI, 0.71-0.99) or Simvastatin; however, SPARCL reported an increase in the
incidence of hemorrhagic stroke for those patients on atorvastatin (OR 1.7; 95% CI, 1.192.50).95,98 It has been well documented that cholesterol-lowering medications taken post
stroke reduces the risk of a recurrent stroke; and SP ARCL may have contributed to the
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rise in statin utilization post stroke event. However, as recently reported by Schwarnm et
aI, as much as one in five stroke patients eligible for a statin are not being prescribed the
medication. 99 Many individual and hospital level factors may be to blame for the lack of
statin utilization, such as women compared to men and hospitals in the south compared to
the west having significantly lower odds of receiving a statin, 13% and 34%,
respectively.99 Antiplatelet therapy such as aspirin, dipyridamole, and clopidogrel have
been shown to be effective in reducing recurrent ischemic stroke reported by the
PRoFESS,100

Second

European

Stroke

Prevention

Study

(ESPS-2),101

and

European!Australasian Stroke Prevention in Reversible Ischaemia Trail (ESPRIT)102
studies. 95 The European Atrial Fibrillation Trail (EAFT)103 demonstrated a reduction in
risk of recurrent stroke to 4% in patients with· atrial fibrillation using anticoagulation
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therapy, Warfarin. 95, 103, 104 The European Carotid Surgery Trial (ECST)105 and North
American Symptomatic Endarterectomy Trial (NASECT)106 studies suggested that
carotid endarterectomy was the procedure of choice iV reducing recurrent stroke for
patients with TIA or minor stroke with greater than 70% ipsilateral carotid stenosis. 95 , 105,
106

Examination of these studies reinforces the importance of the need for efficient

therapies to prevent stroke recurrence as well as to prevent related cardiac events.
Cucchiara et al developed a systemic diagnostic evaluation summary to guide
clinical decision making and optimal treatment regarding prevention of recurrent stroke
based on the index cerebrovascular event. I07 The first step is to detennine the cause of
the initial cerebrovascular event: large-vessel atherosclerosis, cardioembolism, small
vessel disease, or cryptogenic. If the index stroke involves large vessel atherosclerosis
then carotid endarterectomy and antiplatelet therapy should be considered.
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If it is a

cardioembolism, an anticoagulant agent should be the course of action; and for both small
vessel disease and cryptogenic causes, antiplatelet therapy should be considered as well.
For all causes of initial stroke, utilization of blood pressure lowering therapy, statin
therapy and risk factor modification should be addressed. l07
Elderly stroke patients above the age of 80 years may require additional attention
when deciding treatment strategies that will benefit the patient. Nedeltchev et al found
that elderly patients were more often prescribed clopidogrel (p<O.OOOl) and heparin
(p=O.047), whereas aspirin was more common among the younger patients (p=O.016).108
The Hypertension in the Very Elderly Trial (HYVET) showed that antihypertensive
therapy is beneficial in nearly all stroke cases regardless of the patients' age, even above
80 years. 78 , 109
"~~I
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Lalouschek et al showed a high inter-hospital variation in regards to post-acute
stroke medication and therapy utilization. 11 0 Difference between clinical practices and
explanations of reasons for prescribing specific medicatipns were evident, and thus the
need for specific guidelines remains imperative, 110

Occlusion and Stenosis of Precerebral Arteries (433.xl) Inclusion
The

International

Classification

of Diseases,

Ninth

Revision,

Clinical

Modification (ICD-9-CM) uses a coding system to manufacture administrative databases;
however, it has been discovered that using the ICD-9-CM classifications designated for
dlice some co d'lng b'las or mlsc
. Iassl'filcatlon
' 0 f d'lsease, 111-113 In
.
strok e events may lntro
October 1992, a modifier fifth digit was added to the ICD-9-CM codes 433 and 434,
Occlusion and Stenosis of precerebral arteries and cerebral arteries, respectively,114 The
fifth code was designated as "0" without cerebral infarction and "1" with cerebral
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infarction. Thus, ischemic strokes were identified using codes 433.xl and 434.xl, where
the forth digit designated the specific arterial distribution, ie. 433.0x Basilar artery,
433.1x carotid artery, etc. Using this fifth digit modifier code allowed an increase in
specificity and positive predictor value for diagnosing ischemic strokes versus nonstrokes. Ill,

114

The few studies that have incorporated this fifth digit coding technique to

determine stroke diagnoses have specified their subjects based on "presentation type"
labeled Symptomatic or Asymptomatic. 1l5 - 119

Investigators incorporated the subjects

ICD-9-CM procedural codes matched with the diagnostic codes to determine presentation
type. Occlusion and stenosis of both the precerebral and cerebral arteries are known to be
associated with carotid endarterectomy (CEA), angioplasty/atherectomy of precerebral
vessels, and carotid artery stenting (CAS), ICD.:?,,-CM procedure codes 38.12, 00.61, and
'>"J~;' '~J("'
,

00.63, respectively.ll8
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Thus, as McPhee et al described, subjects with a primary

procedure discharge code for CEA or CAS with an accompanying diagnostic code for
carotid stenosis with (433.11) or without (433.10) cerebr'll infarction were considered for
their study.ll8,

119

The investigators further classified the subjects using secondary

diagnoses in any position of "carotid artery stenosis without mention of stroke" with no
accompanying secondary diagnosis of TIA were classified as "asymptomatic".
"Symptomatic" subjects were classified if they had a "carotid artery stenosis with stroke"
diagnosis or if there was no mention of stroke but one of the secondary diagnoses
included TIA. 119
In the McPhee et al study of carotid artery stenosis subjects; they found that
approximately 92.1 % of the subjects were classified as "asymptomatic''', where 7.9%
were classified as "symptomatic" and among these, 4.2% experience a TIA and only
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3.7% experienced a true stroke. 119 In-hospital mortality, OR 3.5 (95% CI, 2.4-5.3), was
significantly associated with symptomatic presentation type when compared to
asymptomatic subjects. 118, 119 Additional studies have found similar findings~ Klijn et al
reported an annual risk of 5-8% of recurrent ischemic stroke with symptomatic internal
carotid artery patients. 12o Leibson et al reported that only 60% of the total stroke patients
identified using ICD-9-CM codes of 430-438.9 were found to be true incident or
recurrent strokes; 113 and Benesch et al found that more than 85% of those patients
diagnosed with an ICD-9-CM code of 433 were actually asymptomatic and thus did not
experience a true stroke event. 112
Another ICD-9-CM coding bias for stroke cases is the coding for post cardiac
surgery or in-hospital stroke events. 121 In-hosp\t~l stroke cases were identified by ICD-9"'~~;' '~/"

,
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eM codes 997.0,997.00,997.01, and 997.02 for post-operative stroke. 1l9, 122 McPhee et
al found that presentation with symptomatic stroke, 433.11, was an independent predictor
of postoperative stroke, OR 2.8 (95% CI, 2.1_3.8).119
Before defining stroke in an epidemiological study it is import to first identify the
goal of the study. If the goal is to detennine trends and patterns of stroke incident and
treatment regimens then using an inclusive definition of stroke, ie 434-434 and 436,
would

se~m

advantageous because this would incorporate all subjects at risk for stroke.

However, if the goal is to examine specific characteristics of acute stroke, then modified
codes should be examined to eliminate potentially high proportion of non-stroke or
asymptomatic cases as to not overestimate the true stroke incidence. I 11
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Validation of Administrative Databases

Administrative data in regards to the medical field are electronic data records that
contain information typically generated for purposes other than scientific research, such
as billing and insurance claims. However, the idea of using such databases to answer
clinical and public health questions was expressed nearly 40 years ago.

White et al

stated, "Parsimonious collection of a minimal data set, through hospital patient discharge
abstracts and claims forms that relate persons, health problems, and hospital charges to
populations and institutions, has more power to influence medical care costs, hospital
utilization, standards of care, and health-services planning than any other health
information system likely to be available in the foreseeable future".123 Nowaday, the
potential of large population-based databases· have been proven and well document and
.4.
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are now available through numerous sources including state, federal, and private
foundations. Although administrative databases are becoming more popular in clinical
research, it is important to understand and address the

str~ngths,

weakness, and bias when

'1"
ut1lzlng
suc hd.c
ata lor researc h purposes. 111124
'

Medical claims administrative data are usually collected at time of hospital
discharge and contains several parameters to include primary and secondary diagnoses
and procedures, date of admission and discharge, discharge status, insurance provider,
and various charges. These types of data can often be linked to other data sources that
contain demographic_ information on individual patients, including age, race, sex, and
county/ zip code of residence, all at the individual level. However, administrative data
can be linked to group-level data as well. 125 This includes combining personal level data
such as death certificates, surveys, disease registries, and medical charts to group level
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data such as United States Census Bureau, area resource files, and the American Hospital
Association in one comprehensive administrative database. 125 Combining such data will
serve to increase the use and effectiveness of both data sources for its role in clinical and
epidemiological research.
Using administrative data allow quick access to readily available and up to date
information over an extended period of time and across multiple regions.

Volume

outcomes analyses can also be assessed using administrative data. The efficiency and
quantity of diagnostics and procedures of both physicians and hospitals can be assessed
based on case-load volumes. 126, 127 One of the most valuable uses of administrative data
are for trend analyses, in which one can assess a disease state or procedure usage over
several years or decades at the state or natioqal level to evaluate changes over long
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periods of time. 126
Applications of Administrative Data

One of the most important strengths of administrative data are "population
coverage", providing detailed information across populations especially regarding
diseases that are rare, have infrequent end-points, have low incidence of events/
outcomes, and those diseases that are difficult to study. 125, 128, 129 Administrative data can
be used to complement randomized clinical trials (RCT), and even have some advantages
over clinical trials. In particular, administrative data are much less expensive and time
consuming, because data are readily available at the individual level and are often kept up
to date at least within the previous year. 126,

130

This level of research is beneficial to

population-based analysis in ways that a randomized clinical trial is not. This is true for
several reasons. First, the exclusion criteria for administrative data are not as stringent as
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that of RCTs and thus are more generalizable with less concern regarding selection
bias. 126, 131 Second, they lend themselves to more of a "real world" view of a disease or
an intervention, whereas RCTs are studied under tightly controlled environments which
are often hard to interpret how interventions will perform in the general population. 132
Descriptive analyses are complimented by administrative data in that it is relatively easy
to assess a specific disease in relationship to demographic distributions, such as age, race,
insurance, etc., and more importantly with mortality, morbidity, and readmission rates. 132
Since administrative databases tend to include a substantial number of patients and
observations, obtaining statistical power is less of a concern, even when examining subset
populations within the database, In addition, having a large number of subjects lends
itself to research on rare outcomes or that which would be considered unethical in a
,,'~ ~I ';~/'-

RCT,126
Along with the extensive sample SIze, the time lapse between the patient
admission and availability of the data in administrative

d~tabases

are significantly shorter

than manual chart reviews and are substantially less costly,124 Additionally, as Roos et al
pointed out, the loss to follow-up is less in administrative data than in usual prospective
Th'IS may especla
, 11y b e true WIt
' h M e d'lcare d ata. 124' 125
'
stud lese
A number of studies have addressed the validity of the information in
administrative databases, and although there are mixed reviews in the literature, a
majority tend to support the validity of the data; as well as the levels of agreement with
patient medical records and self-report surveys.124, 133 A study conducted by Muhajarine
et al examined a cohort of hypertension patients to compare the physician claims data to
patient self-report survey data.

The investigators found a relatively high agreement
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between self-reported and physician claims data (82%, kappa = 0.56), and an 85% (kappa

= 0.60) agreement between clinically measured data and physician claims data for
hypertension; thus each record method can confidently be used to assess hypertension. 134
When assessing mortality in patient level data it is important to consider a risk adjusted
mortality index to compare patients with similar comorbidities and characteristics. This
allows the control of severity of disease between subjects, which has been extensively
validated by DesHarnais et al. 135

Additional analytical components that have been

validated in regards to administrative data are weighting strategies to compare hospital
level data. 136

Weighting is needed when comparing hospitals because of known

associations of outcome measures with bed size, teaching status, patient volume, and
geographical location. This ensures that the confounding parameters are generalized to
':··~;I·;~)r·

the national distribution of hospitals so that a large volume hospital does not
underestimate the outcomes measured. 136
Several studies have examined the use of prim,ry versus secondary diagnosis
codes in classifying stroke events. Both Tirschwell et al and Benesch et al reported that
using only the primary discharge diagnosis code for identifying stroke events maximizes
the specificity and predictive positive value, and thus a stroke diagnosis in the secondary
discharge diagnosis position should not be considered as a stroke incident. U sing only
the primary stroke diagnosis increases the likelihood of diagnostic code agreement with
the medical record review. 112, 114
An important aspect of administrative data that should be considered and makes
its use easier than manually collected data is the fact that most databases offer anonymity
to the individual; however, there is usually a unique personal identifier of sorts that
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allows the linkage of one dataset to multiple additional datasets over various amounts of
time with ease.

Thus, a patient can be longitudinally tracked throughout several

databases while maintaining complete confidentiality.l30

Another vital aspect is the

ability to assess physician specific data while ensuring anonymity to the physician as
well. Unlike direct observation and chart audits, administrative data can assess patientphysician interaction to monitor quality of care over time. Thus, quality of care provided
by the physician plus quality of care the patient is receiving

c~

be examined because

physician identifiers are provided, thus all relevant care can be assess regardless of which
physician treated the patient. 130 This allows the monitoring of patient coverage from
provider to provider. Also, the physician perspective can be examined to detennine the
physicians' patient population characteristics which may lead to improvements in quality
'/~;I

.¥.,

of care. Treatment to target indicators could be addressed as well, and comparisons
between physicians, hospitals, or even regions can be assessed and compared to national
standards. 136

Esposti et al used health care claims d~ta to measure continuation of

antihypertensive therapy use.

This retrospective population-based study found that

discontinuation of antihypertensive therapy was associated with younger age, lower
prevalence of previous hospitalizations for cardiovascular disease, and lower prevalence
of related comorbidities (all p<O.OOl); thus supporting the use of claims data for
pharmacoepidemiological studies. 137 Other study designs that are easily assessed using
administrative data are economical and cost analysis.
Caveats of Using Administrative Data

Although there are many advantages to using administrative data, there are some
limitations that must be considered as well. First, the database was originally established
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to collect billing data and thus not specifically for scientific research; which leads some
researchers to be skeptical of its use because it is in essence "secondary" data and thus
will have inherent biases. 138,

l39

The second major downfall is that most of these

databases include limited clinically relevant parameters. They often do not contain lab
results, or hemodynamic and clinical measures such as blood pressure, height, weight,
etc. The parameters that are generally included are those that are typically needed for
billing and insurance claim purposes. Thus, information on severity of disease, grading
scales, and size or stage of tumors is missing. 125 Therefore, it is important to consider
possible severities in disease states when comparing group-differences, because some
confounding may occur between the groups. Sometimes, the known confounding factors
cannot be controlled because the information.is not available in the database. As well,
,.,.,,~/ ..~;..
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some unknown or unmeasured confounders may exist that are not accounted for and may
affect study findings. 126 However, if the differences are still large even after adjusting for
confounders, then it is likely that the differences cann?t be explained by residual or
unknown confounders. 127 In addition, some important end points such as quality of life,
functional status, and medication adherence are often missing in administrative data.
Administrative data, even though from a single source, often collect data on select
groups of people such as private or public insurances and are usually stripped of personal
identifiers. 129 This can make it difficult to study readmission rates, transfers to facilities
not included in the data system, and even death. 129 Combining databases can also pose a
problem if they vary in content or format. The accuracy of administrative data has also
been called in to question due to miscoding andlor undercoding.

Much of what is

recorded in the claims record is for billing purposes which introduces several biases. 130,
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140 First, the data only includes the visit for which the patient will be billed, which may
not necessarily be the reason for the visit.

Plus, as reported by Katz et aI, many

physicians have admitted that they do not pay attention to detail when coding and often
rely on codes that they use most often or have memorized. 130 . The most reported codes
are those that are directly associated with payment, thus important clinical measures may
not be included or if included may be unreliable in quality.141 Another bias to consider
with administrative data is that only the information on the diagnosed condition will be
included, thus chronic conditions or hard to diagnose conditions may be under diagnosed
as compared to prospective studies. Also, the data only include information on the care
received (or that which is being billed), thus services that are not covered or were not
charged for will not be included. 125

There is no information about additional or

"'~'I'Y'

alternative treatment options or diagnoses that were discussed between the patient and the
provider. Therefore, the data cannot be used to assess how a patient should have been
treated or diagnosed. 125
Another problem that arIses with International Classification of Diseases, 9th
reVIsIon - Clinical Modification (ICD-9-CM) coding methods

is

overcoding.

Reimbursement IS usually based on the complexity of a patient's disease, thus
unintentionally encouragIng hospitals and physicians to overcode for prImary and
secondary diagnoses. This is referred to as diagnosis-related group (DRG) creep. 142 This
is true for reimbursement with pay-for-performance physicians as well. 142 This could
pose a limitation when evaluating stroke diagnoses using administrative data with ICD-9CM codes.

If physicians use the more complex stroke diagnosis code or includes

additional secondary diagnoses that may not be relevant to the stroke event, the analyses
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could be misleading or find associations between comorbidities that aren't truly there.
Thus, interpreting findings of administrative data must be done with caution.
Another drawback of administrative data that could affect stroke analysis is that
each observation is equivalent to one hospitalization, thus one patient may be recorded
several times in the same dataset if they were admitted multiple times during the study
period. If a patient was transferred or moved to another facility that was included in the
database, it may appear as if the patient had multiple events but in reality the second
observation was due to changes in status or billing reference. 129 This could cause an
overestimation of patients with comorbidities; this is especially true with stroke patients,
in that they are often admitted several times for cardiovascular complications or
conditions that eventually contribute to their stroke event.
,>"~.:,.~j>

Therefore, the number of
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entries must be controlled by the date range to prevent bias in estimating comorbidities.
When basing assessments in administrative data using ICD-9-CM coding, it is impossible
to know whether a secondary diagnosis was made pripr to the admission or during
hospitalization. 129 This could create interpretation bias when assessing the association of
comorbid conditions and stroke events. If the patient was not hospitalized for a specific
event prior to the stroke then it will be impossible to tell if the patient has had the
condition for many years or if it was a recent development.

This could lead to

overestimating the association of a specific comorbidity with primary and secondary
stroke risks. 143 The amount of time a patient has been living with a chronic condition,
such as diabetes or hypertension, is highly relevant in determining level of stroke risks.
Thus one possible way to address this is to only include patients that have a prior primary
or secondary diagnosis of the comorbidity and those who do not have a diagnosis of the
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comorbidity at any time prior to or during the stroke hospitalization (excluding those
patients with first appearance of comorbid diagnosis at time of stroke hospitalization).
This will allow the comparison between those with a known comorbid condition with
stroke and those who do not have the condition.

Malenka et al suggested that

comorbidities often appear more frequently in charts than in administrative databases;
however, several studies have stated that the inaccuracy can be successfully controlled
using comorbidity adjustment algorithms for administrative-based data. 144, 145
Assessing true healthcare cost can be restricted when using administrative data
because often the only diagnostic or procedural information provided is that which was
actually billed for by the hospital. 146

As well, the only demographic data available

usually pertain to the information that is needed to process payments.
'>~.J

I'

Thus, items

recorded the most in administrative data are those that are directly linked with payment.
Likewise, items that are not specifically billed for are often not included in the database,
such as counseling or training provided during the adI1fission period. The lack of or
intentional recording of occurrences or procedures can skew cost analysis in either
direction by underestimating or overestimating the true cost of the health care that the
patient received during the admission period.

If professional fees and/or Medicaid

reimbursement rates are factored into the charges, they may be much lower than would
be charged for private insurances, this too can skew the true cost of care per patient. 146
Statistical Considerations with Administrative Data
The statistical significance and the interpretation of administrative data should be
taken into account as well. If the sample size is quite large, very small differences can be
detected as statistically significant; however, these differences may not be clinically
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meaningful. 126 Assessing clinical relevance is also important when using these types of
data to compare multiple hospitals or regions. Weighting the grouped data is one way to
alleviate this concern; however, weighting can have a considerable impact on the
interpretation of the results. 129 Weighting may result in smaller confidence intervals and
standard errors, which may cause the results to appear highly significant and thus give the
impression that the parameters of interest are more important than they might actually
be. 129 It is important to form hypotheses before conducting research using administrative
data to prevent data mining. Data mining has an increased risk of type I error and thus
may lead one to false-positive results. 126

When examining subsets or performing

multiple comparisons, Bonferroni adjustments should be performed to decrease the risk
of type I error. 126, 147
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Although accessible, the Medicare database using the Universal Billing (UB-92)
format has its share of limitations. The primary method used to code the services and
diagnostics is the ICD-9-CM coding system which is of¥n imprecise and contributes to
ambiguity in the data. In particular, this system cannot distinguish between comorbidities
and complications of a disease. Chronic comorbidities that are unrelated to the primary
reason for the visit may not be included in the secondary diagnosis codes; thus more
acute conditions may "crowd out" chronic conditions that may contribute to length of
stay, greater resources used, etc., such as hypertension and diabetes. 148, 149
Before the use of administrative data we lacked the ability to connect information
systems and thus could not track the degree of progress in the health care system over
time. However, administrative data only provides an indirect view of the system, thus it
is not an assessment of the actual care that was given. ISO,
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151

This disconnect inhibits risk

factor and disease surveillance and early detection of epidemiological events. 152 The
validity of administrative data can only be as good as the quality of the original medical
data.
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Preliminary Studies

This project was closely linked with the efforts of the Stroke Education and
Prevention - South Carolina (STEP-SC) project. The mission of STEP-SC was to assess
changes in secondary stroke prevention parameters in response to the need to reduce
strokes in South" Carolina. The STEP-SC database was comprised of stroke
hospitalizations in South Carolina for the discharge period 1996-2009. The state's South
Carolina Office of Research and Statistics (SC ORS) is responsible for collecting and
maintaining data on all hospitalizations in the state. These data contain information on
demographics, diagnostic and procedure codes based on the International Classification
of Diseases 9th Revision (ICD-9-CM) Clinical ,Modification, admission and discharge
Y~.~'
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dates, discharge disposition, and insurance status. The SC ORS provided the study
investigators with a de-identified analytical database comprised of hospitalization records
from the discharge period of 1996-2009. STEP-SC ""as approved by the Medical
University of South Carolina's Institutional Review Board.
Study Population

The preliminary study cohort consisted of 142,791 subj ects discharged with a
primary diagnosis of stroke (ICD-9-CM 430-438) who were at least 45 years of age for
the discharge period 1996-2009 in South Carolina. Stroke sub-types were classified by
ICD-9-CM codes to include ischemic stroke (433, 434, 436, 437.1), subarachnoid
hemorrhage (SAH: 430), intracerebral hemorrhage (ICH: 431, 432), and transient
ischemic attack (TIA: 435).153 Comorbidities to include hypertension (ICD-9-CM 401),
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diabetes (ICD-9-CM 250), and hyperlipidemia (ICD-9-CM) were based on the nIne
secondary discharge diagnosis codes.
This focus of this preliminary study was to assess racial and age differences
among the stroke cohort. There were 28% African Americans and 72% Caucasians
represented in the database; however, less than 1.3% of the population was classified as
other races/ethnicities and thus the analyses were limited to Caucasians and African
Americans only. Age was categorized in ten-year age ranges from 45-54, 55-64, 65-74,
,

75-84, and 2: 85 years of age. Additional analyses on age were stratified by age less than
65 and 2: 65 years of age.
Insurance status was classified as Private, Medicare, Medicaid, or Not Insured. Inhospital death and Disposition (sub-divided. in. to discharge Homel Home Health or
".~ ~~. ;~j'
,

,I

discharged to rehabilitation, nursing home, or long-term care facility) were based on
discharge disposition codes provided by the ORS hospitalization database; as well as
length of hospital stay (days). Comorbid conditions rased on secondary discharge
diagnoses and were classified using the Modified Charlson Index score dichotomized as
low comorbidity burden (index 0 or 1) or high comorbidity burden (index 2: 2).80, 81
The STEP-SC dataset provides a fifteen year assessment of stroke hospitalizations
and related risk factors from baseline to stroke event( s) per subj ect. These data allowed
us to examine secular trends in stroke hospitalizations and to assess underlying
demographics, outcomes, and comorbidities of stroke hospitalizations.
Statistical Analysis

Age and race-specific stroke hospitalization rates were based on the US Census
Bureau population estimates for discharge year 2008, per 100,000 population. 154
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Univariable mixed effects logistic regression models to include a random intercept were
used to compare proportions of recurrent stroke for race (Caucasian! African American),
age «65/65+), and presence of comorbid conditions for hypertension, diabetes, and
dyslipidemia, given age, race, and gender in the analyses. Univariable mixed effects
logistic regression models were used to assess the relationship between age «65/65+)
and race (Caucasian! African American) on comorbid conditions and stroke related
outcomes. Mixed effects models with best subsets regression methods were used to
determine the best model to predict the influence of race on age and stroke related
outcomes. Model fit was examined using the Akaike Information Criterion (AI C). Mixed
effects models with random intercepts were performed using PROC NLMIXED in SAS
9.3 (Cary, NC) to manage the very large sample.size used in this analysis. All statistical
'>'J;;, ..~j-'

analyses were performed with SAS 9.3 (Cary, NC) and were considered significant at the
< 0.05 two-sided level of significance.
Results

There were a total of 142,791 unique stroke hospitalizations in SC from January
1, 1996-December 31,2009 among African Americans (28%) and Caucasians (72%). Of
these hospitalizations 45,994 (32%) were less than 65 years of age (average age 70.4 ±
12.1). Table 1 displays the characteristics of hospitalized stroke patients from 1996-2009.
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Table 1. Characteristics of hospitalized stroke patients in South Carolina, 1996-2009
Characteristics
Race
African American
Caucasian
Age
45-65 years
~ 65 years
Gender
Male
Female
Comorbidities
Hypertension
Diabetes
Hyperlipidemia

N (142,791)

%

39,846
102,945

27.9
72.1

45,994
96,797

32.2
67.8

65,778
77,011

46.1
53.9

90,814
40,945
39,770

63.6
28.7
27.9

Of the 142,791 stroke hospitalizatiorl~}o/893 (60.2%) were admitted for ischemic
stroke, 12,916 (9.0%) for subarachnoid hemorrhage, 3,003 (2.1%) for intracranial
hemorrhage, 36,325 (25.4%) for transient ischemic attack, and 4,654 for other or i11defined stroke. A majority of the cohort was coveredtby private insurance (57.8%),
whereas on 20.7% were covered by Medicare, 9.6% by Medicaid and a total of 120/0 of
the patients were not insured.
African Americans had significantly higher proportions of stroke at age < 65
compared to their Caucasian counterparts, and significantly lower rates among the 65
years and older compared to Caucasians (P

=

0.0005). The characteristics of stroke

hospitalizations by race are displayed in Table 2 and Figure 1; and characteristics
stratified by age 45-64 years,

~

65 years, and all patients comparing African Americans

and Caucasian stroke patients are displayed in Table 3.

43

Table 2. Characteristics of hospitalized stroke patients by Race
Total
African American
Caucasian
Characteristics (%)
(n=142,791)
(n=39,846)
(n=102,945)
p*
Age
45-65 years
32.21
28.05
42.96
~ 65 years
67.79
57.04
71.95
0.0005
Gender
Male
46.07
43.63
47.01
Female
53.93
52.99
0.0013
56.37
* P values of African Americans compared with Caucasians based on mixed effects
regression analyses.
80

o Caucasians
P 'value 0.0225

rn African Americans

70
60

...c::

50
p 'value 0.0133

~ 40

Y J ·.I - ~;··

~

Q,)
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p 'value 0.0058

30
20

10
0
Hypertension

Diabetes

Hyperlipidemia

Figure 1. Racial comparison of comorbid conditions among stroke cohort
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Table 3. Characteristics of Hospitalization: Racial Comparison stratified by Age Group
45-64 Years Old
Characteristi cs
Age, mean (SD)
Sex, % male
Stroke subtype, %
Ischemic
Subarachnoid
hemorrhage
Intracranial
hemorrhage
Transient
Ischemic Attack
Insurance status, %
Private
Medicare
Medicaid
Not Insured
Comorbidities, %
Hypertension
Diabetes
Hyperlipidemia
In-hospital death, %
Disposition, %
Home
Care Facility, %
Length of stay,
mean (SD)
Comorbidity, %
Low burden
High burden

2: 65 Years Old

All Patients

AA

CA

AA

CA

AA

CA

(17,117)
55.2
(5.6)
51.46

(28,877)
56.6
(5.6)
55.7

(74,068)
77.3
(7.5)
43.6

(39,846)
67.6
(12.9)*
43.63*

(102,945)
71.5
(11. 7)
47.0

t
59.58

59.34

(22,729)
77.0
(8.0)
37.73*
*
64.31

63.21

t
62.29

62.14

3.78

4.44

1.31

1.20

2.36

2.10

14.96

7.84

9.43

8.64

11.79

8.41

21.68
*
44.5
24.5
15.5
15.6

28.39

24.95

26.95

27.35

64.9
18.7
6.3
10.1

5.9
92.1
1.2

5.7
93.7
0.2
0.4

23.55
*
22.4
63.1
7.3
7.1

69.85
37.96
27.35
6.32

61.0
27.4
35.5
4.21

62.3
24.1
27.2
6.90

67.94t
38.17t
23.47t
6.83t

61.9
25.0
29.6
6.15

73.98
26.02
7.0
(14.4)*

84.31
15.69
4.4
(8.7)

70.41
29.59
4.7
(5.9)

66.72
33.28
6.6
(11.5)*

74.37
25.63
4.6
(6.8)

86.31
13.69

89.10
10.90

>~;,~
66.51 *
38.34*
20.54*
7.21
*
61.22
38.78
6.3
(8.7)*
*
80.60
19.40

,

22.2
74.9
1.9
3.1

t
86.04
13.96

83.05
16.95

86.90
13.10

* P< 0.0001 and t P< 0.05, when compared with Caucasians based on mixed effects
regression analyses. AA, African American; CA, Caucasian; number is parentheses
represents number of patients in each race group.
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Assessment of secular trends and financial burden

Racial disparities in stroke patients have been well documented but trends of
disparity in the past decade are not clear. Using data from the state uniform billing
hospital discharge database, patients discharged with a primary diagnosis of stroke from
2001 to 2010 were identified. Age, race, stroke subtype, group-specific stroke
hospitalization rates, and hospital charges were compared over the 10 years period.
There were 89,357 stroke hospitalizations from 2001 to 2010.

Stroke

hospitalization rates decreased in all age-race groups but less significant in younger
groups (Figure 2). Rates were persistently higher for AAs in all age groups, but the racial
disparity was more pronounced in the younger group across all stroke subtypes (Figure

3). The highest disparity exists in the 35-4,5 year old group with intracerebral
"'~;1:1"

hemorrhage. Ten year hospital charges totaled $3.0 billion; 39.0% ($1171.0 million) of
this total were attributable to racial disparities, 88.6% ($1037.9 million) is from the < 65
years old group (Table 4).
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Figure 2: Stroke Hospitalization Rates per 100,000 Population by Age and Race in South Carolina from 2001 to 2010
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Figure 3: Average Stroke Hospitalization Racial Disparity Rate Ratios from 2001 to 2010 by Stroke Subtype
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Table 4. Total Hospital Charges and Charges Attributable to Racial Disparities
Year
Stroke
Total charges
Charges attributable to
Charges attributable to
(ATS, ICH,SAH)
racial disparities
racial disparities among
Hospital izati on
(AIS; ICH; SAH)
patients < 65 years old
(n)
(ArS; rCH; SAH)
$85.2 Million
$69.1 Million
10,164
$241.8 Million
2001
(183.1,39.1; 19.6)
(57.2; 26.1; 8.1)
(38.1; 27.1; 8.5)
$250.8 Million
$83.7 Million
$74.1 Million
9,595
2002
(54.2; 24.8; 13.2)
(42.9; 25.8; 9.1)
(191.1; 37.0; 22.8)
$80.1 Million
8,967
$257.0 Million
$106.1 Million
2003
(193.7, 42.7; 20.7)
(72.4; 27.9; 13.0)
(46.4; 29.2; 8.9)
$273.0 Million
$107.6 Million
$87.1 Million
2004
8,659
(44.5; 40.0; 8.8)
(68.6; 35.6; 10.0)
(194.8; 51.7; 26.5)
$116.0 Million
$107.3 Million
2005
8,845
$306.1 Million
(58.7; 44.8; 7.2)
(221.2; 55.7; 29.1)
(72.3; 9.84, 7.4)
$113.5 Million -,~$95.5 Million
$293.0 Million
8,738
2006
(52.0; 44.5; 7.0)
(72.1; 44.2; 7 .8) ~,".
(214.8; 58.0; 20.2)
$133.1 Million
$131.9 Million
2007
8,574
$324.0 Million
(76.3; 57.1; 12.6)
(68.3; 56.4; 12.6)
(222.8; 68.6; 32.6)
$121.6 Million
$332.3 Million
$t26.9 Million
8,609
2008
(232.3; 70.6; 29.4)
(73.3; 52.2; 23.2)
(61.3; 50.3; 21.0)
$365.1 Million
$145.4 Million
$133.1 Million
2009
8,564
(92.3; 52.5; 12.6)
(76.8; 46.4; 13.2)
(256.5; 72.8; 35.8)
$361.9 Million
$138.1 Million
2010
8,642
$153.6 Million
(76.9; 54.5; 10.9)
(255.9; 73.0; 33.0)
(89.9; 62.4; 15.0)
$3.0 Billion
$1037.9 Million
$1171.0 Million
Total
58,272
(2166.2;.569.2; 269.6) (728.5; 425.9; 209.01)
(565.8; 418.5; 107.~)____
<'\.:-~
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Charges attributable to
racial disparities among
patients 2: 65 years old
(ArS; ICH; SAH)
$24.9 Million
(20.7; 4.3; 0.4)
$17.8 Million
(12.6; 4.3; 4.1)
$33.9 Million
(27.4;4.2; 3.8)
$30.7 Million
(25.5; 3.6; 1.5)
$20.4 Million
(15.0; 7.3; 0.2)
$28.7 Million
(22.4; 7.0; 1.1)
$23.5 Million
(13.6; 11. 7; 1.0)
$21.5 Million
( 13 .9; 10.2; 2. 7)
$31.2 Million
(22.1; 13.6; 0.2)
$33.2 Million
(18.8; 15.2; 4.0)
$265.8 Million
(162.74; 191.9; 19.1)

Hospital charge data was inflated to 2010 dollars based on the US Bureau of Labor and Statistic's Consumer Price Index. Hospital charge attributable to racial
disparities = (age group specific stroke hospitalization rate in AA - age group specific stroke hospitalization rate in CA)*average of charges of each
hospitalization*total nunlbers of patients in each age group. AIS: Acute Ischemic Stroke; ICH: intracranial hemorrhage; SAH: Subarachnoid hemorrhage.
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Research Design and Methods

This dissertation project was closely linked with the efforts of the Stroke
Education and Prevention - South Carolina (STEP-SC) project. The mission of STEP-SC
was to assess changes in secondary stroke prevention parameters in response to the need
to reduce strokes in South Carolina. This dissertation project utilizes data from a statewide patient-based analytical database provided by the South Carolina Office of Research
and Statistics (ORS), Columbia, SC in conjunction with hospital-based data collected via
telephone survey of a stroke cohort from the Medical University of South Carolina. The
state-wide and hospital-level data were link by the SC ORS. This dissertation project was
Institutional Review Board. The
approval by the Medical University of South Carolina's
..... ,
,,~./
,
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overall goal was to develop hospital-based and community-based interventions to
improve secondary stroke prevention compliance. The primary objective of this study
focused on changes in stroke risks and related qua\ity indicators associated with
secondary stroke.
Summary of State-wide Data Source

The state-wide database was comprised of stroke hospitalizations in South
Carolina for the discharge period January 1, 1999 to December 31, 2010. The patientbased stroke hospitalization data were provided by the South Carolina Office of Research
and Statistics, Columbia SC and included information on demographics, diagnostic and
procedure codes based on the International Classification of Diseases 9th Revision (ICD9-CM) Clinical Modification, as well as admission and discharge dates for stroke
hospitalizations in South Carolina. Stroke cases included all subjects who were at least
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45 years of age and who had a primary diagnosis of stroke (ICD-9-CM 430-438) at time
of discharge from 1999-2010. All race/ ethnic, gender, socio-economic statuses were
eligible for inclusion in the study. Patients' with a second primary discharge diagnosis of
stroke greater than 1 day but within one year of the index stroke event were classified as
a recurrent stroke; excluding those patients with a stroke admission from 1996-1998. We
could not confirm index stroke admissions prior to 1996, thus we assumed that all index
strokes occurring from 1999-2010 were first-ever stroke events. Patients with their first
documented stroke admission in 2010 were excluded due to lack of knowledge about
possible recurrent stroke admissions after the 2010 index stroke.
Comorbidities to include hypertension (ICD-9-CM 401, 402.1, 402.9, 404.9,
405.1, 405.9) and diabetes (ICD-9-CM 250) wer.e based on secondary diagnosis codes at
"~;~
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time of index stroke discharge. Additional comorbid conditions were classified with a
modified version of the Charlson Index score based on ICD-9-CM secondary discharge
diagnosis codes at time of stroke hospitalization discharg,e. The modified Charlson Index
score allows weighting factors to be applied based on disease severity, and is summed to
provide a total score for each patient. The original Charlson Index includes scores for
cerebrovascular disease (weight 1) and hemiplegia (weight 2); because these diagnoses
are reflected in the primary diagnosis of stroke being evaluated in this study they were
excluded from the Modified Charlson Index score. 80, 81 The index was dichotomized as
low comorbidity (index 0 or 1) versus high comorbidity (index 2:2) to assess comorbidity
level associated with stroke hospitalization. 81 The state-wide dataset provides a ten year
assessment of stroke, recurrent stroke, and related risk factors from baseline to stroke
event( s) per subj ect.
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Summary of Hospital-based Data Source

This study was both a hospital-based and community-based study at the Medical
University of South Carolina Hospital, located in Charleston, South Carolina. All subjects
were selected from the Medical University Hospital whose race/ethnicity, gender, and
socio-economic status were representative of that of the population of Charleston, South
Carolina. All subjects who were at least 45 years of age and who were discharged from
the hospital with a primary diagnosis of stroke (ICD-9-CM 430-438) between October 1,
2008 and September 30, 2009 were eligible for the study. All race/ ethnic, gender, socioeconomic statuses were eligible for inclusion in the study. An attempt was made to
locate and contact all subjects who meet the inclusion criteria for inclusion in the one
year follow up study cohort. We expected ffi'¥.1Y of the subj ects to be intrigued by the
",~./
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follow-up study and thus we expected a high response rate based on the nature, age, and
endured medical experiences of the subject population. Those subjects who consented to
participate in the study completed a telephone interview. 1During the telephone interview
the vital status of the subjects were assessed. The subject was excluded from the study if
the subj ect was deceased. If the subj ect was alive but was unable to answer the survey
questions a proxy was allowed to answer on their behalf, thus these subject were still
included in a majority of the study; however, they were not included in the Valued Life
Assessment analysis. Any subject who did not agree to participate or was determined to
be deceased prior to the telephone interview was excluded from the follow up survey.
The average age of stroke in SC was approximately 70. Stroke is also associated
with many physical and mental disabilities post stroke event. Thus it was essential that
we included the elderly aged and possible cognitively impaired subjects in the study. All
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precautions were made to safeguard these individuals by using proxy interviewees when
needed and to include non-judgmental questions about the health status of the
participants' to maintain minimal burden to the subj ect.
Data Collection Methods

The one year follow up study included all consenting participants from the
hospital-based stroke cohort that we were able to successfully contact who agreed to
participate in the interview.

Subject involvement was limited to the collection of

demographic, behavioral and medical history data from the subj ects pre-existing medical
claims records and from the telephone interview.

All initial data collections were

obtained through pre-existing medical claims records from the subjects' hospital
admissions data, which consisted of: first

an~<_

last name, date of birth, date of stroke

"'''",
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admissions, date of stroke discharge, primary stroke discharge diagnosis, race/ethnicity,
gender, age at time of discharge, vital status at time of discharge, and last known address
and telephone number.
Prior to the telephone interview a letter of introduction was sent to the subj ects'
last known address. The letter explained why they were chosen for the study, the purpose
and importance of the study, what was required of them to participate, explanations of the
types of questions that were asked, and the information on declining to participate. The
letter also indicated that a proxy may be used to assist with the responses to the survey.
The participant who received the letter was asked to share the letter with the proxy. The
letter of introduction very clearly stated that their participation in the study was not
mandatory and was purely voluntary, and will in no way affect their medical treatment.
The letter of introduction is provided in Appendix A. The letter informed the subject or
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their proxy that if they wish not to participate in the telephone interview or if the subject
was deceased to call "Ms. Andrea Boan" at the provided phone number of "843-8761064". The letter explained that the subject (or proxy) would either speak to Ms. Boan

directly or would be prompted to leave a voicemail in the case of a non-answered call
attempt. If the subject /proxy called to decline participation, no inquiry was made as to
why they were selecting not to participate. The only information that was collected was
the subject's first and last name and date of birth. This information was only used to
verify the correct subject in the cohort to ensure that a call was not made to the subject's
residence. If a proxy was calling to inform us that the subj ect is deceased, again the first
and last name and date of birth was recorded for verification purposes. All subjects who
called the telephone number prior to the initiation of the interviews were removed from
,' ......, , .:~1·,'·'
.
the follow up study. This process allowed the participants two methods at two separate
times to decline to participate in the study; and the participant could repudiate consent at
any time during the interview.
Those who did not call to decline participation were contacted via telephone.
Non-threatening social and economical characteristics were obtained through a
confidential self-report (or proxy where appropriate) standardized questionnaire. The one
year follow up interview consisted of non-judgmental questions to assess the subject's
health status. This included questions concerning their stroke profile and related events
and medical history such as smoking, diabetes, hypertension, and cholesterol. The
medical care profile included information about the subject's medical care post stroke
event, level of education received about stroke and stroke symptoms during hospital stay,
and type of therapy/ treatment received post stroke. A behavior profile was obtained from
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the questionnaire to include information on the subject's quality of life, valued life
activities (i.e. driving), and ability to function in the home. A medication profile was
collected to assess current medication usage and type/name of medications for blood
thinners, cholesterol, and blood pressure.

The survey tool was a standardized

questionnaire and the telephone interview was conducted by trained research interview
professionals from a contracted research facility, the Institute for Public Service and
Policy Research at the University of South Carolina, Columbia SC, under the direction of
Robert W. Oldendick, PhD.

All willing and consenting participants from the stroke

cohort were included in the follow-up study analyses. The Survey Center at USC has
experience in handling confidential material and was HIP AA compliant.
For the interview call, if a proxy wa-s needed due to disability, the proxy was
~~~;Iy ~

asked if they were aware of the letter of introduction to the study. It would be reasonable
if the person were handling the affairs of the participant., they would be aware of the
letter. If they were aware of the letter, and they were idelltified as the proxy, and willing
to do the interview, the interview proceeded accordingly. If they were not aware of the
letter or study then: 1] They could refuse to participate during the call; 2] If the proxy
requested more information before agreeing to participate, then a copy of the original
letter was resent to the attention of the proxy, with a follow up interview attempted after
the letter was received by the proxy. The proxy also had the same opportunities to refuse
participation either by (a] calling Ms. Boan after receipt of the letter or b] refusing to
participate when the interview call was made; 3] If the family member reported that the
patient was too ill to participate in the call, then we asked if the family member could
"assist in answering the questions while the patient remains on another phone." The
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patient's participation in the call was used as their consent to participate. This method was
valid even if the patient only participated passively in the beginning of the call.
The data collected during the follow up interview was then merged with the
investigators' pre-existing dataset to assess the importance of multiple stroke versus
single stroke on secondary stroke prevention.

The study investigators provided the

interview data of all subjects with completed surveys to the South Carolina Office of
Research and Statistics. The SC ORS then matched the provided information with a preexisting state-wide database. The information was matched based on first and last name,
date of birth, and stroke discharge diagnosis. Once the information was matched with the
state-wide database a new de-identified dataset was provided to the investigators. No
attempts were made to uncover the matching

s~~~em.

The latest stroke event diagnostics,

'>'~'/~'

procedures, and demographic measures were used to link the survey and UB93 data; thus
we assumed the subjects answers to the survey questions were in regards to their most
recent stroke at time of telephone interview.
Approached to Recruit Minorities

It was highly crucial for minorities to be included in this study, thus every effort
was made to maintain a high response rate for minorities. The aggregate data showed a
significant racial disparity between African-American and Caucasian stroke rates; thus,
focusing on racial and cultural differences was an important element of this study. It was
our intent to survey all eligible subjects, and thus we expect the racial profile of the
completed interviews to be consistent with that of the stroke population of the Medical
University hospital. Thus we expected the official study cohort to both adequately
embody the under-represented minorities in this study and to adequately represent the
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characteristics of the population of South Carolina. All race and ethnic backgrounds
were included in the study. The subjecCs race was determined through the self-report
information provided to the hospital claims data at time of discharge. The interviewers
were trained professionals who have experience in minority interviewing, which is
optimal for a telephone interview process.
Survey Design and Methods

The latest stroke event diagnostics, procedures, and demographic measures were
used to link the survey and UB93 data; thus we assumed the survey questions answers
related to their most recent stroke at time of telephone interview.
Prior to enrolling the subjects in the cohort, and letter of introduction was mailed
to the subjects last known address according lo the hospital medical claims records.

"''-;':1''

Approximately 63 letters were returned to sender, of which 3 were determined to be
deceased, 12 due to incorrect or unknown name, and 48 due to wrong address. There
were approximately 32 subjects who did not know of th, letter at time of phone contact
and requested a letter be re-mailed to their current address, letters were resent twice
during the study; first mailing included 25 and the second mailing included 7 letters.
There were approximately 123 subjects who had incorrect or disconnected phone
numbers. Of these subj ects, a National Death Index online vital status searched was
completed to determine if any of these subjects had expired; 32 were found to be
deceased at time of survey request. Subjects were matched with the NDI database based
on first and last name, date of birth, date of death post last known hospitalization, and
county of last residence matched with the information provided by the Medical
University Hospital claims record. If the patient was not discovered to be deceased, an
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online review of the white pages phone book was used to find potential telephone
numbers to attempt contact. Information on approximately 50 subjects was established in
this manner. A total of 384 subj ects consented to the telephone interview.
Prior to the first survey attempt, a pilot test of the survey was completed on 10
subjects. These subjects were Medical University Hospital patients who had a stroke
(ICD-9-CM 430-438) after September 30, 2009 who were at least 45 years of age. The
pilot test aimed to revise any misleading questions and to modify those questions that
were hard to answer or understand to better improve the quality of the survey for this
specific sample population. Approximately 20% of the pilot test subjects claimed they
did not have a stroke or were not told at the hospital that they had a stroke; therefore, it
was difficult to ask such subj ects details about their "last stroke". Thus, to compensate for
'"~~I

"'?"'

the disagreement between the patients and the medical claims data we changed the
wording of the questions to ask details about their Hlast hospitalization". A list of the
rev~sions

is provided in the Alpha Pilot Survey Report jn Appendix B. After revisions

were made to the first pilot test and second pilot test was completed on an additional 10
subjects. The Beta Pilot Survey Report is provided in Appendix C.
The survey consisted of a telephone interview using a questionnaire that was
adapted from a standardized validated medical questionnaire. A sample of the
questionnaire that was used is displayed in Appendix D. Due to lack of monetary funds,
no incentives were offered to participate in the study. The interview took approximately
20 minutes to complete and contained non-judgmental questions about the subjects'
demographics, health status, medications/ treatments, and quality of life. The interview
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was conducted by the Institute of Public Service and Policy Research, all interview
procedures were in accordance with the protocols set forth by the research institute.
Quality Assurance and Monitoring

Survey: The surveys consisted of non-judgmental questions about the health
status of the participants', the burden on the patient was minimal in that the requests
consisted of a letter of introduction mailed to the home, a phone questionnaire, and
information form pre-existing medical claims records specifically to obtain the subjects'
first and last name, date of birth, date of admissions, date of discharge, discharge
diagnosis, race/ethnicity, gender, age at time of discharge, vital status at time of
discharge, and last

knUWll

address and telephone number. Non-threatening social and

economical characteristics were obtained

tm~?gh

a confidential self-report (or proxy

'~'J; '~l' ~
'I

where appropriate) standardized telephone questionnaire.

Information concerning the

subjects' current health status was evaluated during the telephone interview and included
assessments such as: deceased, alive can complete surve¥, alive cannot complete survey
proxy will on their behalf; additional known comorbidities; smoking status; type of
residence (ie. living at home, nursing facility, etc); function and mobile abilities (ie.
driving or walking capabilities); primary care post stroke event; number of visits with
primary care physician; time since stroke; specific current medications (ie. blood
pressure, anti-platelet, ACE, beta blockers, cholesterol medications).
The interview was conducted by the Institute of Public Service and Policy
Research with trained professionals who have met all of the HIP AA and human subjects
research training and requirements, and all interview procedures were in accordance with
the protocols set forth by the research institute.
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Data Entry:

Data entry and survey data collection was the responsibility of the

contracted research institute, Institute of Public Service and Policy Research, who
conducted the telephone interviews. All data was collected and entered according to a
standard protocol for each variable obtained and standardized recruitment methods were
used to ensure consistency and reduce data entry errors. Tracking logs were used to
document each data collection and entry step for each subject to reduce the likelihood of
error upon entry.
Data Management and Security

All data collection procedures were documented throughout the interview process.
Data editing and range checks were conducted by the data collection institute. The
database was designed using the Institute's- Ci3 WinCati system with conversion to
,,",";' :~j'
,
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Microsoft Office Excel 2003 and analyses were conducted using SAS 9.3 (Cary, NC). A
random study identifier number was assigned to each subject. This number was used to
match all data information from the medical claims

reco~d

office with the data collected

during the interviews to ensure that the data was properly matched to the database
records, along with the subjects' name and date of birth.
As interview data was collected, it was stored electronically in a passwordprotected file that could only be accessed by the USC project manager, data programmer,
and field data collection supervisor, each of whom have completed appropriate training
for conducting Human Subject Research and was certified to do so. The survey data that
was transmitted to the research team at MUSC was sent electronically in a passwordprotected file. This file contained an identification number that allowed the research team
to link the survey information with other data from other components of this study, such
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as background characteristics. Results were reported in percentages and other summary
statistics, so that responses could not be linked to any particular individual.
To ensure data security, once we received the database from the Institute of Public
Service and Policy Research, we stored the database and analyses on the departmental
shared drive that has restricted access and was permanently back-up to an off-site vault
by the MUSC Infonnation Security Office on a nightly basis. Virus prevention was
secured through nightly updates through the MUSC College of Medicine IT department.
After all data was collected and entered, the database used for analyses was deidentified using the random number generator procedure in SAS 9.3 (Cary, NC) to
randomly assign a 4 digit study number to each subject.
Human Subjects Involvement, Characteristics,- and Protection Against Risk
·";·i~;'"

.

."/'

Subject involvement was limited to the collection of demographic, behavioral and
medical history data. All methods of data collection were obtained from pre-existing
medical claims records and from the self/proxy-report 1telephone interview.

Surveys

consisted of non-judgmental questions about the health status of the participants', the
burden on the patient is minimal in that the request consisted of a mail out introduction
letter, a phone questionnaire and existing medical claims record review specifically to
obtain the subjects' first and last name, date of birth, date of admissions, date of
discharge, discharge diagnosis, race/ethnicity, gender, age at time of discharge, vital
status at time of discharge, and last known address and telephone number.

Non-

threatening social and economic characteristics were obtained through a confidential selfreport standardized questionnaire. There was no increased risk to the patient as a study
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participant as no biological samples were collected. All subjects that were willing and
consenting participants of the survey were included in the follow-up study analyses.
Recruitment and Informed Consent

Subjects were made fully aware that participation in the study was not required
and would in no way hinder their medical care received at MUSC or other medical
centers. Information of the possible subjects' current address and telephone number was
obtained through hospital medical claims records. Prior to contacting the subjects, a letter
of introduction was mailed to the subjects' residence. The letter included a summary
about the study and requested that the subject (or appropriate proxy) contact the number
provided if the subject wished to not participate in the study. If a subject did not call the
number then a phone call was made to the residence, at which time we explained the
f..

,
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study and obtain verbal consent to participate. This process allowed the participants two
methods at two separate times to decline to participate in the study; and the participant
could repudiate consent at any time during the interview. 1We requested waiver of written
consent for this study. Verbal consent came from the subj ect or from an appropriate
proxy (i.e. spouse, child, or care-taker of the subj ect) if needed.
Protection Against Risk

The PI, Co-Investigators, and Interviewers were trained in subject confidentiality
and ethical conduct of human subjects research. All investigators and interviewers were
HIP AA qualified. Interview data was collected by telephone, using the computer-aided
telephone interviewing (CATI) facilities of the University of South Carolina's Institute
for Public Service and Policy Research (USC). As a condition of employment, all staff
working on this project have signed agreements to keep confidential all information they
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collect from respondents; violation of confidentiality would result in termination. While
the interviewers knew the names of the respondents the computer-readable data files that
were produced as part of this study contained no information such as name or telephone
number that would have allowed subjects to be identified directly. This study involved
very minimal risk that included loss of confidentiality if the subjects' medical records or
survey results were to be compromised due to computer network security failure or the
unlawful opening of mail documents not addressed to the offender.
Ethical Aspects

We anticipated no ethical issues with the proposed project. All individual-level
data involved with this study and the follow-up survey are de-identified. All data
collected in association with the project have ,Fyceived IRB approval. This dissertation

,",,","*/'

project is seeking IRB approval, application is pending. There are no direct benefits to the
subjects or others; however, we anticipate the results from this study could be used to
establish the need for improved treatment and control as part of secondary stroke
prevention. In addition, hospital discharge system provides a valuable resource to
monitor stroke patterns and risk factors and provides an opportunity for aggressive
treatment of this at-risk population.
Description of Methods for Specific Aims
Aim 1: Study Methods
AIM 1:

To examine the association of one-year recurrent stroke risk with race-age
disparities and comorbid hypertension and diabetes.

This data includes 49,446 subjects discharged with a primary diagnosis of ischemic
stroke (ICD9 433, 434, and 436) who were at least 45 years of age from January 1, 1999
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to December 31, 2010 in South Carolina. Patients' with a second primary discharge
diagnosis of stroke greater than 1 day but within one year of the index stroke event were
classified as a recurrent stroke; excluding those patients with a stroke admission from
1996-1998.

We could not confinn index stroke admissions prior to 1996, thus we

assumed that all index strokes occurring from 1999-2010 were first-ever stroke events.
Patients with their first documented stroke admission in 2010 were excluded due to lack
of knowledge about possible recurrent stroke admissions after the 2010 index stroke.
Patients that died during the stroke admission were excluded from the analyses.
Hospitalizations with a primary ICD-9 diagnosis code of 433.xO (Occlusion and
stenosis of pre cerebral arteries without mention of cerebral infarction) or 434.xO
(Occlusion of cerebral arteries without

m~l)tion

of cerebral infarction) and an

,'~ "~l"
,
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accompanying primary ICD-9 procedure code of 38.12 (Carotid Endarterectomy), 00.61
(Percutaneous angioplasty or atherectomy of precerebral (extracranial) vessel(s)), or
00.63 (Percutaneous insertion of carotid artery stent)

we~e

excluded as these visits were

not considered an acute stroke event and the primary reason for the hospital admission
was a pre-scheduled surgical procedure.
Time from index stroke discharge to recurrent stroke admission was calculated in
days. If the patient did not have a recurrent stroke event within 365 days of the index
event then the patient was censored at 366 days. Patients that died within one year were
censored at days from index stroke admission to date of death. This study provided a ten
year assessment of stroke, recurrent stroke, and related risk factors from baseline to
recurrent stroke event per subject. The outcome variable was single (index) index versus
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recurrent stroke controlling for race, gender, age, and comorbid hypertension and
diabetes. With this data, we tested the following hypotheses:
African-American race will be associated with an increased risk of one-year
recurrent stroke when compared to Caucasian race, controlled for age, gender,
and comorbid covariables.
Age less than 65 years will be associated with an increased risk of recurrent
stroke when compared to subject greater than 65 years of age, controlled for
race, gender, and comorbid covariables.
Ha13:

Comorbid hypertension will be associated with an increased risk of recurrent
stroke, controlled for age, race, and gender.
Comorbid diabetes will be assoc·iated with an increased risk of recurrent
'~;I

.7'

stroke, controlled for age, race, and gender.
Aim 1: Statistical Considerations

The state-wide data was used to assess varlolfs risk factors associated with
recurrent stroke. Exploratory analysis was conducted to compare potential risk factors
among stroke patients using a variety of statistical methods that include: two-tailed T-test
for comparing differences in the means ± SEM, two-tailed Fisher's Exact test to
compared categorical parameters, logistic regression model for odds ratios and 95%
confidence intervals to assess recurrent stroke subj ect profiles.
To address each of the hypotheses in Aim I, univariable and multivariable mixed
effects logistic regression to include a random intercept was used to assess the risk of first
recurrent stroke in relation to race (African Americans (AA)/ Caucasians (CA)) for Hall,
age (45-641 2: 65 years) for Ha12, comorbid hypertension status for Ha13, and comorbid
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diabetes status for Ha1 4 , at index stroke controlling for gender (male/ female) in
multivariable analyses. All variables of interest were included in the model to predict risk
of recurrent stroke, the main outcome variable for Aim 1. 'Recurrent stroke' was defined
using two definitions which were tested in separate models. The first definition of
recurrent stroke included subjects that had a repeat stroke event within one year but not
less than 1 day of the index stroke. The second definition included subjects that had a
repeat stroke event within one year but not less than 30 days post index stroke. The
purpose of the second definition was to control for possible re-admissions due to
complications of the initial stroke to ensure that the risk of recurrent stroke was not
overestimated. After further review of the proposed analyses, the recurrent stroke
definition chosen for the all

furth\~
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. analyses f'Or Aim 1 was any recurrent ischemic stroke
f..
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'~~/o1'

admission within one-year but not less than 1 day post index ischemic stroke discharge
date. The logistic model was a mixed effects model to include a random intercept hence
there was a different random variable alpha for each subj,ct.
The strategy for building the multivariable logistic model was to enter the
clinically relevant covariables when found to differ between groups in the univariable
analysis. A p-value of < 0.2 was used as a guide to detennine covariable entry into the
multivariable model. The Monte Carlo rule of restricting the number of covariables per
events was applied to reduce bias in the regression coefficient estimates. 155 We ensured
that there were enough perceived stroke events to control the number of covariates that
are allowed in the multivariable model, using the rule of thumb of 1 covariate for every
10 events per group, to prevent potential errors in the risk estimate. First and second
order interactions were assessed in the analyses sense we had enough data to justify a two
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factor interaction, however caution was made when interpreting these interactions.
Variance inflation factors were assessed in the multivariable model to test for
collinearity. No large variance inflation factors were found thus we assumed that there
were no serious collinearity problems in regards to inter-correlation with the outcome
variable, one-year recurrent stroke.
Mixed effects models with best subsets regressIon methods were used to
determine the best model to predict recurrent stroke. Model fit was examined using the
Akaike Information

Cr~terion

(AIC) to compare the different models. The best fit model

was chosen based on the lowest value for AIC. The basic form for the multivariable
logistic regression for fixed effects that were used:

Where p represents the proportion of subjects for recurrent stroke, {30 represents the
intercept, {31 - {3k represents the regression coefficients1for age (Xl) dichotomized as less
than or greater than 65 years of age, Race (X 2 ) dichotomized as African American
versus Caucasian, Gender dichotomized as male versus female (X 3 ), and Comorbid
Hypertension (X 4 ) and Diabetes (X 5 ). Comorbidities were all dichotomized as Yes/No
p

based on secondary diagnosis at time of stroke discharge.

L flrX x Xj
i

represents the

i=l

sum of the covariates that are shown to be significant confounders where Xi x Xj
represents any potential interaction terms.
To address each of the hypotheses in Aim 1 we considered random effects in the
mixed model using the logistic-normal model with binomial data method to predict

66

recurrent stroke. The basic form for the mixed model with random effects is displayed
below:

log ( Pi
1- Pi

J== /3

0

+ PlXl + ... + PkXk + ui

Where

i : individuals, i == 1" .. , n
ui

:

represents the different random effect for each subj ect

and is assumed to be i.i.d. N(O, 0-/)
Kaplan-Meier estimates were used to plot race- and age-specific cumulative event
curves compared by a log-rank test. One-year recurrent stroke rates and 95% confidence
intervals (CI) were calculated for patients with hypertension and diabetes stratified by
race and age using Kaplan-Meier survival analysis,

All statistical analyses were

performed with SAS 9.3 (Cary, NC). All ana1'y~'s were considered significant at the 0,05
two-sided level of significance.

Aim 2: Study Methods
AIM 2:

1

To determine the effects of using the traditional International Classification of

Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic
modifier codes for ischemic stroke (ICD-9-CM 433, 434, and 436) on the
estimates of race-age specific stroke rates and the patients' perception of
stroke hospitalization.
State-wide de-identified hospitalization data for South Carolina and data from a
hospital-based cohort of stroke patients from the Medical University of South Carolina
were identified. Data collected from the hospital-based patients who consented to the
telephone follow-up interview post index stroke discharge were used to evaluate patients'
perception of their hospitalization which was coded as an ischemic stroke using the
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standard

(433~ 434~

and 436) definition. Both the state- and hospital-level databases

included hospitalization records for all adult patients, age 2:: 45 years, discharged with a
primary diagnosis of ischemic stroke (433, 434, and 436) from October 1, 2008 to
September 30, 2009 with detailed information on patient demographics, diagnoses, and
procedures.
In October 1992, a modifier fifth digit was added to the ICD-9-CM codes 433 and
434, Occlusion and Stenosis of precerebral arteries and cerebral arteries, respectively.114
The fifth code was designated as "0" without cerebral infarction and "1" with cerebral
infarction. Thus, ischemic strokes were identified using codes 433 .xl, where the forth
digit designated the specific arterial distribution, ie. 433.0x Basilar artery, 433.1x carotid
artery, etc. "Stroke

hospitalizations~'

were

ide1}~ified

using the primary ICD-9-CM code

~~~i?

for ischemic stroke (433, 434, and 436), defined as occlusion or stenosis of
precerebrallcerebral arteries without cerebral infarction (433 .xO and 434.xO) and with
cerebral infarction (433.xl, 434.xl), and acute, but

ill-~efined

cerebrovascular disease

(436). Acute strokes were further classified by presentation type, "asymptomatic" or
"symptomatic". Asymptomatic was defined as a primary diagnosis of occlusion or
stenosis of precerebrallcerebral arteries without mention of cerebral infarction (433.xO or
434.xO) and no accompanying secondary diagnosis code for transient ischemic attack
(TIA, 435). Symptomatic was defined as any primary diagnosis of ischemic stroke with
cerebral infarction (433.xl or 434.xl) or acute but ill-defined stroke (436); or a noncerebral infarct primary code with an accompanying TIA code in one of the secondary
diagnoses positions.
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Recurrent stroke was first calculated by the traditional method which identified
patients' with a second primary discharge diagnosis of ischemic stroke greater than 1 day
but within one year of the index "stroke event" based on the standard expanded
diagnostic codes. All index strokes occurring after October 1, 2008 were considered firstever stroke events for both databases. Patients that died during the stroke admission were
excluded from the recurrent stroke analyses.

Recurrent stroke was recomputed and

renamed "Modified Recurrent Stroke" after removing the asymptomatic index and
recurrent "stroke hospitalizations".
In the state-level data, two subsets of data were used to compare the effects of
excluding asymptomatic hospitalizations on the estimates of racial disparities in stroke.
The first cohort (Traditional) included both symptomatic and asymptomatic ischemic
,~~, ;~;'
i

stroke hospitalizations, while the second cohort (Modified) only included symptomatic
stroke hospitalizations. In the Traditional stroke cohort, recurrent status included both
asymptomatic and symptomatic diagnoses; whereas in l the Modified cohort, both the
index and the recurrent stroke admission had to be classified as symptomatic.
The follow-up telephone survey data was used to assess the patient perceptions of
the hospitalization. Specifically, participants were asked "Were you hospitalized for a
stroke?" with a "yes~' or "no" response.
The objective of this study was to assess the influence of the ICD-9-CM modifier
codes for with and without cerebral infarction on race and age disparities on the
interpretation of state-wide administrative data from hospital admission for ischemic
stroke. In addition, this study will examine the relationship between an asymptomatic
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stroke diagnoses and the patients' perception of their stroke hospitalization. With this
data, we tested the following hypotheses:
Ha2 1:

Race and age disparity estimates will be greater when only symptomatic lCD9-CM codes are considered when compared to the traditional codes for stroke.
The patients' perception of being hospitalized for a stroke will differ based on
symptomatic versus asymptomatic diagnosis at discharge.

Aim 2: Statistical Considerations
The state-wide data was used to assess the differences in age and race disparity
estimates based on traditional versus modified stroke case definitions. Exploratory
anal ysis was conducted to compare potential risk factors among stroke patients using a
variety of statistical methods that include: two:tfiiled T-test for comparing differences in
'~~I

'1

the means ± SEM, two-tailed Fisher's Exact test to compared categorical parameters,
logistic regression model for odds ratios and 95% confidence intervals to assess recurrent
stroke subject profiles.
To address the hypothesis for Aim 2 - Ha2 1, descriptive statistics were used to
compare baseline characteristics. Race-specific population rates (per 100,000) were
calculated by age group (45-641 > 65 years) with the number of strokes as the numerator
and the age-adjusted South Carolina resident population estimate for 2009 as the
denominator. 154 Race- and age-specific stroke rates were used to compare the changes in
the ratio of African Americans to Caucasians in the two cohorts. Race- and age-specific
recurrent stroke rates and racial disparity rate ratios with 95% confidence intervals (Cl)
were calculated from the total number of patients in the respective stroke cohorts to
compare the changes in recurrent stroke racial disparity rate ratio. Univariable mixed
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effects logistic regression to include a random intercept was used to compare baseline
characteristics with symptomatic diagnosis.
To address the hypothesis for Aim 2 - Ha2 2, univariable mixed effects logistic
regression to include a random intercept was used to assess patients' self-reported
perception of being hospitalized for a stroke, classified as "reported yes" or "reported
no", in the hospital-level survey data.
Mixed effects models with best subsets regressIon methods will be used to
determine the best model to predict perceived stroke event. Model fit will be examined
using the Akaike Information Criterion (AIC) to compare the different models. The best
fit model will be chosen based on the lowest value for AIC. The basic form for the
multivariable logistic regression for fixed effects that were used:
'~~I

:1'

In[ ~ ]= f30+ f3I X I + f3 X + f33 X 3+ f34 X 4 + f3 X + ... + f3 X
1 P
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+ I.f3,Xi xX)
i=l

Where p represents the proportion of subjects who perceived a stroke event, {3o
1

represents the intercept, {31- {3k represents the regression coefficients for the variables of
interest for this hypothesis. F or example, clinical stroke status (Xl) dichotomized as
"symptomatic" or "asymptomatic", controlling for Race (X 2 ) dichotomized as African
American versus Caucasian, age (X 3 ) dichotomized as less than or greater than 65 years
..

of age or assessed as a continuous variable depending on linearity in the logit
assumptions, and any other risk factors found to be significant predictors in the models,
p

L fJiX

i

X

Xj

represents the sum of' the covariates that are shown to be significant

i=l

confounders where Xi x Xj represents any potential interaction terms.
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To address each of the hypotheses in Aim 2 we considered random effects in the
mixed model using the logistic-nonnal model with binomial data method to predict
recurrent stroke. The basic form for the mixed model with random effects is displayed
below:

IOg( 1~~;) = Po + PIXt + ... + PkX

k

+U,

Where

i : individuals, i = 1, ... , n
uj

:

represents the different random effect for each subj ect

and is assumed to be i.i.d. N(O,

O"u

2
)

Due to the survey design and collection methods for perception of experiencing a
stroke event, inherent measurement error may be present. Thus, to attempt to control for
the potential error that may lead to biases 'til:~stimating the odds ratio and regression
coefficient, Berkson type error was also considered in the models for the random error
intercept to reduce the biases in the measurements. Using Berkson error rather than
1

classical error may act to reduce or remove the biases in the measurements. The Berkson
error is the "uno bserved random measurement error" which is assumed to be independent
of the "observed predictor variable" in the model

156.

All statistical analyses will be performed with SAS 9.3 (Cary, NC). All final
analyses will be considered significant at the 0.05 two-sided level of significance.
Aim 3: Study Methods
AIM 3:

To assess differential patterns of antihypertensive regImens prescribed at
discharge and persistent use of antihypertensives at one-year post stroke
hospitalization comparing race, age, prior stroke and recurrent stroke among
stroke survivors.
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Aim 3 focuses on a one year follow-up interview of stroke patients, at least 45
years of age, who were discharged with a primary diagnosis of stroke (ICD-9-CM 430 438) between October 1, 2008 and September 30, 2009 from the Medical University
Hospital.

A total of 791 stroke patients were assessed for eligibility, of whom 131

(16.6%) died during the index hospitalization or prior to follow-up, 29 (3.7%) resided in
hospice, or rehab skilled nursing, or long-term care facilities, 98 (12.4%) were lost to
follow-up and 149 (18.8%) patient/proxy refused.

Information on demographics and

discharge variables including discharge medications and last documented blood pressure .;
value prior to discharge were obtained from the patients' electronic medical records. We
excluded patients for whom there were no blood pressure value recorded during hospital
stay or no medications recorded at discharge. A total of 384 subjects consented to the
'~~I

0/-

telephone interview for which 271 met all inclusion criteria for this study. A summary of
the 384 consenting patients is provided in Appendix E. The average time between
hospital discharge and follow-up survey for this cohort 1was approximately ten months.
The post-hospitalization telephone survey was used to assess patient persistence with
stroke discharge medications. Self-reported demographic, behavioral, medication and
medical history data were obtained during the interview. Family members or primary
care giver proxies were used for patients who could not respond due to illness severity or
speech or language deficits. The survey data were matched to the state medical claims
hospitalization records to obtain detailed information on patient demographics,
diagnoses, procedures, and clinical outcomes for all eligible patients in the cohort. For
patients with multiple stroke hospitalizations during the study time period, we used the
latest discharge hospitalization records and assumed all answers to the survey questions
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were in response to their most recent stroke at time of the telephone interview. All
patients included in this study were willing and consenting participants. With this data,
we tested the following hypotheses:
Ra3 l :

Prescribed antihypertensive regimen at discharge and persistent use at oneyear will differ by race, age, and history or prior and recurrent stroke.

Aim 3: Statistical Considerations
Data from the one-year follow-up interview of stroke survivors was used to assess
persistence on antihypertensive treatment regimen post index stroke discharge.
Exploratory analysis was conducted to compare potential risk factors among stroke
patients using a variety of statistical methods that include: two-tailed T-test for
comparing differences in the means ± SEM, .t;V,o-tailed Fisher's Exact test to compared
~ '~~/'1'

categorical parameters, logistic regression model for odds ratios and 95% confidence
intervals to assess stroke patient profiles.
To address the hypothesis in Aim 3, univariable ;nixed effects logistic regression
to include a random intercept was applied to compare baseline characteristics associated
with receipt of antihypertensive therapy at discharge and to assess patient characteristics
associated with persistence on all or at least two discharged antihypertensive medications.
Odds ratios and 95% confidence intervals (el) were calculated. Random effects were
considered in the univariable mixed model using the logistic-normal model with binomial
data method to predict receipt of antihypertensive therapy at discharge and to assess
characteristics associated with persistence medication regimens. The basic form for the
mixed model with random effects is displayed below:
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J

log ( Pi
= /3 + /31Xl + .. , + /3k X k+ ui
1- PI
0

Where

i : individuals, i = 1" .. , n
u i : represents the different random effect for each subject
and is assumed to be i.i.d. N(O, O"u 2)
Due to the survey design and collection methods for medication persistence
inherent measurement error may be present. Thus, to attempt to control for the potential
error that may lead to biases in estimating risk and regression coefficient, Berkson type
error were also considered in the models for the random error intercept to reduce the
biases in the measurements. Using Berkson error rather than classical error may act to
reduce or remove the biases in the measurements. The Berkson error is the "unobserved
random measurement error" which is assutilfd to be independent of the "observed
predictor variable" in the model. 156 All statistical analyses were performed with SAS 9.3
(Cary, NC). All analyses were considered significant at the 0.05 two-sided level of
significance.
Limitations

While this study included a large number of patient-based cases in the state-wide
data assessments, it is not free from limitations. In defining a one-year recurrent stroke
hospitalization, we could not confirm an index stroke admission prior to 1996. Thus we
excluded patients with a stroke admission in 1996-1998 and only included patients with a
first appearance after 1999. However, the average time from index stroke discharge to
recurrent admission in the overall study population was less than two years; therefore we
feel that any over-lunder-estimates for index or recurrent stroke were minimal when
allowing the three year run-in period.

Patients with their first documented stroke
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admission in 2010 were also excluded due to lack of knowledge about possible recurrent
stroke admissions after the 2010 index stroke. These strict exclusion criteria ensured that
patients were defined as accurately as possible within the limitations of this data.
This study also included limitations inherent with the use of administrative
databases. The variables used in this study were based on ICD-9-CM diagnosis and thus
we were unable to assess stroke severity. Comorbidity status consisted of a dichotomous
designation of present/ absent of disease, thus treatment and control could not be
evaluated at the state-wide level. As well, the analyses did not include adjustment for
socio-economic factors known to be associated with risk of cardiovascular disease and
stroke. 157, 158
This study included a number of limitations inherent with self-report and
~~I ~.

telephone administer surveys. There were several recruitment challenges that had to be
addressed.

The first part of the follow-up analysis required locating and recruiting

patients to obtain consent to participate and to complete the survey. We expected a
majority of the subjects to be South Carolina residents and to be a part of the Medical
University's claims record system. We expected the hospital to provide an accurate last
known address and telephone number since the subjects of this cohort were hospitalized
within the year prior to the survey. Therefore, we anticipated locating the subjects to be
less difficult than in standard follow-up studies considering we had accurate information
on a majority of the subjects' name, date of birth, address, telephone number, and vital
status at time of discharge; thus, locating and contacting the subjects' was not too
difficult.
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The second part of the follow-up analysis required the subjects' (or a proxy's)
verbal consent to participate in the one-year follow up phone interview. Thus due to the
nature of the interview process we inevitably excluded those subjects who did not have
access to a telephone in their residence. However, we anticipated a majority of the
subjects to have phone access if they provided a telephone number to the medical claims
office. We hired trained interviewing professionals and the interview only took
approximately 20 minutes which was explained to the subjects in the letter of
introduction; and thus, we expected a sufficient retention rate for completing the
interview.
Data regarding medication persistence represented an assessment of stroke
survivors in a clinical setting in relatively

yo"~~g

,'~/1

(mean age 65) high-risk population.

Most studies involving secondary stroke prevention medication persistence are based on
nationwide, multi -site clinical trials for which data are less generalizable and thus may
overestimate medication persistence. 159,

160

However,

rve

were limited to measuring

medication persistence as opposed to adherence/ continued use as we did not obtain
dosage information at follow-up. Our method of measuring persistence was based on
self-report data which was not validated via pill count or pharmacy claims data; however,
no gold standard has been established to measure medication persistence and studies have
shown sufficient agreement between patient self-report data and pharmacy claims
records. 148, 161, 162 In addition, reasons for discontinuation of medication such as potential
contraindications or adverse effects which may have been physician- as opposed to
patient-initiated were not assessed in this study. Patients who were lost to follow-up or
died were not included in the follow-up assessment and thus may result in overestimates
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of persistence.

All follow-up data was collected via telephone interview; therefore,

results on current and prior medication data are limited by the credibility of the patients
and proxies. Recurrent stroke hospitalizations may have occurred before follow-up meds
were ascertained but medications listed at last stroke hospitalization during study period
were used to compare to the follow-up medication list.

Finally, we did not collect

information on blood pressure throughout the hospital stay which may be affected
prescribed therapies especially since studies have shown that blood pressures within days
of acute stroke may not reflect the patients' baseline levels; 163,

164

however, guidelines

suggest that antihypertensive therapy is beneficial in all stroke survivors as a means of
. regardl ess 0 f h ypertenslon
. status prIor
. to stro ke hosplta
. 1·IzatIon.
. 23 ' 38
sec ondary preventIon
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Study Significance

The goal of this dissertation was the identification of factors associated with
secondary stroke prevention. This dissertation is significant as the factors associated with
recurrent stroke in the high risk population of the Southeast are unclear. This dissertation
assessed hypertension treatment regimens post stroke hospitalization to evaluate clinical
inertia and the limitations associated with initiation and intensity of antihypertensive
therapy. These results could be used to design interventions for improved stroke care and
recommendations on risk factor treatment practices and protocols focused on secondary
stroke prevention.
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Abstract
Background and Purpose: Recurrent stroke is a risk for stroke survivors, yet predictors

of recurrence remain somewhat unclear. This study examined one-year recurrent stroke
risk in relation to race and age disparities with the association of hypertension and
diabetes.
Methods: All South Carolina hospitalized patients discharged with a primary ·diagnosis

of ischemic stroke from 1999-2010 were included. One-year recurrent stroke risk was
determined in relation to race (African Americans; Caucasians), age (45-64; > 65 years),
gender, and hypertension and diabetes status by mixed effects regression. Kaplan-Meier
estimates were used to calculate the cumulative event rates for recurrent stroke.
Results: The assessment identified 49,446 ischemic stroke hospitalizations, with 5,590
. " i ~j

.

"

(11.3%) experiencing a recurrent stroke admission within one-year. Significantly greater
recurrence rates were detected for African Americans, patients age 45-64 years, and
patients with diabetes. When race and age were

conside~ed

together one-year cumulative

recurrent stroke rates were highest for younger African Americans (14.4% (95% CI,
13.6-15.2%) African Americans 45-64 years; 14.1% (95% CI, 13.3-14.90/0) African
Americans 2: 65 years; 12.0% (95% CI, 11.3-12.6%) Caucasians 45-64 years; 11.00/0
(95% CI, 10.6-11.5%) Caucasians 2: 65 years); with the age and race disparities most
evident from 3 months to 1 year.
Conclusions: Recurrent stroke within one year impacted approximately one in ten stroke

survivors. The results indicate that younger age, African American race, and prevalent
diabetes increase recurrent stroke risk and emerge as factors to consider in risk-reduction
strategies.

104

Introduction

Stroke represents a major population risk! with significant geographic 2-4 and
racial disparities. 5- 1o An inherent risk from an incident stroke is recurrence, with nearly
one in ten stroke cases having another event within the first year post index stroke. 11, 12
One-year recurrent stroke rates in observational studies range from 5.1 to 9.4%.11-16 The
risk of a recurrent stroke is further compounded by age and race. 17, 18 Race is associated
with disparities in recurrent stroke risk with higher risks determined for African
Americans. 19, 20 Traditional stroke risk factors including hypertension and diabetes have
also been found to be associated with an increased risk of recurrent stroke. 13, 21 Recurrent
strokes have been considered more severe with higher mortality and greater rates of
adverse outcomes than index strokes. 14, 22-~4

While recurrent stroke has been well

J~i i~i

studied, the confounding effects of race and age are less understood. The objective of
this study was to assess race-age disparities and the impact of hypertension and diabetes
among recurrent stroke patients.
Methods
Data Source

De-identified patient-based stroke hospitalization data, provided by the South
Carolina Office of Research and Statistics, included information on demographics,
diagnostic and procedure codes based on the International Classification of Diseases 9th
Revision (ICD-9-CM) Clinical Modification, as well as admission and discharge dates for
stroke hospitalizations in South Carolina from 1999-2010. This study was approved by
the Medical University of South Carolina's Institutional Review Board.
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Stroke Cases

Subjects at least 45 years of age discharged with a primary diagnosis of ischemic
stroke (ICD-9-CM 433, 434, and 436) from January 1, 1999 to December 31,2010 in
South Carolina were identified from the database.

Patients' with a second primary

discharge diagnosis of stroke greater than 1 day but within one year of the index stroke
event were classified as a recurrent stroke; excluding those patients with a stroke
admission from 1996-1998. We could not confirm index stroke admissions prior to 1996,
thus we assumed that all index strokes occurring from 1999-2010 were first-ever stroke
events. Patients with their first documented stroke admission in 2010 were excluded due
to lack of knowledge about possible recurrent stroke admissions after the 2010 index
stroke. Patients that died during the stroke admission were excluded from the analyses.
"'~I .:~I

Hypertension (ICD-9-CM 401, 402.1, 402.9, 404.9, 405.1, 405.9) and diabetes (ICD-9CM 250) status was based on the secondary diagnosis codes at time of index stroke
discharge.
Hospitalizations with a primary ICD-9-CM diagnosis code of 433 .xO (Occlusion
and stenosis of precerebral arteries without mention of cerebral infarction) or 434.xO
(Occlusion of cerebral arteries without mention of cerebral infarction) and an
accompanying primary ICD-9-CM procedure code of 38.12 (Carotid Endarterectomy),
00.61 (Percutaneous angioplasty or atherectomy of pre cerebral (extracranial) vessel(s)),
or 00.63 (Percutaneous insertion of carotid artery stent) were excluded as these visits
were not considered an acute stroke event and the primary reason for the hospital
admission was a pre-scheduled surgical procedure.
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Time from index stroke discharge to recurrent stroke admission was calculated in
days. If the patient did not have a recurrent stroke event within 365 days of the index
event then the patient was censored at 366 days. Patients that died within one year were
censored at days from index stroke admission to date of death. This study provided a ten
year assessment of stroke, recurrent stroke, and related risk factors from baseline to
recurrent stroke event per subject.
Statistical Analysis

Univariable and multivariable mixed effects logistic regressIon to include a
random intercept was applied to assess the risk of first recurrent stroke in relation to race
(African Americans (AA)/ Caucasians (CA)), age (45-64/ 2: 65 years), gender (male/
female), hypertension and diabetes status at index stroke. Kaplan-Meier estimates were
~~i :~j

used to plot race- and age-specific cumulative event curves compared by a log-rank test.
One-year recurrent stroke rates and 95% confidence intervals (CI) were calculated for
patients with hypertension and diabetes stratified by rafe and age using Kaplan-Meier
survival analysis. All analyses were performed with SAS 9.3 (SAS Inc. Cary, NC) and
were considered statistically significant at p< 0.05.
Results

A total of 49,446 ischemic stroke hospitalized cases were included in the analyses
with nearly one-third occurring among African Americans (32.7%). The average age of
these patients was 70.2 (± 12.8), with 33.9% in patients 45-64 years of age. First stroke
recurrence was identified in 5,590 (11.3%) of the patients within one year of index
stroke. Index and recurrent stroke characteristics of the study population are shown in
Table 1. African Americans and patients 45-64 years of age had higher rates of recurrent
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stroke than index stroke.

Two-thirds of index and recurrent stroke patients had

hypertension while the proportion with diabetes was higher in the recurrent stroke
patients.
Table 2 shows the associated predictors of one-year recurrent stroke. African
American patients had a 32% higher risk (odds ratio [OR] 1.32 (95% CI, 1.21-1.42)) of
recurrent stroke compared to Caucasians, after adjustments for age, gender, hypertension
and diabetes. The younger age group had higher risk for stroke recurrence than the older
age group (OR 1.24 (95% CI, 1.13-1.33)). While hypertension was not a significant
independent predictor for recurrent stroke, race, age and diabetes were strong predictors.
The Kaplan-Meier cumulative rate of recurrent stroke was 1.1 % (95% CI, 1.0-1.2)
at 7 days; 1.9% (95% CI, 1.8-2.l) at 14 days; 2)% (95% CI, 3.0-3.3) at 1 month; 4.8%
Ujtll .

.

/

(95% CI, 4.6-5.0) at 2 months; 6.0% (95% CI, 5.8-6.2) at 3 months; 8.6% (95% CI, 8.48.9) at 6 months; 10.5% (95% CI, 10.2-10.8) at 9 months; and 12.3% (95% CI, 12.012.6) at 1 year. The cumulative rate for first recurrence yaried by race and age as shown
in the Kaplan-Meier event curves in Figure 1. African Americans (14.2% (95% CI, 13.714.8) vs. Caucasians 11.3% (95% CI, 10.9-11.7)) and patients 45-64 years of age (13.0%
(95% CI, 12.5-13.6) vs. > 65 years 11.8% (95% CI, 11.5-12.2)) had worse outcomes at
one year when compared to their counterparts.

The younger Caucasian patients had

similar rates of recurrent stroke compared to both younger and older African American
patients throughout the first 3 months; however African Americans 45-64 years followed
by African Americans 2: 65 years of age had increasingly higher recurrent stroke rates
from 3 months to 1 year.

The event rates between race groups were significantly

different by 1 month in the older patients and 6 months in the younger patients. The
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event rates were similar for younger and ,older patients among African Americans over
the one year follow-up period. Caucasians > 65 years had consistently lower recurrent
stroke rates compared to African Americans from 14 days to one year. The younger
Caucasian patients had considerably higher event rates from 14 days to 10 months when
compared to older Caucasians. After 10 months, the gap between the younger and older
Caucasians slightly decreased. The cumulative rate of recurrent stroke at one year was
14.4% (95% CI, 13.6-15.2) for African Americans 45-64 years, 14.1 % (950/0 CI, 13.314.9) for African Americans

~

65 years, 12.0% (95% CI, 11.3-12.6) for Caucasians 45-

64 years, and 11.0% (95% CI, 10.6-11.5) for Caucasians ~ 65 years.
The event rate for first recurrent stroke for patients with hypertension was 12.1 %
(95% CI, 11.7-12.4), slightly less than the overall rate for the study cohort; however, the
. ~. i ~;'j
,

/

event rate for patients with diabetes was much higher than the overall event rate (14.4%
(95% CI, 13.5-14.6)). The cumulative rate of recurrent stroke varied when stratified by
age and race as shown in Table 3.

The recurrent tstroke rates for patients with

hypertension were significantly higher for African Americans than Caucasians in both the
younger and older age groups. While the event rates for patient with diabetes was higher
for African Americans than Caucasians in both age groups, the rates were only
significantly different in the older age group. When compared to the overall event rates
for each race-age strata, the rates for hypertension patients were slightly lower; whereas
the rates among patients with diabetes were substantially higher; however these
differences were not statistically significant.
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Discussion

The primary finding of our study is that one-year recurrent stroke hospitalization
was identified as a significant outcome for stroke patients with African American race,
young age, and diabetes associated with higher risks.

The cumulative rate of first

recurrence varied by race and age; with rates highest in the younger followed by older
African Americans, intermediate in the younger Caucasians, and lowest in the older
Caucasians. Our findings were identified using a very large, comprehensive database of
stroke hospitalizations in South Carolina.
The event rate differences in time to recurrent stroke hospitalization between the
race-age specific groups were not detectable within the first 14 days and were similar for
the younger Caucasians and both younger and older African Americans throughout the
~~I

?l

"/

first 3 months. After 3 months the cumulative event rate increased progressively with
each additional month for African Americans compared to their Caucasian counterparts.
The event rates were similar for both the younger and qlder African American patients
throughout the year; among Caucasians there appeared to be an early risk of recurrent
stroke for the younger patients throughout the first 10 months but this was not statistically
different at one year.
The one-year recurrent stroke rate for patients with hypertension was significantly
higher for African Americans than Caucasians in both age groups.

While the rates

associated with diabetes were higher for African Americans than Caucasians in both age
groups, the rates were not significantly different in the younger age group. The recurrent
rates were highest for African Americans and Caucasians in the younger group
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identifying the importance of the race-age relationship when considering the impact of
co-morbid conditions with recurrent stroke risks.
Recurrent stroke has been considered an outcome for multiple observational
studies',11-16

likewise

many

randomized

clinical

trials

including

MATCH ,25

CHARISMA,26 PROFESS,27 and AAASPS 28 also used recurrent stroke as an end point.
However, with the extent of the inter-study variability it is difficult to determine
predictors of recurrent stroke. The 12.3% recurrence reported in this study represents a
"real world" observation rate that is considerably higher than rates previously described
in clinical trials including MATCH,25 CHARISMA,26 and PROFESS,27 reporting
approximately 5% or less at one year, suggesting that the intense intervention could
reduce outcome risks.

Even among the '-1-AASPS28 trial enrolling only African
~~I '~I

'

!

Americans, the rates of recurrent stroke at one year were approximately 9.0%,
substantially less than the 14.2% reported among African Americans in our study. The
rates reported in these secondary prevention trials are t'1"o to three times less than the
12.3% in our study, indicating a target of what could be achieved with improved
treatment and compliance efforts in a real world practice.
Observation studies have reported lower rates of stroke recurrence as well, with
one-year recurrent rates ranging from 5.1 to 9.4%.1l-16 The Northern Manhattan Stroke
Study reported a 7.7% recurrent stroke rate at one year. 14 Allen et al reported a one-year
recurrence rate of 9.4% among US Medicare beneficiaries. 12 Allen et aI's study only
included patients ~ 65 years of age and excluded recurrent stroke events within 7 days of
the index stroke 12 and thus could contribute to the differences in recurrent stroke rates. In
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our study, these exclusions reduced the rate of one-year recurrent stroke to 9.6%,
comparable to that reported by Allen et a1.
The relative higher recurrent rates reported in this study may be due to higher
stroke risks in the Southeast region of the US. 2-4 A South Carolina hospital discharge
study in 2002 estimated a cumulative rate of 8.0% for one-year recurrent stroke. ll The
difference in these findings compared to ours may be related to the multiple stroke
subtypes and patients of all age groups included in their study; whereas our study was
limited to ischemic strokes and patients older than 45 years of age. In addition rates
found in the 2002 study were possibly a result of the limited data available whereas our
study analyzed data from a large cohort over a 10 year period.
While this study included a large number of patient-based cases, it is not free
. ~~I

~I
!

from limitations. In defining a one-year recurrent stroke event, we excluded patients with
a stroke admission in 1996-1998. Thus, we could not confirm the index stroke prior to
this time period and may have captured the second

st~'oke

event as the index event.

However, the average time from index stroke discharge to recurrent admission in the
overall study population was less than two years; therefore we feel that any over-/underestimates for index or recurrent stroke are minimal. Patients with their first documented
stroke admission in 2010 were also excluded due to lack of knowledge about possible
recurrent stroke admissions after the 2010 index stroke. Recurrent stroke patients' index
stroke had to occur between 1999 and 2010. The strict exclusion criteria ensured that
patients were defined as accurately as possible within the limitations of this data.
This study also included limitations inherent with the use of administrative
databases. The variables used in this study were based on ICD-9-CM diagnosis and thus
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we were unable to assess stroke severity. Hypertension and diabetes status consisted of a
dichotomous designation of present/ absent of disease, thus treatment and control could
not be evaluated. As well, the analyses did not include adjustment for socio-economic
factors known to be associated with risk of cardiovascular disease and stroke. 29 , 30
The results of this study identify one-year recurrence as a major outcome for all
stroke patients in clinical studies. The "real world" observational rate reported in this
study is significantly higher than rates reported in clinical trials,25-28 suggesting the
potential benefit of protocol-driven intense acute and post stroke management. While
this study confirms the'racial disparity in one-year recurrent stroke, the additional risks of
a race-age relationship was identified in the analyses with young African Americans
demonstrating the greatest disease burden.

Hyp~rtension

and diabetes were confirmed as

"'~i~l

significant risk factors for recurrent stroke among African Americans and Caucasians,
with higher rates among young African Americans. Future research should focus on the
benefit of secondary prevention strategies on younger African American and Caucasian
stroke patients.
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Table 1. Index and recurrent stroke patient characteristics.
Index Stroke, n (%)
Recurrent Stroke, n (%)
Characteristics

(n = 49,446)

(n = 5,590)

African American

16,146 (32.7)

2,130 (38.1)

Age 45-64 y

16,769 (33.9)

2,130 (38.1)

Race-Age group
African American 45-64 y

7,375

(1~.9)

1,031 (18.4)

Caucasian 45 -64 Y

9,394 (19.0)

1,099 (19.7)

African American > 65 y

8,771 (17.7)

1,099 (19.7)

Caucasian 2: 65 y

23,906 (48.4)

2,361 (42.2)

Male

22,854 (46.2)

2,530 (45.3)

Hypertension

32,885 (66.5)

3,724 (66.6)

Diabetes

15,570 (31.5)

2,036 (36.4)
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Table 2. Independent predictors for one-year recurrent stroke: odds ratio (95%
confidence interval)
Univariable
Multivariable
OR (95% CI)

OR (95% CI)

African American

l.41 (1.30-1.52)

1.32 (1.21-1.42)

Age (45-64 years)

1.30 (1.20-1.40)

1.24 (1.14-1.33)

Male

0.95 (0.88-1.01)

0.92 (0.85-0.99)

Hypertension

1.01 (0.93-1.08)

0.96 (0.87-1.03)

Diabetes

1.38 (1.27-1.49)

1.31 (1.21-1.42)

Predictors
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Table 3. Kaplan-Meier one-year recurrent stroke rates for hypertension and diabetes patients stratified by age and race: cumulative
percent (950/0 confidence interval).

Age ~ 65 Years

Age 45-64 Years
Characteristics

Caucasian

African American

Caucasian

African American

Hypertension

11.7 (10.9-12.5)

13.8 (12.9-14.8)

10.8 (10.3-11.4)

13.9 (13.0-14.8)

Diabetes

14.6 (13.4-15.9)

15.2 (14.0-14.6)

12.7 (11.8-13.6)

14.8 (13.6-16.1)
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Figure 1. Cumulative rates of recurrent stroke (%) by (A) race (African American vs.
Caucasian), (B) Age (45-64 vs. 2: 65 years), (C) Race-Age groups (African American 4564 years, African Americans 2: 65 years, Caucasians 45-64 years, vs. Caucasians 2: 65
years). Event curves for the groups were compared by a log-rank test.
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Abstract
Background: While standard International Classification of Diseases, Ninth Revision,

Clinical Modification (ICD-9-CM) diagnostic codes are routinely used in epidemiologic
u

stroke research, inclusion selection criteria of different ICD-9-CM codes may introduce
bias in the interpretation of trends and disparities. This study assesses the effects of ICD9-CM modifier code selection on race-age specific stroke rate estimates from
administrative databases.
Methods: ICD-9-CM diagnostic codes were used to define two cohorts of data:

Traditional (asymptomatic and symptomatic) and Modified (symptomatic only) ischemic
stroke hospitalizations, from the state-wide hospital discharged database (Oct. 20082009). Race- and age-specific rate ratios for stroke incidence and recurrence were
.-. J . ~;'i
. !

compared between the Traditional and Modified cohorts.
Results: While African Americans had higher age-specific rates of incident stroke

compared to Caucasians in both the Traditional (n=7 t 973) and Modified (n=5,979)
cohorts, the magnitude of the racial disparity rate ratios were significantly higher in the
Modified compared to the Traditional cohort (rate ratio 1.60 (95% CI, 1.52-1.69) vs. 1.21
(95% CI, 1.15-1.27), respectively); and was most prominent in patients 45-64 years old
(rate ratio 2.37 (95% CI 2.17-2.58) Modified vs. 1.81 (95% CI, 1.67-1.96) Traditional).
Among the Traditional index stroke survivors, 9.7% experienced a recurrent stroke
admission within one-year; however only 52% of these patients had a symptomatic index
followed by a symptomatic recurrent admission; effectively reducing the estimated rate
of stroke recurrence to 6.80/0 when only symptomatic hospitalizations were considered.
The African American to Caucasian recurrent stroke rate ratios were significantly less in
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the Traditional cohort than in the Modified cohort (rate ratio 1.02 (95% CI, 0.88-1.19) vs.
1.56 (95% CI, 1.28-1.89), respectively); and was most prominent in the

~

65 years age-

group (rate ratio 1.78 (95% CI, 1.38-2.31) Modified vs. 1.08 (95% CI, 0.88-1.32)
Traditional).
Conclusions: The results of this assessment indicate the inclusion of specific ICD-9-CM

asymptomatic codes for stroke without case adjudication introduces bias and potential
overestimation of incidence and recurrence and an underestimation of racial and age
disparities.
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Introduction

Hospital administrative databases have become increasingly used in health
services research providing an accessible resource for the assessment of conditions such
as stroke. However, this approach requires consideration of the bias associated with this
methodology!' 2 Administrative databases are based on the standard International
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) coding
system which includes a current detailed summary of stroke hospitalization records based
on physician diagnoses and clinical parameters. However, identification of acute strokes
using the ICD-9-CM system may lead to some misclassification of disease and disease
rates. 1, 3, 4 In October 1992, a fifth digit modifier was added to ICD-9-CM codes 433 and
434, Occlusion and stenosis of precerebral and cerebral arteries, respectively. The fifth
.

"~i '~1

digit code was designated as "0" without cerebral infarction and "1" with cerebral
infarction, and the forth digit designated the specific arterial distribution. Using this fifth
digit modifier code allowed an increase in specificity apd positive predictive value for
diagnosing acute ischemic strokes versus non-acute strokes.

1,5

Previous reports on the

accuracy of ICD-9-CM coding identified major discrepancies in the use of the 433 and
434 inclusive codes when defining acute ischemic stroke hospitalizations.

1,3-10

Studies using the ICD-9-CM coding system have described racial disparities in
stroke incidence, 11-14 severity, 15,

16

mortality,17-19 and recurrence,20, 21 with higher rates

determined for African Americans (AAs). As well, AAs are less likely to undergo
revascularization surgery than Caucasian Americans (CAs), especially at high-volume
hospitals?2-24 Thus, counting the pre-scheduled preventative procedures as an index or
recurrent stroke event may greatly overestimate stroke and recurrent stroke rates and

127

introduce biases in age, race, and gender comparisons. For studies using the ICD-9-CM
coding system to identify ischemic strokes that cannot afford the expense of adjudication,
one aspect to consider is the effect of using the inclusive ICD-9-CM codes 433.00-434.91
on population and disparity estimates. Estimates of recurrent stroke rates may similarly
be affected. The objective of this study was to assess the influence of the ICD-9-CM
modifier codes for with and without cerebral infarction on race and age disparities on the
interpretation of state-wide administrative data from hospital admission for ischemic
stroke.
Methods
Data Sources

De-identified hospitalization data for the state (excluding Veterans Administration
hospitals) were obtained from the South Catall1la Office of Research and Statistics. Data
from a hospital-based cohort of stroke patients from the Medical University of South
Carolina, in Charleston, South Carolina who were given standard interviews post
1

discharge were used to evaluate patients' perception of their hospitalization which was
coded as an ischemic stroke using the standard (433, 434, and 436) definition. Both the
state- and hospital-level administrative databases included hospitalization records for all
adult patients, age

~

45 years, discharged with a primary diagnosis of ischemic stroke

(433, 434, and 436) from October 1, 2008 to September 30, 2009 with detailed
information on patient demographics, diagnoses, and procedures. This study was
approved by the Medical University of South Carolina's Institutional Review Board.

Classification of Stroke Patients
"Stroke hospitalizations" were identified using the primary ICD-9-CM code for
ischemic

stroke

(433,

434,

and 436),
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defined

as

occlusion or stenosis

of

precerebral/cerebral arteries without cerebral infarction (433.xO and 434.xO) and with
cerebral infarction (433.x1, 434.x1), and acute, but ill-defined cerebrovascular disease
(436). Acute strokes were further classified by presentation type, "asymptomatic" or
"symptomatic". Asymptomatic was defined as a primary diagnosis of occlusion or
stenosis of precerebral/cerebral arteries without mention of cerebral infarction (433.xO or
434.xO) and no accompanying secondary diagnosis code for transient ischemic attack
(TIA, 435). Symptomatic was defined as any primary diagnosis of ischemic stroke with
cerebral infarction (433.xl or 434.xl) or acute but ill-defined stroke (436); or a noncerebral infarct primary code with an accompanying TIA code in one of the secondary
diagnoses positions.
The analyses were limited to CAs and, AAs since less than 1.8% of the population
~ ~I ~~j

were classified as other racelethnicities. Age was categorized as 45 to 64 years and 2: 65
years. Various comorbid conditions based on secondary discharge diagnoses were
classified using the Modified Charlson Index score

di~hotomized

as low comorbidity

(index 0 or 1) or high comorbidity (index 2: 2).25,26 Revascularization procedure status
was based on ICD-9-CM primary procedure codes for carotid endarterectomy (CEA,
38.12),

angioplasty/ather~ctomy

of precerebral vessels (00.61), or carotid artery stenting

(CAS, 00.63). Insurance status was classified as private, Medicare, Medicaid, and not
insured. In-hospital death was obtained from the discharge hospitalization data and postoperative stroke was defined using ICD-9-CM code 997.0 in any secondary coding
position.
Recurrent stroke was first calculated by the traditional method which identified
patients' with a second primary discharge diagnosis of ischemic stroke greater than 1 day
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•
but within one year of the index "stroke event" based on the standard expanded

diagnostic codes. All index strokes occurring after October 1, 2008 were considered firstever stroke events for both databases. Patients that died during the stroke admission were
excluded from the recurrent stroke analyses.

Recurrent stroke was recomputed and

renamed "Modified Recurrent Stroke" after removing the asymptomatic index and
recurrent "stroke hospitalizations".
A follow-up telephone survey was completed with survivors within one year post
stroke discharge to assess the patient perceptions of the hospitalization. Specifically,
participants were asked "Were you hospitalized for a stroke?" with a "yes" or "no"
response.
Statistical Analysis

In the state-level data, two subsets of data were used to compare the effects of
excluding asymptomatic hospitalizations on the estimates of racial disparities in stroke.
The first cohort (Traditional) included both symptomatic and asymptomatic ischemic
stroke hospitalizations, while the second cohort (Modified) only included symptomatic
stroke hospitalizations. In the Traditional stroke cohort, recurrent status included both
asymptomatic and symptomatic diagnoses; whereas in the Modified cohort, both the
index and the recurrent stroke admission had to be classified as symptomatic.
Descriptive statistics were used to compare baseline characteristics. Race-specific
population rates (per 100,000) were calculated by age group (45-641 2: 65 years) with the
number of strokes as the numerator and the age-adjusted South Carolina resident
population estimate for 2009 as the denominator. 27 Race- and age-specific stroke rates
were used to compare the changes in the ratio of AAs to CAs in the two cohorts. Race-
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and age-specific recurrent stroke rates and racial disparity rate ratios with 95%
confidence intervals (CI) were calculated from the total number of patients In the
respective stroke cohorts to compare the changes in recurrent stroke racial disparity rate
ratio. Univariable mixed effects logistic regression to include a random intercept was
used to compare baseline characteristics with symptomatic diagnosis; as well as to assess
patients' self-reported perception of being hospitalized for a stroke, classified as
"reported yes" or "reported no", in the hospital-level survey data. All p values are two
sided and were considered statistically significant at p< 0.05. All statistical analyses were
performed using SAS 9.3 (SAS Inc. Cary, NC).
Results

The Traditional state-level

administr~.tive

. "., 'fll
i

cohort included 7,973 patients

.'/

discharge with an ischemic stroke. Of these, 1,994 (25%) were classified as
asymptomatic and were excluded from the Modified cohort analyses. Baseline
characteristics for the Traditional and Modified

cohort~

are sho\\m in Table 1.

The

average age in both cohorts was approximately 70.3 (±12) years. AA race represented
28% of the Traditional strokes, when the 1,994 asymptomatic hospitalizations were
excluded, the proportion of AAs increased to 34% in the Modified cohort. The proportion
of patients 45-64 years of age increased by approximately 20/0 in the Modified cohort. A
primary procedural code for CEA, CAS, or Angioplasty was identified in 23% of the
Traditional stroke cohort (88% among the asymptomatic hospitalizations) compared to
the 1% identified in the Modified cohort, suggesting that an asymptomatic stroke
diagnosis is highly correlated with revascularization procedures rather than an acute
stroke hospitalization.
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The overall estimate of stroke incidence in the Traditional cohort was 220.6 (95%
CI 215.8-225.5) strokes per 100,000; however, this rate dropped to 165.4 (95% CI 161.3169.6) per 100,000 when asymptomatic hospitalizations were excluded. In both stroke
cohorts, AAs had higher age-specific rates (per 100,000) than CAs (Table 2). However,
the rate ratios of AAs to CAs were significantly less in the Traditional cohort than in the
Modified cohort (rate ratio 1.21 (95% CI, 1.15-1.27) vs. 1.60 (95% CI, 1.52-1.69)).
Furthermore, the rate ratio for this disparity was most prominent in the younger age
group, where AAs 45-64 years old were 2.37 (95% CI, 2.17-2.58) times more likely to
have a symptomatic stroke hospitalization than their young CA counterparts; however,
this ratio fell to 1.81 (95% CI, 1.67-1.96) when asymptomatic hospitalizations were
included in the analyses. By age

~

65 years, the differences in the racial disparity
, J~i :~j
.'

between the Traditional and Modified stroke cohorts were slightly attenuated, although
the ratio remained significantly higher in the Modified cohort.
Among the 7,640 index stroke survivors, 740 \9.7%) experienced a recurrent
stroke admission within one-year of their index stroke. However, approximately half of
these patients had either an asymptomatic index or recurrent stroke admission (Table 3).
Only 51.6% of the patients had a symptomatic index admission followed by a
symptomatic recurrent stroke admission.

Among the symptomatic to symptomatic

hospitalizations very few had a revascularization procedure during the index or recurrent
stroke admission (0.8 and 3.4%, respectively). Whereas a large proportion of both index
and recurrent asymptomatic admissions were associated with a revascularization
procedure; especially among asymptomatic to asymptomatic hospitalizations where 141
of the 199 (70.9 %) had a procedure at both their index and recurrent stroke admissions
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(the average time between admission was approximately 80 days, data not shown). Only
4.3% of the recurrent stroke patients had an asymptomatic admission followed by a
subsequent symptomatic admission (average time between admissions was 153 days).
The overall rate of recurrent stroke in the Traditional cohort was 9.7%; whereas
the rate dropped to 6.8% when only symptomatic index and recurrent admissions were
considered in the Modified cohort. Similar to the overall stroke population rates, AAs had
higher age-specific recurrent stroke rates in both datasets; except in the younger age
group among the Traditional cohort, where young CAs had slightly higher recurrent
stroke rates compared with young AAs (rate ratio 0.89 (95% CI, 0.71-1.13)) although not
significant (Table 4). However, the recurrent stroke rate ratios of AAs to CAs were
considerably less in the Traditional cohort than in the Modified cohort (rate ratio 1.02

.u,
,

~~j

.j

. (95% CI, 0.88-1.19) vs. 1.56 (95% CI, 1.28-1.89)). Unlike seen in the overall stroke rates,
the rate ratio for this disparity was most prominent in the older age group, where AAs 2::
65 years old were 78% more likely to have a sYIIfptomatic index and recurrent
hospitalization than their older CA counterparts. When asymptomatic hospitalizations
were included in the analyses, this ratio fell to only 8%.
The hospital-level survey data included 197 ischemic stroke patients with 25%
occurring among AAs and 51 % in males. The average age of the surveyed patients was
68.6 (±11) years, with 34% of patients 45-64 years of age. Symptomatic admissions were
identified in 135 (68.5%) of the patients (62 (31.50/0) asymptomatic) (Table 5). Thirtyfive (17.8%) of the surveyed patients reported that they were not hospitalized for a stroke,
30 (85.7%) of these patients had an asymptomatic admission whereas only 5 (14.30/0) had
a symptomatic admission. However, 96.3 % of the patients classified as symptomatic
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reported that they were hospitalized for a stroke, while only 48.4% of the patients
classified as asymptomatic reported that they had not had a stroke. AAs and patients 4564 years had significantly higher rates of symptomatic stroke hospitalizations and
significantly lower rates of revascularization procedures as compared to their
counterparts.
Discussion

This is the first evaluation of the impact of ICD-9-CM modifier codes for
ischemic stroke on racial and age disparity estimates. Retrospective stroke studies using
administrative databases more often than not identify acute ischemic stroke
hospitalizations using the inclusive

ICD-9~CM

codes 433.00-434.91, and 436; despite the

numerous reports on the inaccuracies of using. these codes in defining acute stroke
. uj

~;'j

'/

events. 1, 3-10 This study, using state-wide hospitalization data, showed that using the
traditional

ICD-9-CM

codes

for

ischemic

stroke

hospitalizations) impacted the stroke incidence rate

(including

asymptomatic

iq this population; as well as

significantly affected the racial and age disparity estimates for stroke incidence. Although
AAs had higher age-specific rates of stroke in both the Traditional and Modified cohorts,
the ratios of AAs to CAs were significantly lower when asymptomatic hospitalizations
were included in the numerator, especially in patients less than 65 years of age. The
reduction in the racial disparity estimates of stroke incidence could be due in large part to
the higher rate of asymptomatic diagnosis in CA patients.

Furthermore, the

asymptomatic diagnosis is often associated with revascularization procedures as a means
of index or recurrent stroke prevention. 22 , 28-31 Recent reports suggest that CAs are two to
three times more likely to receive the procedure?2-24
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This type of revascularization

procedure is often a planned scheduled hospital admission and not an acute stroke
event. 32

Therefore, including the pre-scheduled preventative procedures as an acute

stroke event may not only result in the overestimation of true stroke incidence, but may
also vastly underestimate the racial disparities in stroke. The same may hold true for
recurrent stroke estimates, as these procedures are used as a means of recurrent stroke
prevention. Thus, if an asymptomatic recurrent admission is counted as an acute
secondary stroke event, the rates of recurrent stroke will be significantly overestimated.
In this analysis, the traditional recurrent stroke rate was estimated at 9.7%, with
approximately half of the admissions having an asymptomatic diagnosis at either the
index or recurrent stroke admission. A majority of the asymptomatic readmissions were
associated with a vascular procedure, with 71 ~. 9f the patients having a revascularization

. ~~~ ?!

procedure at both the index admission and at the subsequent admission approximately 80
days after the index discharge. The rate of recurrent stroke was reduced to 6.8% when
only symptomatic index and recurrent admissions were cqnsidered.
Studies using the ICD-9-CM coding system have shown increased recurrent
stroke rates among AAs.20, 21 In this study., when both asymptomatic and symptomatic
stroke hospitalizations were included, the recurrent stroke rates were highest for young
CAs (rate ratio 0.89 (95% CI, 0.71-1.13)). When only symptomatic hospitalizations were
included the rate ratio increased to 1.21 (95% CI, 0.90-1.64 )for AAs versus CAs. The
rate ratio for this disparity was most prominent in the older AAs with a 70% higher
likelihood of having a symptomatic index and recurrent stroke admission than older CAs,
compared to only 8% higher rate in the Traditional cohort. The drastic difference in ratios
between traditional and modified recurrent stroke estimates may too be a reflection of the
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higher rates of revascularization procedures among older CAs. 22 -24 Therefore, including
asymptomatic diagnoses at index or subsequent admissions, especially for admission
associated with vascular procedures could greatly overestimate both the incident and
recurrent stroke rates in a given population and may affect the reported rates of racial
disparities.
Two recent studies excluded the asymptomatic diagnosis codes for ischemic
stroke in their analyses. 33 , 34 Lichtman et al. reported on readmission rates in a Medicare
population excluding the asymptomatic codes in the readmission rates. 33 The authors
repeated the risk-standardized mortality rate (RSMR) and risk-standardized readmission
rate (RSRR) analyses restricting the cohort to ICD-9-CM 433.xl, 434.xl, and 436. In the
repeat analyses they found an increase in the ,.RSMRs and RSRRs as compared to the
'J~;"1

cohort using the traditional index stroke diagnoses. Thus the exclusion of the
asymptomatic stroke codes can have an effect on estimated mortality and readmission
rates in addition to affecting the racial disparity ratio.
Furthermore, the

incl~sion

of the asymptomatic diagnoses in the concept of

"stroke admission" may be confusing in the interpretation of the patients' perception of
their "stroke hospitalization". Among the 17.8% of the patients who reported not having
been hospitalized for a stroke, most were consistent with a non-stroke hospitalization
based on the specific discharge codes. But a few patients reported not having a stroke
when they in fact were hospitalized for stroke based on their discharge coding. Further
research is required to identify reasons for these misperceptions.
Administrative databases using the ICD-9-CM coding system continues to be a
valuable resource for convenience samples; however, when identifying acute stroke
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hospitalizations, it is important to understand the principal usages and caveats associated
with these codes. Before defining stroke in an epidemiological study it is import to first
identify the goal of the study. If the goal is to determine trends and patterns of both stroke
and cerebrovascular recognition and treatment then using a traditional definition of
ischemic stroke, i.e. 433, 434, and 436, would seem advantageous as this would
incorporate all subjects at risk for stroke. However, if the goal is to examine specific
characteristics of acute or recurrent stroke especially in regards to estimating disparities,
then modified codes should be examined to eliminate potentially high proportion of nonstroke or asymptomatic cases as to not overestimate the true stroke incidence and
recurrence. Thus, for studies using the ICD-9-CM coding system to identify ischemic
stroke incidence, recurrence, and potential disp<:lrities that cannot afford the expense of
'~~J-1

adjudication, the asymptomatic codes for stroke should be excluded, especially when the
hospitalization is associated with a primary ICD-9-CM code for a revascularization
procedure, as including the asymptomatic codes may lea" to an overestimate in incidence
and recurrence and an underestimate in racial and age disparities.
In conclusion, the inclusion of the codes for asymptomatic conditions has a large
impact

on

disparity

estimates,

reducing

the

apparent

AA -CA

differences.

Epidemiological studies should consider excluding the asymptomatic codes to gaIn a
better understanding of true stroke disparity.
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Table 1. Patient characteristics for index stroke admission
Traditional
Asymptomatic *
Patient Characteristics, n (%)
(n =1,994)
(n = 7,973)

Modified!
(n==5,979)

African American

2,253 (28.3)

201 (10.1)

2,052 (34.3)

Age 45-64 years

2,600 (32.6)

509 (25.5)

2,091 (34.5)

Male

3,930 (49.3)

1,081 (54.2)

2,849 (47.7)

1,397 (53.7)

319 (62.7)

1,078 (5l.6)

Medicare

581 (22.4)

115 (22.6)

466 (22.3)

Medicaid

297 (11.4)

41 (8.1)

256 (12.2)

Not Insured

325 (12.5)

34 (6.7)

291 (13.9)

Low (0-1)

4,861 (61.0)

1,260 (63.2)

3,601 (60.2)

High (2: 2)

3,112 (39JJ.) ~?'

734 (36.8)

2,378 (39.8)

Insurance status
(% in < 65 years old)

Private

Comorbidity Index, %

Procedure

1,804 (22.6)

1,744 (87.5)

60 (1.0)

CEA

1,621 (20.3)

1,574 (78.9)

47 (0.8)

CAS/Angioplasty

183 (2.3)

170 (8.5)

13 (0.2)

In-hospital mortality

333 (4.2)

t 6 (0.3)

327 (5.5)

Post-operative stroke

29 (0.4)

17 (0.9)

12 (0.2)

740 (9.7)

231 (11.6)

382 (6.8)

Recurrent stroke t

CEA: carotid endarterectomy; CAS: carotid artery stenting.
* Profile of asymptomatic hospitalizations that were excluded in the Modified cohort.
t Recurrent stroke excludes patients that died during index stroke admission in the
denominator and the Modified recurrent rate only includes patients that were classified as
symptomatic for both the index and recurrent stroke admissions.
t Asymptomatic and symptomatic status is significantly different for all variables (p <
0.05).
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Table 2. Index stroke rates and racial disparity rate ratios by age
Traditional

Modified

Rate Ratio
Stroke Rates

Rate Ratio

CA

AA

AA vs. CA

CA

AA

AA vs. CA

209.9

253.6

1.21 (1.15-1.27)

144.1

231.0

1.60 (1.52-1.69)

Age 45-64 years

89.1

161.3

1.81 (1.67-1.96)

63.8

Age ~ 65 years

427.3

497.2

1.16 (1.09-1.24)

All Ages

151.0 2.37 (2.17-2.58)

288.6 441.9

1.53 (1.43-1.64)

AA: African American; CA: Caucasian; Age-adjusted rates per 100,000 population,
racial disparity rate ratio and 95% CIs.
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Table 3. Index to one-year recurrent stroke admissions by presentation type (n = 740).
Index to Recurrent Admission
Procedure at
Presentation Type

Procedure at

Total, n (%)

Index Admission

Recurrent Admission

Symptomatic to Symptomatic

382 (51.6)

3/382 (0.8)

13/382 (3.4)

Symptomatic to Asymptomatic

127 (17.2)

4/127 (3.2)

116/127 (91.3)

Asymptomatic to Asymptomatic

199 (26.9)

152/199 (76.4)

180/199 (90.5)

32 (4.3)

24/32 (75.0)

1/32 (3.1)

Asymptomatic to Symptomatic
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Table 4. Recurrent stroke rates and racial disparity rate ratios by age.
Traditional Recurrent Strokes

Modified Recurrent Strokes*

Rate Ratio

Rate Ratio

Recurrence, %

CA

AA

AA vs. CA

CA

AA

All Ages

9.62

9.86

1.02 (0.88-1.19)

5.66

8.82

1.56 (1.28-1.89)

Age 45-64 years

11.31

10.10

0.89 (0.71-1.13)

7.08

8.58

1.21 (0.90-1.64)

Age ~ 65 years

8.96

9.64

1.08 (0.88-1.32)

5.07

9.05

1.78 (1.38-2.31)

AA vs. CA

AA: African American; CA: Caucasian; excludes patients that died during index stroke admission (n=7,640 for
Traditional Recurrent Strokes and n=5,652 for Modified Recurrent Strokes); racial disparity rate ratio and 95% CIs.
* Both index and recurrent strokes were classified as symptomatic.
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Table 5. Survey patients' perception of stroke hospitalization by race and age.
Race
Overall

CA

AA

(n=197)

(n=147)

(n=50)

Stroke Perception*

P

Age

45-65

2: 65

(n=67)

(n=130)

0.047

0.039

Reported No

35 (17.8)

32 (21.8)

3 (6.0)

5 (7.5)

30 (23.1)

Reported Yes

162 (82.2)

115 (78.2)

47 (94.0)

62 (92.5)

100 (76.9)

Presentation Type

0.003

0.008

Asymptomatic

62 (31.5)

55 (37.4)

7 (14.0)

10(14.9)

52 (40.0)

Symptomatic

135 (68.5)

92 (62.6)

43 (86.0)

57(85.1)

78 (60.0)

53 (26.9)

49 (33.3)

4 (8.0)

8 (11.9)

45 (34.6)

Procedure

0.001

AA: African American; CA: Caucasian; values reported as: n (%).
* Stroke Perception based on patients' self-reported response to having been hospitalized for a stroke.
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P

0.01

Appendix. International Classification of Diseases, 9th Revision, Clinical Modification
diagnostic and procedural codes.
Procedure
Diagnosis
Procedure
Diagnosis
code
code
Occlusion and stenosis of precerebral
arteries without mention of cerebral

433.xO a

Carotid

38.l2

endarterectomy
infarction
Occlusion and stenosis of precerebral

433.x1 a

arteries with cerebral infarction
Occlusion of cerebral arteries without

Angioplasty or
434.xO b

mention of cerebral infarction
Occlusion of cerebral arteries with

atherectomy of

00.61

precerebral vessels
434.x1 b

cerebral infarction
Transient ischemic attack

Percutaneous

Acute, but ill-defined cerebrovascular

insertion of

disease

436

00.63

carotid artery stent

digit modifier for 433.xO/l represents: 433.0 basilar artery, 433.l carotid' artery,
433.2 vertebral artery, 433.3 multiple and bilateral, 433.8 other specified precerebral
artery, or 433.9 unspecified precerebral artery
b Forth digit modifier for 434.xO/l represents: 434.0 cerebral thrombosis, 434.1 cerebral
embolism, or 434.9 unspecified cerebral artery occlusion
a Forth
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CHAPTER 4

Antihypertensive Medication Persistence at Discharge and within One-year Post
Stroke Hospitalization
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Abstract
Background and Purpose: Excellent blood pressure control post stroke reduces stroke

risk. However, data suggest that blood pressure control after stroke is suboptimal. In
order to continue to reduce blood pressure post stroke persistence is important. This study
assesses the persistent use of antihypertensive medications one-year post stroke
hospitalization in stroke survivors.
Methods: Stroke survivors were surveyed VIa structured telephone interviews to

determine antihypertensive regImen persistence from hospital discharge to one-year.
Risk factors associated with receipt of antihypertensive medication at discharge and
independent predictors of persistence at one-year were analyzed by logistic regression
analyses.
c
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Results: Interviews were completed on 271 stroke survivors, of which 213 (79%) were

discharged on antihypertensive therapy (two-thirds on 2: 1 antihypertensive). Factors
associated with receiving antihypertensive therapy at discparge included advanced age (2:
65 years), comorbidity, uncontrolled blood pressure

(~

140/90 mm Hg), premorbid

antihypertensive therapy, and receipt of antilipidemics or antithrombotics at discharge.
Within one-year post stroke hospitalization, 87% of the treated patients remained on
some type of antihypertensive therapy, with 30% persistent on all medications from
discharge to follow-up. Similarly, 39% of the patients were persistent on all or at least
two antihypertensives within the same drug class as prescribed at discharge. Persistence
was highest in patients on ACE inhibitors (69%) and lowest for patients on diuretics
(24%). African Americans (OR 0.43, 95% CI 0.21 to 0.87) and comorbid conditions (OR
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0.10, 95% CI 0.02

to

0.43) were inversely associated with persistence on

antihypertension therapy.
Conclusions: The results of this study indicate a high rate of persistence In
antihypertension therapy In stroke patients from discharge to one-year follow-up.
However, the persistent rate for specific treatment regImen was relatively low.
Persistence was significantly lower for certain antihypertensive medication classes,
African Americans, and patients with high comorbidities. Recurrent stroke risk for these
high risk groups could be reduced by understanding the effects of race and comorbid
conditions on medication persistence.
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Introduction

Blood pressure is recognized as an important risk factor for stroke in both
hypertensives and nonhypertensives. 1-4 The most effective method to reduce stroke risk
is to reduce the incidence of hypertension. 5-7 Hypertension poses a maj or public health
burden and will continue to do so if the lifetime risk of elevated blood pressure remains
unattenuated. 8- 10 Thus, antihypertension therapy has become imperative in the prevention
of primary and recurrent stroke. 1 1-16 The Perindopril Protection Against Recurrent Stroke
Study (PROGRESS), found that a angiotensin-converting enzyme (ACEs) inhibitorbased blood pressure lowering regimen in combination with thiazide-type diuretic
reduced the risk of stroke for both hypertensive and normotensive patients with a prior
history of stroke. 8 Current guidelines have inc~qJorated hypertension treatment to reduce

. k .19
recurrent stro ke rls
'

. "'", 'III
'I

Growing evidence suggests that blood pressure remains poorly controlled in a
substantial number of patients after stroke discharge. 17 -20 tStudies suggest that in-hospital
initiation of antihypertensive therapies prior to stroke discharge may not only improve
" daherence,'
24 25 but mayal
'
treatment rates 21-23 and me d'IcatIon
so'Inf1 uence communIty
practices 21 , 25, 26 as well as reduce the risk of recurrent vascular events post index stroke
discharge. 26 ,27 While benefits of antihypertension treatment regimens after a stroke are
clear, the persistence of therapy after long-term follow-up post hospital discharge are less
clear.
The purpose of this study was to assess antihypertensive medication regimen
persistence post stroke discharge among patients from a Primary Stroke Center.
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Patients and Methods

This observational follow-up study was based on a one-year stroke cohort
(October 1, 2008 - September 30,2009) from a Joint Commission Primary Stroke
Center, Medical University of South Carolina, Charleston, SC. All patients discharged
with a primary diagnosis of stroke (ICD-9-CM 430-438) who were at least 45 years of
age were eligible for this study. Information on demographics and discharge variables
including discharge medications and last documented blood pressure value prior to
discharge were obtained from the patients' electronic medical records. A posthospitalization telephone survey of stroke survivors was used to assess patient persistence
with stroke discharge medications. The survey tool was adapted from a standardized
validated medical questionnaire and was conducted by trained research interview
, ~., ~~j
'/

professionals from a contracted research facility. Self-reported demographic, behavioral,
medication and medical history data were obtained during the interview. Family members
or primary care giver proxies were used for patients who cpuld not respond due to illness
severity or speech or language deficits.
Current medication information was collected by asking the patient/ proxy to read
the names from the patients' current medication bottles to assess current usage and
name/class of drug. The patient/ proxy was asked in a series of questions if they were on
the medications prior to their stroke hospitalization (premorbid treatment) and if the
doctor changed the medication, class or dosage, after the stroke hospitalization. The
survey data were matched to the state medical claims hospitalization records, provided by
the South Carolina Office of Research and Statistics, Columbia, SC, to obtain detailed
information on patient demographics, diagnoses, procedures, and clinical outcomes for
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all eligible patients in the cohort. For patients with multiple stroke hospitalizations
during the study time period, we used the latest discharge hospitalization records and
assumed all answers to the survey questions were in response to their most recent stroke
at time of the telephone interview. All patients included in this study were willing and
consenting participants. This study was approved by the Medical University of South
Carolina~s

Institutional Review Board.

Analytical Population
A total of791 stroke patients were assessed for eligibility, of whom 131 (16.6%)
died during the index hospitalization or prior to follow-up, 29 (3.7%) resided in hospice,
or rehab skilled nursing, or long-term care facilities, 98 (12.4%) were lost to follow-up
and 149 (18.8%) patient/proxy refused. To be yligible for inclusion in this study,
.

~ ~I
,

-,1/
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documentation on a specific medication or class of medication at discharge was required.
A total of 384 subjects consented to the telephone interview for which 271 met all
inclusion criteria for this study. The average time betweeIf hospital discharge and followup survey for this cohort was approximately ten months. All patients that met the
inclusion criteria were of Caucasian and African American race, no patients were
classified as other race/ethnicities. Age was categorized as 45 to 64 years and 2: 65 years.
Patients on private, Medicare, or Medicaid insurance were considered to have insurance
coverage. Comorbid conditions were based on secondary discharge diagnoses and were
classified using the Modified Charlson Index score dichotomized as low comorbidity
burden (index 0 or 1) or high comorbidity burden (index 2: 2).28,29 Patients were
classified as being controlled (BP <140/90 mm Hg) or uncontrolled (BP 2: 140/90 rnm
Hg) based on last reported blood pressure prior to discharge. First stroke hospitalization
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during the study time period was considered the index stroke. Recurrent stroke was
defined as a second primary discharge diagnosis of stroke greater than 1 day but within
one year of the index stroke.
For this analysis, only antihypertensive medications were assessed in detail. We
categorized the classes of antihypertensive medications into: diuretics, beta-blockers,
angiotensin-converting enzyme (ACEs) inhibitors, angiotensin receptor blockers (ARBs),
calcium channel blockers (CCBs), and "other" antihypertensives. Antilipidemic
medications were classified as statins and nonstatins and antithrombotic medications
were classified as anti platelets and anticoagulants. Medication continuation was
ascertained by comparing medications at discharge with the current medications reported
at follow-up. Persistence was defined as

contin~ation

of antihypertensive medications

, ~-/-'''l
'/

based on drug class prescribed at hospital discharge and was assessed in four levels of
persistence. Patients who remained on all discharged medication classes at time of
follow-up were classified as absolute persistence. Two+ l?ersistence refers to patients
that remained on all or at least two, if prescribed two or more, discharged medications
within the same drug class at follow-up. One+ persistence refers to patients that
remained on all or at least one discharged medications within the same drug class at
follow-up. Any persistence refers to patients that remained on any antihypertensive
therapy at follow-up.
Univariable mixed effects logistic regression to include a random intercept was
applied to compare baseline characteristics associated with receipt of antihypertensive
therapy at discharge and to assess patient characteristics associated with persistence on all
or at least two discharged antihypertensive medications. Odds ratios and 95% confidence
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intervals (CI) were calculated. All p values are two sided and were considered
statistically significant at p<O.05. All analyses were performed using SAS 9.3 (SAS Inc.
Cary, NC).

Results
A total of 271 stroke survivors were included in the analyses, of whom 22% were
African American and 41 % were female, with an average age of 64.9 (± 11.3) years.
Sixty-three percent of the patients were discharged with a secondary diagnosis of
hypertension, 38 % were discharged with an uncontrolled blood pressure (BP 2: 140/90
mm Hg), with 28% discharged with both a secondary hypertension diagnosis and an
uncontrolled blood pressure at discharge. Patients with comorbid hypertension, diabetes,
or atrial fibrillation were more likely to be" discharged with an uncontrolled blood
'~"i

'*"

'/

pressure (data not shown).
Of the 271 stroke survivors, 213 (79%) were discharged on antihypertensive
therapy. Baseline characteristics associated with antihypertensive therapy at discharge are
shown in Table 1. Older age, patients with comorbid hypertension, diabetes,
hypercholesterolemia, or heart disease, and patients also receiving statin or antiplatelet
therapy were more likely to be discharged on antihypertensive therapy. Patients
discharged on antihypertensive therapy had, on average, a higher systolic but not diastolic
blood pressure. Approximately 21 % of the patients with an uncontrolled blood pressure
at discharge were not started on antihypertensive therapy. There was no difference in
length of hospital stay, insurance coverage, or discharge disposition between patients
discharged on antihypertensive therapy versus not on therapy. Patients with premorbid
use of antihypertensive medications were more likely to be continued on therapy.
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Beta-blockers (112, 52.6%) and ACE inhibitors (110, 51.6%) were the most
prescribed class of antihypertensives among the cohort, followed by diuretics (82, 38.5%)
and calcium-channel blockers (67, 31.5%), and the least prescribed classes vvere ARBs
(41, 19.3%) and other (16, 7.5%). An ACE inhibitor and a beta-blocker was the most
common regimen used in combination among the 140 patients on two or more
antihypertensives, with 55 (39.3%) of the patients discharged on both classes. Among the
patients discharged on antihypertensive therapy, 186 (87.3%) remained on some
antihypertensive regimen at follow-up, with 164 (77.0%) remaining on at least one drug
within the same class as their discharge regimen; whereas, absolute persistence and
persistence on all or at least two antihypertensives within the same drug class were
significantly less at follow-up (30.1 % and 39.0%, respectively) (Figure 1). The
J

K/ ~~I
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persistence rates varied by antihypertensive drug class, with highest rates of persistence
among ACE inhibitor users and lowest among diuretic users.
African Americans and patients with a high comorbidity burden were
significantly less likely to be persistent on their discharged antihypertensive regimen at
follow-up (Table 3). As well, persistence was significantly associated with monotherapy
as compared to combination therapy at discharge. Older age, prior history of stroke,
insurance status, and premorbid antihypertensive therapy was not associated with
medication persistence. Persistence was slightly lower for antilipidemic therapy (81.3 %),
but similar for antithrombotic therapy (88.8%) compared to antihypertensive therapy
(87.3%).
Among the patients discharged on antihypertensive therapy, 152 (71.4%) of the
patients reported premorbid antihypertensive treatment, of which 42% claimed that the
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physician altered their antihypertensive medication via dosage or medication! brand
change after their stroke hospitalization.

Of the 58 patients not discharged on an

antihypertensive, 15 (26%) were started on an antihypertensive regimen prior to followup (16% on ACE inhibitor); whereas 74% never had therapy initiated after hospital
discharge.
Discussion

In this study, nearly 80% of stroke survivors were discharged on at least one
antihypertensive medication, with a majority (66%) discharged on two or more agents.
While 87% of stroke survivors prescribed an antihypertensive at discharge remained on
some antihypertensive regimen after discharge, only 39% remained on the same
regImens.
Older patients, patients with stroke related comorbidities and with premorbid use
of antihypertensive therapy were more likely to be prescribed an antihypertensive at
discharge. However, 43% of the patients receiving therapy were discharged with an
uncontrolled blood pressure of> 140/90 mm Hg. The results of this study identified 21 %
of the stroke survivors were discharged on no antihypertensive therapy. The patterns for
the lack of prescribed therapy were not associated with contraindications andlor other
barriers to antihypertensive therapy, such as inadequate length of stay to initiate
hypertension management, lack of insurance coverage, or advanced end organ diseases
such as End-stage Renal Disease. As well, all patients not prescribed antihypertensives,
received other medications at discharge with 50% receiving statins. Further analysis on a
case-by-case basis is needed to assess the justifications for not initiating antihypertensive
therapy in these patients with an uncontrolled blood pressure at discharge.
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The Acute Candesartan Cilexetil Therapy in Stroke Survivors (ACCESS) trial
reported improved outcomes among patients receiving antihypertensive therapy shortly
after stroke onset, supporting the safety and efficacy of early implementation,30 especially
since the risk of recurrence is highest in the first few weeks and months after initial
stroke. 31 -33 In hospital initiation of antihypertensive therapies have been shown to be
associated with significant improvement in rates of hospital discharge treatment
utilization,23 as well as medication adherence24, 25 and achievement of target biomarker
goals within the months following stroke hospitalization in the Preventing Recurrence Of
Thromboembolic Events through Coordinated Treatment (PROTECT) study?3, 34

In

addition, in-hospital initiation of therapy was associated with a reduction in recurrent
stroke risks?6, 27

Healthcare providers shOUld take advantage of the opportunity to

,

~7/1

institute evidence-based prevention strategies during the acute stroke hospitalization;
otherwise, long-term initiation of treatment may be deferred to the post discharge clinical
setting in which there is a risk of loss of adequate fPllow-up of care and reduced
medication persistence. 21 , 25
Therapy regimens are critical considerations in the assessment of therapy
persistence. The PROGRESS, found that a ACE inhibitor-based blood pressure lowering
regimen reduced the risk of recurrent stroke in both hypertensive and normotensive
patients. 8

Combination therapy produced larger risk reduction and blood pressure

reductions than monotherapy and should be considered for all patients with a history of
stroke irrespective of the patients' age. 8 Further, the PROGRESS study showed that a
combination of ACE inhibitor and thiazide-type diuretic significantly reduced recurrent
stroke risks. 8,

9

However, it should be noted that in our study only 18% of stroke
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survIvors were discharged on a combination of an ACE inhibitor and diuretic.
Individuals with an increased risk as indicated with a history of prior stroke may be
treated differently based on their medical history.9 However, in this study a history of
prior stroke was not associated with receipt of antihypertensive medications at discharge,
despite the current guidelines suggesting antihypertensive use in secondary stroke
prevention, even among normotensive patients. I, 9
The rate of persistence with any antihypertensive therapy is consistent with other
studies of stroke patients.

However, the rates for specific treatment regimens were

substantially lower than other assessments. The PROTECT 35 study reported high rates of
persistence on ACE inhibitor/ ARB (89%) and thiazide diuretics (82%) at 1 year followup, which was higher than the 71 %

persistel1:.c~
."'~;,
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on ACE inhibitor/ARB and 24% for

diuretics in this current study. The higher persistence rates in the PROTECT study may
be affected by the intense structure of a controlled clinical trial that incorporated
strategies to enhance adherence. 35

Sappok et al. ~ showed high rates of any

antihypertensive persistence (91 %) at one year post stroke in a German cohort of patients
discharged on antithrombotic therapy.36 However, the rate of persistence on all discharge
regimens was higher (56%) as compared to 30% persistence on all discharge regimens
found in our study.

Similarly, the Adherence Evaluation After Ischemic Stroke-

Longitudinal (AVAIL) Registry study reported significantly higher rates of absolute
persistence (66%) on antihypertensives by drug class at one-year in patients hospitalized
in American Heart Association! American Stroke Association Get With The Guidelines Stroke (GWTG-Stroke) hospitals. 37
In this study, patients with lower rates of persistence at one year post stroke
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hospitalization included African Americans and stroke surVIvors with comorbid
conditions.

The differences in therapy persistence between African Americans and

Caucasians could be due in part to socio-economic factors?8, 39 While these indicators
were not assessed in detail in this study, the majority (96%) of patients had insurance
coverage. Higher comorbidity burden was inversely associated with persistence, which
may be associated with additional medications and increased rates of contraindications
for antihypertension treatment. 6, 9 Similarly, monotherapy prescribed at discharge was
significantly associated with increased treatment persistence. 37, 40 Simplified medication
regimens, such as fixed-dose combination pills in antihypertensive medications, have
been shown to increase adherence;41 however, fixed-dose combination therapy was not
significantly associated with persistence in

Otl~"" ~tudy.
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The AVAIL study found that the

most common reason for non-persistence was the discontinuation of therapy based on the
recommendations of their post-discharge health care provider?7 In our study, having a
post-stroke follow-up appointment at the hospital outpafient clinic or seeing a primary
care provider on a regular basis was not associated with persistence (data not shown).
Frequent contact with a physician may contribute to an increase in changes made to the
patients therapeutic regimen due to non-adherence or adverse effects of the medication,
and thus decrease persistence on discharged regimen, although not significant in this
study.
When comparIng persistence on other secondary stroke prevention therapies,
persistence on any antilipidemic at one year post discharge was slightly lower than
antihypertensive therapy persistence, but was similar for antithrombotic therapy.
However, these rates are substantially lower than the rates reported in the Ovbiagele et
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al 35 and Lummis et al 42 studies where rates of persistence on antilipidemics were 99%
and 91 %, and antithrombotics were 98% and 96%, respectively.
The strengths of our study are that it represents an assessment of antihypertensive
treatment regimens in a clinical setting in relatively young (mean age 65) high-risk
population. Most studies involving secondary stroke prevention medication adherence
and persistence are based on nationwide, multi-site clinical trials for which data are less
.
.
43 ' 44
, bl e and th us may overestImate
generaI Iza
me d"Icatlon perSIstence.
We were limited to measuring medication persistence as opposed to adherence/
continued use as we did not obtain dosage information at follow-up,

Our method of

measuring persistence was based on self-report data which was not validated via pill
count or pharmacy claims data; however, nq" gold standard has been established to
~~I
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measure medication persistence and studies have shown sufficient agreement between
patient self-report data and pharmacy claims records. 42 ,

45, 46

In addition, reasons for

discontinuation of medication such as potential contraindipations or adverse effects which
may have been physician- as opposed to patient-initiated were not assessed in this study.
Patients who were lost to follow-up or died were not included in the follow-up
assessment and thus may result in overestimates of persistence. All follow-up data was
collected via telephone interview; therefore, results on current and prior medication data
are limited by the credibility of the patients and prOXIes.

Recurrent stroke

hospitalizations may have occurred before follow-up meds were ascertained but
medications listed at last stroke hospitalization during study period were used to compare
to the follow-up medication list.

Finally, we did not collect information on blood

pressure throughout the hospital stay which may have affected prescribed therapies
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especially since studies have shown that blood pressures within days of acute stroke may
not reflect the patients' baseline levels;47, 48 however, guidelines suggest that
antihypertensive therapy is beneficial in all stroke survivors as a means of secondary
prevention regardless of hypertension status prior to stroke hospitalization. 7, 8
In conclusion, long-term persistence on at least one secondary stroke prevention
therapy in this cohort was high; however persistence on specific treatment regimen
prescribed at discharge was relatively low.

Persistence varied considerably by

antihypertensive drug class, with highest persistence at one year for ACE inhibitors and
lowest for diuretics. African American race and high comorbidity burden was inversely
associated with persistence; whereas fewer prescribed antihypertensive medications at
discharge increased persistence on recommenged treatments. The results of this study
'''~I
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have identified impact of antihypertension treatment on long-term follow-up of stroke
patients and secondary prevention. Additional studies are needed to identify modifiable
target risk factors and effective interventions to imprpve long-term persistence and
quality of secondary stroke prevention.
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Table 1. Baseline characteristics of patients discharged on an antihypertensive (n=271 ).
On
Not on
Antihypertensive Antihypertensive
(n=213,790/0)
(n=58, 21 %)
P
Characteristics
0.53
African American, %
49 (23.0)
11 (19.0)
119(55.9)
18(31.0)
0.008
Age 2: 65 years, %
0.0497
95 (44.6)
16 (27.6)
Male, %
12 (20.7)
Uncontrolled BP (> 140/90 mm Hg), %
92 (43.2)
0.009
0.0001
SBP at discharge, mm Hg, mean ±SD
136 ± 22
124 ± 20
0.19
69 ± 14
71 ± 14
DBP at discharge, mm Hg, mean ±SD
Comorbidities, %
<.0001
17 (29.3)
Hypertension
154 (72.3)
3 (5.2)
52 (24.4)
0.007
Diabetes
16 (27.6)
98 (46.0)
0.036
Hypercholesterolemia
0.025
3 (5.2)
41 (19.3)
Heart Disease
5 (8.6)
0.58
24(11.3)
Atrial Fibrillation
0.16
19 (32.8)
Prior Stroke
46 (21.6)
0.40
3 (5.2)
21 (9.9)
Recurrent Stroke
2 (3.5)
0.015
. ~~/4f(19.3)
High comorbidity burden, %
5.2± 7.2
5.7± 5.7
0.66
Length of hospital stay, mean ±SD
0.76
55 (94.8)
Insurance coverage, %
204 (95.8)
0.14
50 (86.2)
Discharged to home, %
163 (76.5)
Discharge Medicationt, %
168 (78.9) ~
Antilipidemic
30 (51.7)
0.013
0.016
163 (76.5)
30 (51.7)
Statin
5 (8.6)
0.086
41 (19.3)
Nonstatin
29 (50.0)
0.015
159 (74.7)
Antithrombotic
24 (41.4)
0.011
141 (66.2)
Antiplatelet
8 (13.8)
0.45
39 (18.3)
Anticoagulant
Antihypertensive therapy, %
Premorbid
152 (71.4)
7 (12.1)
<.0001
186 (87.3)
15 (7.5)
<.0001
On at follow-up
t Some patients were discharged on > 1 drug per drug type and class. SBP, systolic blood
pressure; DBP, diastolic blood pressure; SD, standard deviation.
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Figure 1. Proportion of persistent users among patients discharged on an
antihypertensive medication by drug class and level of persistence (n = 213). The
denominator for persistent users for each drug class is use at discharge. Absolute
Persistence refers to patients that remained on ,all discharged medication classes at
follow-up. Two+ Persistence refers to patient~, t~t remained on all or at least two, if
prescribed two or more, discharged medications' within the same drug class at follow-up.
One+ Persistence refers to patients that remained on all or at least one, if prescribed one
or more, discharged medications within the same drug class at follow-up. Any
Persistence refers to patients that remained on any antihypertensive therapy at follow-up.
Percentages across groups do not total to 100% because sd>me patients were persistent
users on > 1 antihypertensive medication. CCB, calcium channel blocker; ARB,
angiotensin receptor blocker; ACE, angiotensin-converting enzyme inhibitor.

175

Table 3. Characteristics associated with persistence on all or at least two * discharged
antihypertensive medications (n = 213)
Persistence
Univariate
Characteristics
OR (95%CI)
P
n (%)
n
Race
Reference
Caucasian
164 71 (43.3)
0.0242
12 (24.5)
0.43 (0.11, 0.74)
African American
49
Age
Reference
< 65 years
94
37 (39.4)
0.92
119 46 (38.7)
0.97 (0.43, 1.51)
2: 65 years
Gender
Reference
Female
118 47 (39.8)
0.92 (0.41,1.44)
0.77
36 (37.9)
Male
95
BP Uncontrolled
(~ 140/90 mmHg)
45 (37.2)
Reference
121
No
1.19 (0.52, 1.85)
0.54
38(41.3)
92
Yes
Comorbidity Burden
Reference
Low
172 77 (44.8r~
0.0017
0.21 (0.01, 0.42)
41
6 (14.6)
High
Prior Stroke
Reference
167 66 (39.5)
No
0.75
17 (37.0)
0.90 (0.29, 1.51)
Yes
46
~
Recurrent Stroke
No
192 71 (37.0)
Reference
0.0849
2.27 (0.15, 4.40)
12 (57.1)
21
Yes
Prernorbid
Antihypertensive Therapy
21 (34.4)
Reference
No
61
62 (40.8)
1.31 (0.49,2.13)
0.39
Yes
152
Antihypertensive Regimen
Reference
52 (71.2)
Monotherapy
73
0.0001
0.46 (0.27, 0.64)
Combination therapy
140 31 (22.1)
Fixed Dose Combination
Regimen
Reference
176 70 (39.8)
No
13 (35.1)
0.82 (0.21, 1.43)
0.60
Yes
37
*Persistence refers to patients that remained on all or at least two, if prescribed two or
more, discharged medications within the same drug class as their discharge regimens at
follow-up. OR, odds ratio; CI, confidence interval; BP, blood pressure.
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CHAPTERS
Conclusion

Stroke is the fourth leading cause of death and is a major cause of long-term
disability in the United States. Despite the declines in stroke mortality rates, the public
health burden of stroke remains high. Stroke represents a major population risk with
significant geographic and racial disparities. An inherent risk from an incident stroke is
recurrence, with as much as 25% of stroke cases having another stroke hospitalization
within the first year post index stroke. The ~aa.arse impact of a recurrent stroke is often
more severe than the index stroke, and is associated with twice the 30-day mortality rate.
The risk of a recurrent stroke is further compounded by age and race, with higher risks
l

determined for African Americans. Traditional stroke risk factors including hypertension
and diabetes have also been found to be associated with an increased risk of recurrent
stroke. The purpose of this dissertation was to examine the confounding effects of race
and age on recurrent stroke risk and the consistency of secondary stroke prevention
treatment regimens one-year post stroke discharge.
In Paper 1 (Chapter 2), we examined one-year recurrent stroke risk in relation to
race and age disparities with the association of comorbid hypertension and diabetes. We
found that recurrent stroke within one-year of the index stroke impacted approximately
one in ten stroke survivors. The ';'real world" observational rate reported in this study is
significantly higher than rates reported in clinical trials, suggesting the potential benefit
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of protocol-driven intense acute and post stroke management. The results indicate that
younger age, African American race, and prevalent diabetes increase recurrent stroke risk
and emerge as factors to consider in risk-reduction strategies. While this study confirmed
the racial disparity in one-year recurrent stroke, the additional risks of a race-age
relationship was identified in the analyses with young African Americans demonstrating
the greatest disease burden. Hypertension and diabetes were confirmed as significant risk
factors for recurrent stroke among African Americans and Caucasians, with higher rates
among young African Americans. The results of this study identify one-year recurrence
as a maj or outcome for all stroke patients in clinical studies. Future research should
focus on the benefit of secondary prevention strategies for younger African American and
Caucasian stroke patients.

~~I
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In Paper 2 (Chapter 3), we considered the effects of standard International
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic

modifier code selection on race-age specific stroke

rate~

estimated using administrative

databases. The results of this assessment indicated the inclusion of specific ICD-9-CM
asymptomatic codes for stroke without case adjudication introduces bias and potential
overestimation of incidence and recurrence and an underestimation of racial and age
disparities. When identifying acute stroke hospitalizations using administrative databases
and ICD-9-CM codes, it is import to identify the goal of the study. If the goal is to
determine trends and patterns of stroke recognition and treatment then using a traditional
definition of ischemic stroke, i.e. 433, 434, and 436, would seem advantageous as this
would incorporate all subjects at risk for stroke. However, if the goal is to examine
specific characteristics of acute or recurrent stroke especially in regards to estimating
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disparities, then modified codes should be examined to eliminate potentially high
proportion of non-stroke or asymptomatic cases as to not overestimate the true stroke
incidence and recurrence. Thus, epidemiological studies that cannot afford the expense
of adjudication should consider excluding the asymptomatic codes to gain a better
understanding of true stroke disparity.
In Paper 3 (Chapter 4), we assessed the persistent use of antihypertensive
medications one-year post stroke hospitalization among stroke survivors. We found that
long-term persistence on at least one secondary stroke prevention therapy in this cohort
was high; however persistence on specific treatment regimen prescribed at discharge was
relatively low.

Persistence varied considerably by antihypertensive drug class, with

highest persistence at one year for ACE inhibjtors and lowest for diuretics. Persistence
'",~;"1

was significantly lower for African Americans and patients with high comorbidities. The
results of this study have identified the impact of antihypertension treatment on long-term
follow-up of stroke patients and secondary prevention. 1Recurrent stroke risk for these
high risk groups could be reduced by understanding the effects of race and comorbid
conditions on medication persistence.
The results of this dissertation suggest that race and age disparities in stroke and
recurrent stroke risk remain despite improved guidelines in the management and
treatment of stroke risk factors. African American race was significantly associated with
an increased risk of stroke and recurrent stroke. The racial disparity was further evident at
younger ages; with African Americans age 45-64 years representing the highest disease
burden. Administrative databases using the ICD-9-CM coding system continues to be a
valuable resource for convenience samples; however, findings from this work emphasize
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the need for a standard definition for identifying acute stroke hospitalizations when using
non-adjudicated administrative data as to not overestimate stroke incidence and
recurrence or underestimate the potential race and age disparities. More aggressive risk
factor prevention and management is needed to reduce or eliminate race and age
disparities, especially in a population with excess burden of stroke risk factors.

In

addition, risk factor prevention strategies should be initiated at younger ages. Recurrent
stroke risk for these high risk groups could be reduced by understanding the effects of
these disparities with persistence on secondary prevention therapies.
Future research should assess additional confounding variables with race and
recurrent stroke risk, including adjustments for National Institute of Health Stroke Scale
(NIHSS) scores at admission and discharge, age at onset of premorbid comorbidities such

,u,

~1

as hypertension and diabetes, and socio-economic factors that may affect recurrent stroke
risk. This study focused on stroke risk factors at the state-level and within one hospitalbased cohort, more detailed analyses employing geographjcal information systems (GIS)
are needed to assess potential geographic or segregation disparities within the high risk
population of South Carolina, considered the buckle of the stroke belt. Additional longterm cohorts should be established to include younger patients with a focus on the benefit
of initiating secondary prevention strategies at younger ages. Further studies are needed
to identify modifiable target risk factors and effective interventions to improve long-term
persistence and quality of secondary stroke prevention.
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APPENDICES
Appendix A - Letter of Introduction
Date:

XXlXX/XXXX

RE: Stroke Survey
Dear (Insert Patient Name):
You have been selected to receive this letter because you were a patient at Medical University Hospital
(MUSC) within the last 18 months and were treated for a stroke. Stroke is an extremely important health
problem in South Carolina, and we are very interested in trying to improve the treatment of stroke patients.
For that reason we are asking for your help. Sometime within the next month, you will receive a telephone
call from a telephone interviewer who will ask you to take about 10 minutes of your time to answer some
questions over the phone regarding your stroke. Please take your time to complete this survey. However,
you are certainly free to say no to participating in the survey. If you decide not to participate, it will not
affect your treatment in any way.
The questions we will ask have to do with what you learned about stroke in the hospital, your current
medications, and how you are functioning now at home. If you believe that any specific questions are
sensitive or embarrassing, you are certainly free not to answer that question or any other questions you may
object to.
So~e patients ~~y be .too disabled to answer. the qu~§~i~ the~selves: If you are a relative of the ~trok.e
patIent and partICIpate In the care of your famIly member/on a dally baSIS, you may answer the questIons If
the patient has agreed for you to answer for him/ her.

If the patient has died since their hospitalization, we apologize for intruding on your privacy.
MUSC employees may participate in the survey but have no obligation to do so.
t

If you do not wish to be called regarding this survey, please call the number below. You may leave a
message or talk directly with Ms Andrea Boan who is working with us on this project. If the patient is
deceased you may also call the number to let us know so that way we will be sure not to bother you further.
Thank you in advance for helping us with this project. The information you provide will help us do a better
job in preventing and treating stroke in South Carolina.
Andrea Boan, MS
Phone Number: 843-876-1064
Best wishes,

David L. Bachman, MD
Director, Division of Adult Neurology
Professor of Neurosciences
Medical University of South Carolina

Daniel T. Lackland, DrPH
Professor of Epidemiology and Medicine
Medical University of South Carolina
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Appendix B - Alpha Pilot Test Report
STROKE PREVENTION PATIENT SURVEY
Pretest res olts - 1/14/10

Questions, comments and recommendations based on the pretest of the questionnaire:
The time to complete the survey ranged from 16 to 27 minutes, with an average of 20
minutes.
About 20 percent of the people that we contacted said that they never had a stroke. They
had all been recently hospitalized at MUSC, but said that they had an aneurysm, brain
surgery, blood clot, or some other diagnoses, but were firm in claiming that they did not
have a stroke or that no one told them that they had a stroke. I don't know if this a
problem with the pre-test list, whether a stroke was a secondary diagnosis, or if people
are not recalling their diagnosis correctly, but it is not possible to ask people a series of
questions about "their last stroke" when they insist that they did not have a stroke. We
need to decide whether or not to conduct interviews with those that say they did not have
a stroke or provide alternate wording for those questions that refer to "last stroke" and
ask about "last hospitalization." The advance letter may reduce this problem slightly, but
this happened frequently enough in the pretest that it will be an issue.

,~~;. ,~1

At least three respondents questioned the interviewers about HIPP A during the
introduction. While we have standard responses that the interviewers used for questions
about how we got their number, the purpose of the study, the confidentiality of the data,
etc., we need to develop a standard response to use when questions related to RIPP A
arise. I'm not sure the restrictions you are working under" but I would suggest something
along the lines of "In accordance with HIPPA regulations, your contact information was
provided to the University of South Carolina which is partnering with MUSC in this
research project. All information will be kept confidential and your name and telephone
number will not be associated with the responses you provide in this survey." I need your
help with this to make sure that the information we provide to respondents is accurate.
If we contact a respondent and they are not able to complete the survey but refer us to
another person (sibling, child, etc.) living at a different phone number, I'm amusing that
it is OK to go ahead and contact this person for a proxy interview.
If during the introduction and obtaining informed consent with a proxy respondent
determines that the patient is still alive, can Q.4a be skipped?
Q.7a: Does "new" stroke mean "another" stroke? Should we add a "Don't know" option
to the responses for this question?
Q.7b: Should this question be asked of proxy respondents? (It is not necessarily relevant
if the proxy can give an example of a warning sign of a new stroke and I'm not sure that a
proxy could reliably answer this type of knowledge item.)
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Q.9b: Suggest adding "with you" at the end of this question.
Q9. b What is the difference between vii. "importance of taking medication regularly" and
ix. "medication compliance (importance of taking medication on a regular basis),'?
Suggest dropping ix.
Q.lla: Suggest changing "recheck you for the stroke" to "recheck you for your most
recent stroke"
Q.11 b: What if they saw more than one doctor for follow-up (e.g., a specialist and their
family doctor)? Do we want to leave room for multiple responses or ask which they saw
most frequently (which would still be a problem in situations where they saw each doctor
once)?
Q.12a: This question was a little ambiguous. I would suggest "Do you have ... " rather
than "Do you see ... " An alternative would be ~'Do you have a family doctor that you see
on a regular basis?" or to put a time bound on this question and ask "Have you seen a
regular family doctor in the past twelve months?"
Q.12b: Several respondents said "Family Doctor" in response to this question. Should
this be recorded as a General Practitioner or si'l~d the interviewers probe (by reading the
choices) and then record as a "Don't Know" if the respondent is not sure? Also several
people wanted to give more than one response to this question. Should we allow for
multiple responses or probe by asking, "What type of doctor do you see most often?"
Q.13b: Since several respondents asked, "Do you mean PtT?" I would ask this question as
"physical therapy or PT"?
Q.14: "as known as" should be "also known as."
For the series of questions, Q .18a through Q .22b, the interviewers found that when asked

in this order, a number of respondents named blood pressure medications when asked the
question about blood thinners. This seemed to be reduced when the order of these sets
were reversed and respondents were first asked about blood pressure medications (Q.21a
- Q.22b) then about cholesterol (Q.19a - Q.20b), then blood thinners (Q.18a -- Q.18c).
This is the order that I would recommend for these questions.
Q.21 b: Need to add a "Don't know" response.
Q.23a: Should this read "health insurance coverage" instead of "insurance coverage"?
Q.23b: Do we want to allow for more than one response for this question? (For example,
to capture people who are on Medicare but also have a (private) Medicare supplement?
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[FUNCTION ASSESSMENT] - Given the number and length of some of the response
choices, this section was very difficult, particularly for respondents who said in the first
question, "I'm independent - I can do everything myself." Many respondents were not
hearing all the choices, or they would get to the end and say "the second thing you said"
- which could be ambiguous and was not really responsive to the question~ I would
suggest a method that would reduce respondent/interviewer burden and produce more
reliable results. That is to divide most of these questions into two components: a "no
problems," "some difficulties," "can't do at all" screener, followed by a question on types
of problems for those that have difficulties. This approach seemed to work much better
for the interviewers and allows us to map back to the original categories in the questions.
Also, in Q.31, Q.34, and Q.35, the "no problems" option had two components - one for
those who had no problems and did these functions and the other to cover those people
who are capable of doing them but do not do so for some reason. For each of these I
would suggest removing the second clause in these options and replacing it with "even if
you do not routinely do so." Also on Q.30(b), options 3 and 4, would simply reading
~'tube" communicate the same thing to respondents as reading "nasogastric tube or
gastrostomy"? My suggestion revisions to this section follows:

"1 would now like to ask you some questions about your/ (PATIENT'S NAME) ability to
function in the home."
J

~I '~i
/

24. "Grooming is the ability to tend to personal hygiene needs - for example, washing
face and hands, hair care, shaving or make-up, teeth or denture care, and fingernail care.
Which of the following best describes your/(PATIENT'S NAME) grooming:"
1. You are/He is/She is able to groom yourselflhilliselflherself unaided with or
without the use of assistive
devices or adapted methods; -------- GO TO Q.25
2. You/He/She needs some assistance in grooming; or
3. Yow'he/she depends entirely upon someone else for grooming needs ---- GO
TO Q.25
4. Unknown --- GO TO Q.25
b. What type of assistance do you/does he/does she need ..
1. Grooming utensils such as comb, a toothbrush, or razor must be placed within

reach before you arelhe is/she
is able to complete grooming activities; or
2. Someone must assist you/himlher with grooming
3. Unknown
25. "The next question is about the ability to dress the upper body, with or without
dressing aids, including undergarments, pullovers, front-opening shirts and blouses,
managing zippers, buttons, and snaps. Which of the following best describes
your/(PATIENT'S NAME) ability to dress yourlhis/her upper body:"
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1. You are/He is/She is able to dress with or without dressing aids; ------- GO TO
Q.26
2. You/He/She needs some assistance in dressing the upper body
3. You/he/she depends entirely upon someone else to dress your/his/her upper
body. ----- GO TO Q.26
4. Unknown ----- GO TO Q.26
b. What type of assistance do you/he/she need in dressing the upper body ...
1. You are/He is/She is able to dress the upper body without assistance if clothing
is laid out or handed to
you/him/her; or
2. Someone must help you/him/her put on upper body clothing;
3. Unknown
26. "And what about the ability to dress the lower body, with or without dressing aids,
including undergarments, slacks, socks or nylons, shoes. Are you/Is he/Is she ...
1. Able to obtain, put on, and remove clothing and shoes without assistance; ----GO TO Q.27
. ~~I .~1
2. You/He/She needs some assistance in dressing the lower body
3. Do you/Does he/Does she depend entirely upon someone else to dress the
lower body. ---- GO TO Q.27
4. Unknown ---- GO TO Q.27
~

b. What type of assistance do you/he/she need in dressing the lower body ...
1. You are/He is/She is able to dress the lower body without assistance if clothing
and shoes are laid out or handed to you/him/her; or
2. Does someone have to help you/him/her put on undergarments, slacks, socks,
or nylons and shoes?
3. Unknown
27. "Bathing is the ability to wash the entire body, not just washing face and hands. Are
you/Is he/Is she ...
1. Able to bathe in the SHOWER OR TUB independently; ------ GO TO Q.28
2. Do you/Does he/Does she need some assistance in bathing, or
3. Are you/Is he/Is she not able to participate in bathing and are/Is totally bathed
by another person? - GO TO Q.28
4. Unknowll------ GO TO Q.29
b. What type of assistance do you/he/she need in bathing:
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1. Are you/Is he/Is she able to bathe in the shower or tub independently, with the
use of devices;
2. Able to bathe in the shower or tub with the limited assistance of another person
to supervise or encourage you/them, to help you/them in and out of the shower or
tub, or to wash in difficult areas;
3. Do you/he/she in require the presence of another person throughout the bath for
assistance or supervision.
4. Are you/Is he/Is she not able to use the shower or tub and are/is bathed in bed
or a bedside chair?
5. Unknown
28. "Toileting is the ability to get to and from the toilet or bedside commode. Are you/Is
he/Is she:
1. Able to get to and from the toilet independently, with or without a device; -----GO TO Q.29
2. Do you/Does he/Does she need some assistance in toileting; or
3. Are you/Is he/Is she totally dependent in toileting? ------ GO TO Q.29
4. Unknown ------ GO TO Q.29
b. What type of assistance do you/he/she need in toileting:
~ ~~/ ~1

1. Are you/Is he/Is she able to get to and from the toilet when reminded, assisted
or supervised by another person;
2. Unable to get to and from the toilet, but able to use a bedside commode, with or
without assistance; or are
3. Y oulhe/she unable to get to and from the toilet 9r bedside commode, but able to
use a bedpan?
4. Unknown
29. "The next question is about the ability to walk SAFELY, once in a standing position,
or to use a wheelchair once in a seated position, on a variety of surfaces."
1. Are you/Is he/Is she able to walk independently on uneven surfaces and climb
stairs with or without
railings (i.e., needs no human assistance or assistive devices); ------ GO TO
Q.30
2. Do you/Does he/Does she need some assistance in walking; or
3. Are you/Is he/Is she bedfast, unable to ambulate or be up in a chair? ----- GO
TO Q.30
4. Unknown ------ GO TO Q.30
b. What type of assistance do you/he/she need in walking:
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1. Do you/does he/does she require the use of a device, such as a cane or walker
to walk alone OR require supervision or assistance from another person to climb
stairs or steps or uneven surfaces;
2. Are you/Is he/Is she able to walk only with the supervision or assistance of
another person at all times;
3. Are you/Is he/Is she chairfast, that is unable to ambulate but able to wheel
yourself/himself/herself
Independentl y; or
4. Chairfast, and not able to ambulate or to wheel yourself/himself/herself
5. Unknown
30. "Thinking about your/his/her ability to feed yourselflhimself/herself meals and
snacks. By this I mean the process of EATING, CHEWING, and SWALLOWING, NOT
PREPARING the food to be eaten.'~
1. Are you/Is he/Is she able to independently feed yourself/himself/herself; ----GO TO Q.31
2. Do you/Does he/Does she need some help feeding yourself/himselflherself; or
3. Are you/Is he/Is she unable to take nutrients orally or by tube feeding? ----- GO
TO Q.31
4. Unknown ------- GO TO Q.31

,

~~;, ~1

b. What type of assistance do you/he/she need in eating:
1. Are you/Is he/Is she able to feed yourself/himself/herself independently but
need the meal set up; or some assistance or supervision from another person, or a
liquid, pureed or ground meat diet;
.
2. Are you/Is he/Is she UNABLE to feed yourself/himself/herself and must be
assisted or supervised throughout the meal or snack;
3. Are you/Is he/Is she able to take in nutrients orally AND receives supplemental
nutrients through a nasogastric tube or gastrostomy; or
4. Are you/Is he/Is she UNABLE to take nutrients orally and are/is fed nutrients
through a nasogastric tube or gastrostomy
5. Unknown
31. "And what about planning and preparing light meals, for example, a cereal or
sandwich or reheating delivered meals:
1. Are you/Is he/Is she able to independently plan and prepare all light meals for
yourself or reheat delivered meals or are you/he/she physically, cognitively, and
mentally able to prepare light meals on a regular basis but have/has not
routinely performed light meal preparation in the past; even if you do not
routinely do so;
2. Are you/he/she UNABLE to prepare light meals on a regular basis due to
physical, cognitive, or mental limitations; or
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3. Are you/he/she unable to prepare any light meals or re-heat any delivered
meals?
4. Unknown
32. "By transportation we mean the physical and mental ability to safely use a car, taxi,
or public transportation like a bus, train or subway:
1. Are you/Is he/Is she able to independently drive a regular or adapted car or use
a regular handicap-accessible public bus;
2. Are you/Is he/Is she able to ride in a car only when driven by another person
OR able to use a bus or handicap van only when assisted or accompanied by
another person; or
3. Are you/Is he/Is she UNABLE to ride in a car, taxi, bus, or van, and require
transportation by ambulance?
4. Unknown
33. "And what about the ability to do your/his/her own laundry; that is, to carry laundry
to and from the washing machine, to use a washer and dryer, and to wash small items by
hand."
1. Are you/Is he/Is she able to independently take care of all laundry tasks OR
physically, cognitively, and mentally"'ab~to do laundry and access facilities, BUT
has not routinely performed laundry tasks in the past (i.e., prior to home care
admission).
2. Are you/Is he/Is she able to do only light laundry, such as minor hand washing
or light washer loads and need/needs assistance with heavy laundry such as
carrying loads of laundry due to physical, cogniti'fe, or mental limitations; or
3. Are you/Is he/Is she UNABLE to do any laundry due to physical limitations or
need/needs continual supervision and assistance due to cognitive or mental
limitations
4. Unknown

34. "And what about housekeeping - that is, the ability to safely and effectively perform
light housekeeping and heavier cleaning tasks:
1. Are you/Is he/Is she able to independently perform all housekeeping tasks; QR:
are you/he/she physically,
cognitive!y, and mentally able to perform l\:LL housekeeping tasks and
havelhas not routinely participated in
housekeeping tasks in the past (i.e., prior to this come care admission); even if
you do not ro.utinely do so; -- GO TO Q.35;
2. Do you/Does he/Does she need some assistance performing light housekeeping
and heavier cleaning tasks; or
3. Are you/Is he/Is she unable to effectively participate in any housekeeping
tasks? ----- GO TO Q.35
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4. Unknown ----- GO TO Q.35

b. What type of assistance do you need with light housekeeping and heavier
cleaning tasks:
1. Are you/Is he/Is she able to perform only LIGHT housekeeping, such as
dusting or wiping kitchen counters, independently;
2. Are you/Is he/Is she able to perform housekeeping tasks with some assistance
or supervision from another person; or
3. Are you/Is he/Is she UNABLE to consistently perform any housekeeping tasks
unless assisted by another person throughout the process?
4. Unknown
35. "What about shopping - that is, the ability to plan for, select and purchase items in a
store and to carry them home or arrange for delivery"
1. Are you/Is he/Is she able to plan for shopping needs and independently perform
shopping tasks, including carrying packages, OR are you/is he/is she physically,
cognitively, and mentally able to take care of shopping but havelhas not done
shopping in the past (i.e., prior to home care admission); even it you do not
routinely do so. ----- GO TO Q.36
2. Do you/Does he/Does she need some~~sistance with shopping; or
3. Do you/Does he/Does she need someone to do all shopping and errands? ----GO TO Q.36
4. Unknown --------- GO TO Q.36
b. What kind of assistance do you/does he/does sh1 need with shopping:
1. Are you/Is he/Is she able to go shopping, but need/needs someone to do
occasional major shopping, OR are you/is he/is she unable to go shopping alone,
but can go with someone to assist; or
2. Are you/Is he/Is she UNABLE to go shopping but able to identify items
needed, place orders and arrange home delivery
3. Unknown

36. "And what about the ability to answer the phone, dial numbers, and EFFECTIVELY
use the telephone to
communicate:
1. Are you/Is he/Is she able to dial numbers an answer call appropriately and as
desired; ----- GO TO Q.37
2. Do you/does he/does she need some assistance with using the telephone; or
3. Are you/Is he/Is she able to answer the telephone only some of the time or able
to carryon only a limited conversation. ------ GO TO Q.37
4. Unknown ----- GO TO Q.37
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b. What type of assistance do you need with using the telephone:
1. Are yowls he/Is she able to use a specially adapted telephone, such as a phone
with large numbers on dial or teletype for the deaf, to call essential numbers; or
2. Are yowls he/Is she able to answer the telephone and carryon a normal
conversation but havelhas difficulty with placing calls?
3. Unknown

37. "Which of the following best describes your/(PATIENT'S NAME) level of physical
activity:
1. Yowhe/she walks frequently You ~!alk/he Ytvalks/she that is walks outside the
room at least twice a day and inside the room at least once every two hours during
waking hours;
2. Yowhe/she walks occasionally- You \valklhe yyvalks/she that is walk
occasionally during the day but for very short distances, with or without
assistance.
3. Youlhe/she is chairfast; that is, your/his/her ability to walk is severely limited
or non-existent; you/he/she cannot bear your/his/her ovm vleight and/or must be
assisted into a chair or wheelchair; or ~ j
4. You arelhe is/she is bedfast and confined to bed

'1
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Appendix C - Beta Pilot Test Report
STROKE PREVENTION PATIENT SURVEY
Pretest 2 results and field version comments - 1/21/10

Three general issues to discuss based on the results of the second pretest and in
preparation for interviewer training:
( 1) Is the requirement that the person have read the letter an IRB requirement for
informed consent? In the past when we have sent letters it has been more to alert people
that they would be receiving a call and establishing the legitimacy of the survey rather
than providing an extensive explanation of the study, with the consent language and
agreement to participate done over the phone.
I have not seen the letter, so I'm not sure how much it says about "stroke," but
given our experience in the pretests, about one-fourth of those contacted said they did not
have a stroke, so this may have an impact on their willingness to participate and on how
we handle the questions on "previous strokes" (described in the following point).
(2) Four of the ten respondents in this round said they had not had a stroke, and
two of these were pretty adamant about it In terms of asking questions related to
previous strokes, some of the items can be~h¢dled straightforwardly by asking about
"last hospitalization" but there are others for which we need to make a decision as to
whether the item should be skipped or if we need to develop different wording.
Specifically, for those patients who say they have not had a stroke:
Q.6a: "before the stroke" becomes "before your l~t hospitalization"
Q.6c: "hospital stay for the stroke" becomes "last hospital stay"
Q.6d: "stroke hospitalization" becomes "last hospitalization"
Q.11a: "after discharge from the hospital to recheck you for the stroke" becomes
"after discharge from the hospital."
Q.12c: "stroke hospitalization" becomes "hospitalization"
Q.18b, Q.20a, Q.22a: "your stroke" becomes "your most recent hospitalization"
Q.18c, Q.20b, Q.22b, Q.23a: "stroke" becomes "most recent hospitalization"
The items from Q.7a through Q.lOc (specifically Q.7a, Q.7b, Q.8a, Q.8b, Q.8c, Q.8d,
Q.9a, Q.10a, Q.lOb, and Q.10c) are a little more problematic. One option would be to
skip those respondents who said they have not had a stroke around these items.
A second would to ask these questions, but if respondents ask "Why are you asking me
these questions; I told you I didn't have a stroke," the interviewers could say something
like (for Q.7a, Q.7b, Q.8a, Q.8b, Q.9a, Q.9b): "We would like this information from all
patients, whether they were hospitalized for a stroke or for some other reason." That
leaves Q.8c, Q.8d and Q.10a, Q.10b, and Q.10c as potential problem questions. If we
make (the I think reasonable) assumption that most respondents who claim they have not
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had a stroke will answer "No" to Q. 8a, they will skip Q. 8c and Q. 8d, leaving Q.1 Oa,
Q.10b, and Q.1 OC as questions that would be skipped for these respondents.
(3) In the FUNCTION ASSESSMENT section we need to develop a protocol for
handling those cases in which a proxy respondent (although this could also apply to a
patient) informs the interviewer -- in response to Q.24 -- that the patient is paralyzed and
cannot do anything for themselves or is otherwise totally dependent. In the case we
encountered in the pretest, attempting to ask the rest of the questions was burdensome
and upsetting to the respondent and resulted in a termination. In such cases I would
recommend that the interviewer say something like the following, "There are several
functions that I need to ask about, so let me just go through and check that (you/he/she) is
totally dependent on someone else to do them. Are (you/he/she) totally dependent on
someone else:
"to dress the upper body"
"to dress the lower body"
"to bathe the entire body"
"for getting to and from
the toilet"
"to walk safely"
"to
feed
(yourself/himself/herself)
"
"to plan and prepare light
meals"
"for all transportation"
"for doing laundry"
"for housekeeping"
"for shopping"
"to use the telephone to
communicate"
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This process will yield valid responses to these items~ while reducing respondent burden
and avoiding some terminations, the trade-off being that not all cases will be responding
to the same question.
There is a similar issue - although in the two cases that we encountered it, it does not
seem to be as much of a problem - with respondents at the other end of the scale; that is
patients who say~ "I'm totally independent; the stroke did not affect me a bit." In the two
cases in which this was encountered in the pretest, respondents tended to cut the
interviewer off after the first choice (e.g., after "you are able to dress with or without
dressing aids" in Q.25) and not let them read all the choices (although they did complete
the interview). Having a set of "totally independent" questions similar to that for those
who are totally dependent would eliminate some problems with the administration of the
questionnaire.
Finally in this section, Q.36 did not have an option for those people who were not able to
use the phone at all. I'd suggest revising this question as follows:
36. "And what about the ability to answer the
use the telephone to communicate:

phone~

dial numbers, and EFFECTIVELY

1. Are you/Is hells she able to dial 'nu¥ers an answer call appropriately and as
desired; ----- GO TO Q.3 7
2. Do you/does heldoes she need some assistance with using the telephone; or
3. Are you/Is hells she not able to use the telephone at all? ------ GO TO Q.3 7
4. Unknown ----- GO TO Q.37
b. What type of assistance do you need with using'the telephone:
1. Are youlls hells she able to use a specially adapted telephone, such as a phone
with large numbers on dial or teletype for the deaf, to call essential numbers;
2. Are you/Is hells she able to answer the telephone and carryon a normal
conversation but havelhas difficulty with placing calls; or
3. Are you/Is hells she able to answer the telephone only some of the time or able
to carryon only a limited conversation.
4. Unknown
Additional comments:
• The second round of pretests took between 15 and 20 minutes, so we probably
should change "10 minutes" to "15 minutes" in the consent script.
• The other changes that were made based on the first pretest results seemed to
work, so we should be ready to start data collection once we resolve the above
questions.
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Appendix D - Stroke Survey: Interview Questionnaire

PATIENT SlJRVEY REQUEST
Draft - 1/08/2010

"Hello, this is _ _ _ _ _ _ _ _ _ _ calling from the Medical University of South
Carolina.
"May I please speak to ( PATIENT'S NAME )?"
[INTERVIEWER SPEC: IF PATIENT IS UNABLE TO COMPLETE THE
INTERVIEW (CANNOT SPEAK, NOT PHYSICALLY ABLE, ETC.) SAY: "I would
like to speak with someone who would be able to answer questions about (PATIENT'S
NAME) health and activities. Would that be you or someone else?" IF THE PATIENT IS
ON THE PHONE, CONTINUE WITH THE INTERVIEW. IF SOMEONE ELSE, ASK
TO SPEAK WITH THAT PERSON OR IF THE PROXY ANSWERS THEN SAY: "If (
PATIENT'S NAME) has agreed you may respond for him/her". IF THE PATIENT OR
PROXY IS NOT AVAILABLE MAKE AN APPOINTMENT FOR CALL-BACK.]
[ONCE SELECTED INDIVIDUAL OR PRO~.! RESPONDENT IS ON THE PHONE:
'~~;'1

"'The lJniversity is conducting a confidential study with individuals who have
experienced a stroke, and we'd really appreciate your help and cooperation.
You should have already received a letter from MUSC explaining the purpose of this
survey. Do you remember receiving the letter?"
If yes, proceed to next paragraph
t
If no, "We would like you to have the opportunity to read the letter explaining
about the survey before we get started. I will see that you receive a copy of the letter
before we talk. If you don't mind, I will call you another time after you've had a chance
to read the letter. (Confirm correct mailing address) Thank you." (End survey)
"The purpose of this study is to learn more about the experiences and needs of
individuals who have experienced a stroke. The information will be used to improve the
treatment and services available to these individuals. This survey was approved by the
Investigational Review Board at MUSC and should take no more than 10 minutes.'~
"Your participation is voluntary, and any information you provide will be kept
confidential. We are interested in learning about your opinions and experiences, but your
name and phone number will not be connected to any information you provide as part of
the interview .. "
"If there is any question that you do not want to answer, let me know and I will move to
the next question. You may stop the interview at any time. "
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"Before we begin I would like to ask if you have any questions or concerns?" [ANSWER
QUESTIONS OR CONCERNS IF POSSIBLE.]

"Were you/was CPATIENT'S NAME) hospitalized for a stroke?"
1. YES
2.NO

INTERVIEWER CHECK:
1. PERSON RESPONDING IS THE PATIENT ---- GO TO Q.5
2. RESPONDENT IS NOT THE PATIENT --------- CONTINUE
1. "What is your relationship to LPATIENT'S NAME ) ... are you a family member, a
friend, or other?"
1. FAMILY MEMBER
2. FRIEND
3. OTHER (SPECIFY) _ _ _ _ _ _ _ _ _ __
4. REFUSED
2. "Do you live with LPATIENT'S NAME~y!'

1. YES
2.NO
3. OTHER (e.g. stays with them a couple of days a week, one week a
month; three months a year, etc.)
4. REFUSED
3. "Do you help provide care or supervision for LP ATIENT' S NAME )?"

1. YES
2.NO
3. REFUSED
4a. "Is CPATIENT'S NAME) living?"
1. YES
2.NO
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4b. (IF PATIENT NOT LIVING): "What was the date of their death?"

MONTH

DAY

YEAR

99999998. DON'T KNOW/REFUSED
[INTERVIEWER SPEC: IF THE PATIENT IS DECEASED - "That's all the questions I
have. Thank you very much for your cooperation." END CALL.]

5. "Do you/Does LPATIENT'S NAME) currently live in your/their own home, a
family member's or friend's home, an independent living or residential care facility, an
assisted living facility, a skilled nursing facility, a V A nursing facility, or at some other
location?"
1.
2.
3.
4.
5.
6.
7.

OWN HOME
FAMILY MEMBER OF FRIEND'S HOME
INDEPENDENT LIVING OR RESIDENTIAL CARE FACILITY
ASSISTED LIVING FACILITY
SKILLED NURSING FACILITY
V A NURSING FACILIT-Y' -~1
OTHER (SPECIFY:
)

6a. "Were you/was CPATIENT'S NAME) smoking cigarettes the week before the
stroke?"
1. YES
2. NO --------------------------------------------- GO TO Q. 7
3. DON'T KNOW ------------------------------ GO TO Q. 7
6b. "Approximately how many cigarettes were you/they smoking a day?"
RECORD NUMBER OF CIGARETTES:
998. DON'T KNOW (PROBE: "Approximately ... ")
6c. "Were you/was LPATIENT'S NAME) told to stop smoking at some time during
your hospital stay for the stroke?"
1. YES
2. NO --------------------------------------------- GO TO Q. 7
3. DON'T KNOW ------------------------------ GO TO Q. 7
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6d. "Who advised you! ( PATIENT'S NAME) to stop smoking during the stroke
hospitalization?":
i. A physician
ii. A nurse
iii. Someone else (SPECIFY:

)
iv Don't remember

7a. "Do you/Does CPATIENT'S NAME) know what the warning signs of a new stroke
are?"
1. YES

2. NO --------------------------------------------- GO TO Q. 8

7b.

~'Can

you give me one example of a warning sign of a new stroke?"

98. DON'T KNOW/CAN'T REMEMBER
t

8a. "During the hospitalization for stroke, did someone explain to you/to (PATIENT'S
NAME) the warning signs of stroke?"
1. YES
2. NO --------------------------------------------- GO TO Q. 9
3. DON'T KNOW ------------------------------ GO TO Q. 9

8b. "Who discussed the warning signs during the stroke hospitalization?":
i. A physician
ii. A nurse
ii. Someone else (SPECIFY:

--------------------------------~)
iv Don't remember
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8c. "Did the person providing the counseling emphasize that you/the patient must return
to the emergency room immediately if any new signs of stroke were to occur?"
1. YES
2.NO
3. DON'T KNOW

8d. "Did someone explain to you/the patient that anyone who has had a stroke may be at
increased risk of another stroke in the future?'"
1. YES
2. NO
3. DON'T KNOW

9a. "During the hospitalization for stroke, did someone talk to yoU/(PATIENT'S NAME)
about health factors that could help prevent a future stroke?"
1. YES
2. NO --------------------------------------------- GO TO Q. 10
3. DON'T KNOW ___________'_:.~.i-~------------ GO TO Q. 10

9b. "Were any of the following health factors discussed?"
VESt

NO

DK

1

2

3

i. smoking

1

ii. diabeteslblood sugar
iii. hypertension (high blood pressure)

2

3

1

2

iv. diet

1

2

3

v. exerCIse

1

2

3

1

vi. cholesterol

1

vii. importance of taking medication regularly
viii. obesity (overweight)

1

ix. medication compliance (importance of
taking medication on a regular basis)

198

2
1

1

x. excessive use of alcohol

2

2

3

3

2

3

3

2
3

3

10a. "Was this your first hospitalization for stroke?"
1. YES -----------------------------------;------- GO TO Q. 11
2.NO
3. DON'T KNOW ------------------------------ GO TO Q. 11

10b. "How many stroke hospitalizations have you / (PATIENT'S NAME) experienced?"
PROVIDE NUMBER
-------------98. DON'T KNOW/CAN'T REMEMBER

10c. "In what year did you / (PATIENT'S NAME) experience the previous stroke(s)?"
SPECIFY YEAR(S) _ _ _ _ _ _ _ _ _ _ __
98. DON'T KNOW/CAN'T REMEMBER

lla. "Were yoU/Was (PATIENT'S NAME) provided with a follow up appointment to see
a doctor after discharge from the hospital to recheck you for the stroke?"
'''~I ~1

1. YES
2 . NO --------------------------------------------- GO TO Q. 12
3. DON'T KNOW ------------------------------ GO TO Q. 12

11 b. "What kind of doctor did you / (PATIENT'S NAME) see?"
1. GENERAL PRACTICTIONER
2. NEUROLOGIST
3. CARDIOLOGIST
4. INTERNIST
5.0THER(SPECIFY: _ _ _ _ _ _ _ _ _ _ _ _ _~)
6. DON'T KNOW

12a. "Do you / (PATIENT'S NAME) see a regular family doctor?"
1. YES
2. NO --------------------------------------------- GO TO Q. 13
3. DON'T KNOW ------------------------------ GO TO Q. 13
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12b. "What kind of doctor do you I (PATIENT'S NAME) see on a regular basis?"
1.
2.
3.
4.

GENERAL PRACTICTIONER
NEUROLOGIST
CARDIOLOGIST
INTERNIST

5.0THER(SPECWY:~~~~~~~~~~~~~~)

6. DON'T KNOW

12c. "How often have you I has (PATIENT'S NAME) seen this doctor since yourl hisl
her stroke hospitalization?"
NUMBER OF VISITS (record 0 if no visits): _ _ _ _ _ _ __
98. DON'T KNOW/CAN'T REMEMBER

13a. "Did yoU/(PATIENT'S NAME) receive physical therapy or other types of therapy
either in the home or at a therapy center after discharge from the hospital?"
1. YES
2. NO __________________________ ~.:~L:..:~---------------- GO TO Q. 14
3. DON'T KNOW ---------------------------------- GO TO Q. 14

13b. "Did yoU/(PATIENT'S NAME) receive" ....
YES

NO

1

DK

i. physical therapy

1

2

3

ii. occupational therapy

1

2

3

iii. speech therapy

1

2

3

iv. some other type of therapy

1

2

3

(SPECIFY)

14. "Have youl Has (PATIENT'S NAME) ever been told you! hel her hadl has high
blood pressure (as known as hypertension)?"

1. YES
2.NO
3. DON'T KNOW
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15. "Have you/ Has (PATIENT'S NAME) ever been told you! he/ her had/ has
Diabetes ?"
1. YES
2.NO
3. DON'T KNOW

16. "Have you/ Has (PATIENT'S NAME) ever been told you! he/ her had/ has high
cholesterol ?"
1. YES
2.NO
3. DON'T KNOW

17. "Have you! Has (PATIENT'S NAME) ever been told you! he/ her had a heart
attack?"
1. YES
2.NO
3. DON'T KNOW

J~i'1

18a. "Are you!Is (PATIENT'S NAME) currently taking any of the following medications
that act as "blood thinners" ...

1.

YES

NO

DK

1

2

3

aspIrIn

ii. plavix or clopidogrel

1

2

3

iii. aggrenox or dipyridamole

1

2

3

iv. warfarin or coumadin

1

v. some other type of blood thinner

1

2

2

3

3

(SPECIFY)

18b. "Were you! Was (PATIENT'S NAME) taking blood thinners prior to your stroke?"

1. YES
2. NO ---------------------------------------------~--- GO TO Q. 19
3. DON'T KNOW ---------------------------------- GO TO Q. 19
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18c. "Did your/ (P A TIENT~ S NAME) doctor change this medication after your/ his/ her
stroke?"

1. YES
2.NO
3. DON'T KNOW

19a. "Are you/Is (PATIENT'S NAME) currently taking any medications to help lower
cholesterol, such as Lipitor, Pravachol, Zocor, or Crestor?"
1. YES
2. NO ------------------------------------------------- GO TO Q. 20
3. DON'T KNOW ---------------------------------- GO TO Q. 20

19b. "What type of medication are you/is (PATIENT'S NAME) taking to help lower
cholesterol ?"
1.
2.
3.
4.
5.
6.
7.
8.

CADUET (AMLODIPINEf,A1K>RVASTATIN)
CRESTOR (ROSUV AST ATIN)
LESCOL (FLUVASTATIN)
LIPITOR (ATORVASTATIN)
PRAVACHOL (PRAV AS TAT IN)
VYTORIN (EZETIMIBE/SIMV ASTATIN)
ZOCOR (SIMVASTATIN)
OTHER (SPECIFY): _ _ _ _ _ _ _ _ _ _ __

9. Don't know

20a. "Were you! Was (PATIENT'S NAME) taking any medication to help lower
cholesterol prior to your/ hisl her stroke?"

1. YES
2. NO ------------------------------------------------- GO TO Q. 21
3. DON'T KNOW ---------------------------------- GO TO Q. 21
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20b. "Did your/ (PATIENT'S NAME) doctor change this medication after your/ his/ her
stroke?"

1. YES
2.NO
3. DON'T KNOW

21a. "Are you/Is (PATIENT'S NAME) currently taking any medications to help lower
blood pressure~ such as Fosinipril, Prinivil, Vasotec, or Zestril?"
1. YES
2. NO ------------------------------------------------- GO TO Q. 22
3. DON'T KNOW ---------------------------------- GO TO Q. 22

21 b. ~'What type of medication are you/is (PATIENT'S NAME) taking to help lower
blood pressure?"

01. ACCUPRIL (QUINAPRlL)'r
02. ACCURETIC (QUINAPRIL/DIURETIC)
03. AL T ACE (RAMIPRIL)
04. AMLODIPINE (GENERIC)
05. CAPOTEN (CAPTOPRIL)
06. ENALAPRIL (GENERIC)
07. FOSINIPRIL (GENERIC)
08. LISINOPRIL (GENERIC)
09. LOTENSIN (BENAZEPRIL)
10. LOTREL (COMBINATION DRUG)
11. MONOPRIL (FOSINIPRIL)
12. PRINIVIL (LISINIPRIL)
13. RAMIPRIL (GENERIC)
14. TARKA (COMBINATION DRUG)
15. V ASERETIC (COMBIMATION DRUG)
16. VASOTEC (ENALAPRIL)
17. ZESTRIL (LISINOPRIL)
18. OTHER(SPECIFY): _ _ _ _ _ _ _ _ __
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22a. "Were you! Was (PATIENT'S NAME) taking any medication to help lower blood
pressure prior to your! his! her stroke?"
1. YES
2. NO ------------------------------------------------- (}O TO ~. 23
3. DON'T KNOW ---------------------------------- (}O TO ~. 23

22b. "Did your! (PATIENT'S NAME) doctor change this medication or dose after your!
his! her stroke?"
1. YES
2. NO
3. DON'T KNOW

23a. "Did you! (PATIENT'S NAME) have insurance coverage at the time of your! his!
her stroke hospitalization?"
1. YES
2. NO ------------------------------------------------ (}O TO FUNCTION
ASSESSMENT
' ~~/~1
3. DON'T KNOW ---------------------------------- (}O TO FUNCTION
ASSESSMENT
23b. "What type of insurance coverage did you! he! she hp.ve?"

1.
2.
3.
4.

PRIVATE
MEDICARE
MEDICAID
OTHER (SPECIFY) _ _ _ _ _ _ _ _ __

5. DON'T KNOW
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[FUNCTION ASSESSMENT]
""I would now like to ask you some questions about your/ (PATIENT'S NAME) ability to
function in the home."
.
24. "Grooming is the ability to tend to personal hygiene needs - for example~ washing
face and hands, hair care, shaving or make-up, teeth or denture care, and fingernail care.
Which of the following best describes your/(PATIENT'S NAME) grooming:"

o 0- You arelHe is/She is able to groom yourself/himself/herself unaided with or without
the use of assistive devices or adapted methods;.
o 1- Grooming utensils such as comb, a toothbrush, or razor must be placed within reach
before you are/he is/she is able to complete grooming activities;
o 2- Someone must assist youlhimlher with grooming; or
o 3- Youlhe/she depends entirely upon someone else for grooming needs.
o UK- Unknown

25. "The next question is about the ability to dress the upper body, with or without
dressing aids, including undergarments, pullovers, front-opening shirts and blouses,
managing zippers, buttons, and snaps. Whi~1).,o~She following best describes
your/(PATIENT'S NAME) ability to dress yout1his/her upper body:"

o 0- You arelHe is/She is able to dress with or without dressing aids;

o 1- You are/He is/She is able to dress the upper body without assistance if clothing is
laid out or handed to youlhimlher;
o 2- Someone must help you/him/her put on upper body tlothing; or
o 3- Youlhe/she depends entirely upon someone else to dress yourlhis/her upper body.
o UK- Unknown.

26. "And what about the ability to dress the lower body, with or without dressing aids,
including undergarments, slacks, socks or nylons, shoes. Are you/Is he/Is she ...

o 0- Able to obtain, put on, and remove clothing and shoes without assistance;
o 1- Able to dress the lower body without assistance if clothing and shoes are laid out or
handed to you/him/her;
02- Does someone have to help yoU/himlher put on undergarments, slacks, socks, or
nylons and shoes; or
o 3- Do you/Does he/Does she depend entirely upon someone else to dress the lower
body.
o UK- Unknown
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27. "Bathing is the ability to wash the entire body, not just washing face and hands. Are
you/Is he/Is she ...

o 0- Able to bathe in the SHOWER OR TUB independently;
o 1- Able to bathe in the shower or tub independently, with the use of devices;
o 2- Able to bathe in the shower or tub with the limited assistance of another person to
supervise or encourage you/them, to help you/them in and out of the shower or tub, or to
wash in difficult areas;
o 3- Do you/he/she in require the presence of another person throughout the bath for
assistance or supervision.
o 4- Are you/Is he/Is she not able use the shower or tub and are/is bathed in bed or a
bedside chair; or
o 5- Are you/Is he/Is she not able to participate in bathing and are/is totally bathed by
another person.
a UK- Unknown.

28. "Toileting is the ability to get to and from the toilet or beside commode. Are you/Is
he/Is she:

o 0- Able to get to and from the toilet indep~t;1d~tly, with or without a device;
o 1- Able to get to and from the toilet when reminded, assisted or supervised by another
person;
o 2- Unable to get to and from the toilet, but able to use a bedside commode, with or
without assistance;
o 3- Unable to get to and from the toilet or bedside commode, but able to use a bedpan;
a 4- Are you/Is he/Is she totally dependent in toileting. 1
o UK- lJnknown
~

29. "The next question is about the ability to walk SAFELY, once in a standing position,
or to use a wheelchair once in a seated position, on a variety of surfaces."

o 0- Are you!Is he/Is she able to walk independently on uneven surfaces and climb stairs
with or without railings (e.g., needs no human assistance or assistive devices);
o 1- Do you!does he/does she require the use of a device, such as a cane or walker) to
walk alone OR require supervision or assistance from another person to climb stairs or
steps or uneven surfaces;
o 2- Are you/Is he/Is she able to \valk only with the supervision or assistance of another
person at all times;
o 3- Are you/Is he/Is she chairfast, that is unable ambulate but able to wheel
yourself/himselflherself independently; or
I 0 4- Chairfast, and not able to ambulate or to wheel yourself/himself/herself
LQ 5- Bedfast, unable to ambulate or be up in a chair.O UK,- Unknown
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30. "Thinking about yourlhis/her ability to feed yourselflhimselflherself meals and
snacks. By this I mean the process of EATING, CHEWING, and SWALLOWING, NOT
PREPARING the food to be eaten."

o 0- Are you/Is he/Is she able to independently feed yourselflhimselflherself;
o 1- Are you/Is he/Is she able to feed yourself/himself/herself independently but need the
meal set up; or some assistance or supervision from another person, or a liquid, pureed or
ground meat diet;
o 2- Are you/Is he/Is she UNABLE to feed yourself/himself/herself and must be assisted
or supervised throughout the meal or snack;
o 3- Are you/Is he/Is she able to take in nutrients orally AND receives supplemental
nutrients through a nasogastric tube or gastrostomy;
o 4- Are you/Is he/Is she UNABLE to take nutrients orally and are/is fed nutrients
through a nasogastric tube or gastrostomy; or
o 5- Are you/Is he/Is she unable to take nutrients orally or by tube feeding.

31. ~'And what about planning and preparing light meals, for example, a cereal or
sandwich or reheating delivered meals:

o 0-

Are you/Is he/Is she able to independentl~JJlan and prepare all light meals for
yourself or reheat delivered meals or are yoUih~she physically, cognitively, and mentally
able to prepare light meals on a regular basis but have/has not routinely performed light
meal preparation in the past
o 1- Are you/he/ she UNABLE to prepare light meals on a regular basis due to physical,
cognitive, or mental limitations; or.
o 2- Are you/he/she unable to prepare any light meals ortre-heat any delivered meals.
o UK- Unknown

32. '''By transportation we mean the physical and mental ability to safely use a car, taxi,
or public transportation like a bus, train or subway:

o 0- Are you/Is he/Is she able to independently drive a regular or adapted car or use a
regular handicap-accessible public bus;
o 1- Are you/Is he/Is she able to ride in a car only when driven by another person OR
able to use a bus or handicap van only when assisted or accompanied by another person;
o 2- Are you/Is he/Is she UNABLE to ride in a car, taxi, bus, or van, and require
transportation by ambulance.
o UK- Unknown
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33. "And what about the ability to do your/hislher own laundry; that is, to carry laundry
to and from the washing machine, to use a washer and dryer, and to wash small items by
hand."
o 0- Are you/Is he/Is she able to independently take care of all laundry tasks OR
physically, cognitively, and mentally able to do laundry and access facilities, BUT has
not routinely performed laundry tasks in the past (i.e., prior to home care admission).
o 1- Are you/Is he/Is she able to do only light laundry, such as minor hand washing or
light washer loads and need/needs assistance with heavy laundry such as carrying loads
of laundry due to physical, cognitive, or mental limitations; or
o 2- Are you/Is he/Is she UNABLE to do any laundry due to physical limitations or
need/needs continual supervision and assistance due to cognitive or mental limitations.
o UK- Unknown

34. "And what about housekeeping - that is, the ability to safely and effectively perform
light housekeeping and heavier cleaning tasks:

o 0- Are you/Is he/Is she able to independently perform all housekeeping tasks; OR are
you/he/she physically, cognitively, and mentally able to perform ALL housekeeping tasks
and havelhas not routinely participated in housekeeping tasks in the past (i.e., prior to this
come care admission);
.-.' ~~'
o 1- Are you/Is he/Is she able to perform only ,fIGHT housekeeping, such as dusting or
wiping kitchen counters, independently;
o 2- Are you/Is he/Is she able to perform housekeeping tasks with some assistance or
supervision from another person;
o 3- Are you/Is he/Is she UNABLE to consistently perform any housekeeping tasks
unless assisted by another person throughout the process~ or
o 4- Are you/Is he/Is she unable to effectively participate in any housekeeping tasks.
o UK- Unknown

35. "What about shopping - that is, the ability to plan for, select and purchase items in a
store and to carry them home or arrange for delivery"

o 0- Are you/Is he/Is she able to plan for shopping needs and independently perform
shopping tasks, including carrying packages, OR are you/is he/is she physically,
cognitively, and mentally able to take care of shopping but have/has not done shopping in
the past (i.e. prior to home care admission);
o 1- Are you/Is he/Is she able to go shopping, but need/needs someone to do occasional
major shopping, OR are you/is he/is she unable to go shopping alone, butcan go with
someone to assist;
o 2- Are you/Is he/Is she UNABLE to go shopping but able to identify items needed,
place orders and arrange home delivery; or
o 3- Do you/Does he/Does she need someone to do all shopping and errands.
o UK- Unknown
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36. "And what about-the ability to answer the phone, dial numbers, and EFFECTIVELY
use the telephone to communicate:

o 0- Are you/Is he/Is she able to dial numbers an answer call appropriately and as
desired;
o 1- Are you/Is he/Is she able to use a specially adapted telephone, such as a phone with
large numbers on dial or teletype for the deaf, to call essential numbers;
o 2- Are you/Is he/Is she able to answer the telephone and carryon a normal
conversation but havelhas difficulty with placing calls; or
o 3- Are you/Is he/Is she able to answer the telephone only some of the time or able to
carryon only a limited conversation.

37. ~'Which of the following best describes your/CPATIENT'S NAME) level of physical
activity:
1. y oulhe/she walks frequently - You walk/he walks/she walks outside the room
at least twice a day and inside the room at least once every two hours during
waking hours;
2. Youlhe/she walks occasionally- You walk/he walks/she walk occasionally
during the day but for very short distances, with or without assistance.
3. Youlhe/she is chairfast; that is, YOllrlKis/her ability to walk is severely limited
or non-existent; you/he/she cannot bear your/his/her own weight and/or must be
assisted into a chair or wheelchair; or
4 . You are/he is/she is bedfast and confined to bed
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Valued Life Activities
38. "How much has your/(PATIENT'S NAME) stroke affected yourlhislher ability to
take part in activities you enjoy and that are valuable to you, such as hobbies, church,
recreational activities and spending time with friends ... has it had no effect, some effect,
or a great effect?"
1. NO EFFECT
2. SOME EFFECT
3. A GREAT EFFECT

Driving
39a. "Are you currently able to drive - even to a limited degree?"
1. YES

2. NO, BUT I DID NOT DRIVE BEFORE THE STROKE ---------- GO TO END
OF SURVEY
3. NO, ALTHOUGH I DID DRIVE BEFORE THE STROKE ------ GO TO END
OF SURVEY
~~I :~I
4. DON'T KNOW, HAVEN'T TRIED ~--------------------------------- GO TO END
OF SURVEY
39b. "How soon after your stroke did you start driving again ...
1.
2.
3.
4.
5.

WITHIN A WEEK
BETWEEN ONE WEEK AND FOUR WEEKS
BETWEEN ONE MONTH AND THREE MONTHS
MORE THAN THREE MONTHS
DON'T KNOWINOT SURE

39c. "Did you have any type of driving evaluation or training before you started driving
again?"
1. YES
2.NO

39d. "Since you started driving again, have limited your driving in any way?"
1. YES
2. NO --------------------- GO TO END OF SURVEY
J. DON'T KNOW ------ GO TO END OF SURVEY
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3ge. "How have you limited your driving?"
RECORD:

-----------------------------------------------

[END OF SURVEY]
"That's all the questions I have. Thank you very much for your cooperation."

..
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Appendix E - Survey Results
There were a total of 9,474 stroke events in South Carolina between October 1,
2008 and September 30, 2009. Of those, 844 (,.... 9%) strokes occurred at MUSC during
the study period. A description of the study cohort is list in the Appendix E - Table 1
below. A total of 384 surveys were conducted from January thru May of 2010. Of those
subjects who completed the survey, 96 (25%) stated that they had not been hospitalized
for a stroke, most completed the survey questions and were asked to address the
questions based on their "last hospitalization at MUSC" despite their belief that they did
not experience a stroke.

A total of 288 (75%) of the subjects completed the survey

questionnaire in its entirety. The average age for this cohort was 65.55 (± 11.37). The
characteristics of the survey cohort are li~ste'~ in Appendix E - Table 2 below. 'The
characteristic profiles of those patients who claimed they did not have a stroke are
described in Appendix E -- Table 3 below. The mean age for this group was 65.48 (±
10.29).
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Appendix E - Table 1: MUSC Stroke Cohort Disposition
Subject Status
MUSC Stroke Admissions

Cohort
(n)

Unique Patients

Total # of strokes discharged from MUSC

844

Multiple stroke admissions

Explanation

Percent
(%)

6.3 50 patients had 2 strokes, 3 had 3 stroke admissions

53

Total # of unique patients

791

:

In-hospital death
Eligible for Letter of Introduction

I

11.4 # of case fatalities

90

Letter mailed to last known address

701

Deceased

41

5.9 Called hotline or returned letter with deceased indication

Decline prior to survey

24

3.4 Called hotline to decline participation

Eligible for Survey Call Attempt

636

Hospice/Skilled Nursing Facility

29

Unable to Contact

98

Eligible Survey Subj ects
Declined Consent/ Unreachable

Completed Survey

509
125
384

Call

att~mpt

made to last known telephone number

4.6 Consi~~ed not eligible
15.4 Missing or incorrect contact information

-

Call attempt to working telephone number was made
24.6 Declined in phone request or unreachable after 10 attempts
75.4 Response rate for eligible subjects
I

Completed Medication Profile
Denied stroke hospitalization
Acknowledged stroke hospitalization

271

70.6 Subjects/Proxies completed medication assessment portion of survey!

96

25.0 Claimed Not to have been hospitalized for a stroke

288

75.0 Subjects acknowledge stroke and completed survey
- --,,-

-------
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Appendix E - Table 2: Survey Cohort Baseline Characteristics
Characteristics

Cohort
(n=384)

Proportion
(%)

Race
Caucasian
African American
Other
Gender
Male
Female
Age
45-65 years
~ 65 years
State Resides
SC
Other
Recognized
Stroke
No
Yes
Respondent
Subject
Proxy
Primary
Diagnosis
430
431
432
433
434
435
436
437
438
Stroke Subtype
Cerebral
Hemorrhagic
Ischemic

269
4

70.05
28.91
l.04

168
216

43.75
56.25

182
202

47.40
52.60

365
19

95.05
4.95

III

96
288

25.00
75.00

303
81

78.91
21.09

45
32
16
89
110
21
0
65
6

11.72
8.33
4.17
23.18
28.65
5.47
0.00
16.93
l.56

68
89
205

18.78
24.59
56.63

Cohort
(n=384)

Proportion
(%)

Comorb idities
Hypertension
Diabetes
Hyperlipidemia
CHF
CHD
IHD
CKD
MI
Obesity
Atrial Fibrillation
Renal Failure
Diagnostic

233
90
158
24
0
65
22
293
17
56
11

64.36
24.86
43.65
6.63
0.00
17.96
6.08
80.94
4.70
15.47
3.04

CT Scan

119

32.87

MRI Scan
EKG
~"I
EEG
Therapy
Physical

208
114
260

57.46
31.49
7l.82

137

37.85

Occupational

160

44.20

Speech
Cardiac Rehab
Dialysis
Disposition
Home
Nursing Facility
Other Facility
Insurance Status
Self-pay
Medicare
Medicaid
Commercial
Not recorded
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42
43

56.35
10.94
11.20

291
9
84

75.78
2.34
21.88

17
189
21
90
42

4.97
55.26
6.14
26.32
10.94

Characteristics

<l

*SC, South Carolina; CHF, Congestive Heart Failure; CHD, Coronary Heart Disease;
IHD, Ischemic Heart Disease; CKD, Chronic Kidney Disease; MI, Myocardial
Infarction; CT Scan, Computed Tomography Scan; MRI Scan, Magnetic Resonance
Imaging Scan; EKG, Electrocardiogram; EEG, Electroencephalogram.
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Appendix E - Table 3: Baseline Characteristics among Surveyed Patients Who Claimed
that they were Not Hospitalized for a Stroke.
Cohort
(n=94)

Characteristics

Proportion
(%)

Race

Characteristics

Cohort
(n=94)

Proportion
(0/0)

64
18
40
2
0
18
5
70
4
11
1

71.11
20.00
44.44
2.22
0.00
20.00
5.56
77.78
4.44
12.22
1.11

52
75
49
48

57.78
83.33
54.44
53.33

63
70
82
8
8

70.00
77.78
91.11
8.51
8.51

1

1.16

1
46
3
27
8

1.16
53.49
3.49
31.40
8.51

Comorbidities

Caucasian
African American
Other

76
16
2

80.85
17.02
2.13

Male
Female

38
56

40.43
59.57

< 65 years
65 + Years

45
49

47.87
52.13

85
9

90.43
9.57

Gender

Age

Respondent
Subject
Proxy

Hypertension
Diabetes
Hyperlipidemia
CHF
CHD
IHD
CKD
MI
Obesity
Atrial Fibrillation
Renal Failure

Diagnostic

Primary Diagnosis
430
431
432
433
434
435
436
437
438

12
1
4
32
2
5
0
33
1

13.33
1.11
4.44
35.56
2.22
5.56
0.00
36.37
1.11

Stroke Subtype
Cerebral
Hemorrhagic
Ischemic
433.10
433.11
433.30
433.80
433.81

Therapy
Physical
Occupational
Speech
Cardiac Rehab
Dialysis

Disposition
34
17
39

37.78
18.89
43.33

Diagnosis of 433.xx
With Out CI:
With CI:
With Out CI:
With Out CI:
With CI:

~~;'~I

CT Scan
MRI Scan
EKG
EEG

Home Health
Nursing Facility
Other Facility

Insurance Payor
29

1
1
1
1

Self Pay
Medicare
Medicaid
Commercial
Not recorded

30.85
1.06
1.06
l.06
1.06

*433.xx - Occlusion and stenosis of pre cerebral arteries: 433.XO - without mention of
cerebral infarction (el), 433.XI - with cerebral infarction. CHF, Congestive Heart

Failure; CHD, Coronary Heart Disease; IHD, Ischemic Heart Disease; CKD, Chronic
Kidney Disease; MI, Myocardial Infarction; CT Scan, Computed Tomography Scan;
MRI Scan, Magnetic Resonance Imaging Scan; EKG, Electrocardiogram; EEG,
Electroencephalogram.
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